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Abstract  
Oxygen sensing is a fundamental biological process which is critical for 
appropriate development of the eye and implicated in neovascular eye disease 
including age-related macular degeneration, diabetic retinopathy and retinopathy 
of prematurity. This thesis describes a programme of work designed to 
investigate the role of hypoxia-inducible transcription factors (Hif’s), its 
downstream effector proteins, and its upstream regulator, the von Hippel Lindau 
protein (Vhl), in the development of the eye and neovascular eye disease.  
The first part of this work investigates the consequences of Hif activation in the 
developing retinal pigment epithelium (RPE) using a tissue specific knockout 
technology in mice. It demonstrates that appropriate regulation of Hif’s by Vhl is 
essential for normal RPE and iris development, ocular growth and vascular 
development and indicates that ocular hypoxia may be a previously 
unrecognised mechanism in the development of microphthalmia.  
The second part of this work studies the role of Hif1a in myeloid cells in the 
development of pathological neovascularisation using tissue-specific knockout 
technology and murine models for retinal and choroidal neovascularisation. It 
demonstrates that Hif1a signalling in myeloid cells contributes substantially to 
the development of retinal and choroidal neovascularisation and provides a 
rationale for developing antiangiogenic treatments that target Hif1a signalling in 
myeloid cells in neovascular eye disease. 
The third part of this work investigates the oxygen distribution in the vitreous and 
its relation to HIF1a and its downstream molecules in proliferative diabetic 
retinopathy (PDR) in man. It identifies significant intraocular oxygen gradients in 
PDR with areas of hyperoxia and hypoxia and demonstrates increased levels of 
HIF1a in the vitreous in PDR which correlate with increased levels of 
inflammatory and angiogenic cytokines in PDR. These findings suggest that 
HIF1a activation by inflammation and/or hypoxia is a central feature in the 
progression of PDR and that its inhibition may potentially serve as a target for 
therapeutic intervention.  
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1. Introduction 
The retina has a uniquely high metabolic demand for oxygen that is normally 
met by an efficient vascular supply (Ames, III et al., 1992). Oxygen is used as an 
electron acceptor in many intracellular biochemical reactions and contributes to 
the synthesis of adenosine triphosphate (ATP) through aerobic metabolism that 
is required to support the metabolic demand of the developing and functioning 
retina, in particular that of the visual cycle. The functional reserve of oxygen in 
the retina is small and local oxygen deficiency (hypoxia) can cause neuroretinal 
dysfunction and degeneration that lead directly to vision loss. Maintenance of 
normal retinal function therefore depends on a continuous supply of oxygen and 
on the capability to detect and respond rapidly to hypoxia.  
 
Local oxygen sensing mechanisms control adaptive responses that can help 
protect against hypoxic injury. In the retina, oxygen sensing mechanisms rapidly 
detect alterations in intracellular oxygen tension and respond with adaptive 
changes that redress the balance between oxygen supply and demand. These 
responses include changes in blood flow, protective metabolic adaptations and 
angiogenesis. The angiogenic response to retinal hypoxia is typically associated 
with oedema, haemorrhage and fibrosis that can exacerbate hypoxic 
neuroretinal injury, causing severe vision loss. This detrimental response is the 
target of novel therapies including inhibitors of vascular endothelial growth factor 
(VEGF). These therapies, however, fail to address the underlying hypoxia and 
do not consider appropriate beneficial adaptive responses to hypoxia. 
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With the aim to improve our understanding of oxygen sensing mechanisms and 
its adaptive responses in the retina, this thesis has investigated the role of 
hypoxia-inducible transcription factors (HIFs) in ocular development, in 
experimental models of retinal and choroidal neovascularisation and in the 
pathogenesis of diabetic retinopathy in man.  
1.1 Anatomy of the human retina and its vasculature 
The wall of the eyeball contains three main layers: an outer fibrous layer (the 
sclera), a middle vascular layer (the choroid) and an inner nervous tissue layer 
(the retina, figure 1.1A-B). The retina carries out the various functions required 
to achieve phototransduction – the process by which light is received and 
converted into neuronal impulses. The retinal layers of cells are generally 
viewed as two distinct tissue compartments: the inner, neurosensory retina, and 
the outer, retinal pigment epithelium (RPE).  
1.1.1 Anatomy of the retina 
1.1.1.1 Neurosensory retina 
The neurosensory retina is a thin translucent tissue that varies in thickness from 
0.5 mm at the disc to 0.1 mm at the ora serrata. It is firmly attached to the RPE 
at the ora serrata and the optic nerve head and held in place by intraocular 
pressure in the intermediate regions. The neurosensory retina is structured in a 
distinct layered pattern consisting of three nuclear layers and two sandwiched 
synaptic, plexifom layers (figure 1.1A-B):  
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The outer nuclear layer (ONL) contains the cell bodies of both cones and rod 
photoreceptors. The inner and outer segments (IS, OS) of photoreceptors are 
located in the photoreceptor layer (PR) between the ONL and the retinal 
pigment epithelium. Rod and cone photoreceptors differ in the visual pigment 
they contain and as a result respond to different light stimuli; rods contain the 
pigment rhodopsin and are sensitive to conditions of dim light whereas cones 
hold different cone opsins, depending on which subtype of cone cell they belong 
to, and respond to bright light of varying wavelengths allowing colour vision. In 
the human eye, a central portion of the retina, the macula, contributes most to 
visual acuity, as it contains the highest concentration of cone cells (150.000 
cones cells/mm2). Rods dominate the photoreceptor population in the periphery 
of the mammalian eye and are therefore responsible for peripheral vision.  
The outer limiting membrane (OLM) is located between the plasma 
membranes of the inner segments and the apical processes of Müller glia. The 
OLM comprises a series of zonula adherens junctional complexes which seal off 
the light-sensitive photoreceptor inner and outer segments from the rest of the 
retina, limiting the diffusion of phototransduction cascade components (West et 
al., 2008). 
The outer plexiform layer (OPL) consists of a dense network of synaptic 
connections between photoreceptor cells and neurons of the inner nuclear layer. 
The inner nuclear layer (INL) contains bipolar, amacrine, horizontal and Müller 
glia cells which coordinate and modify the signals coming from photoreceptors. 
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The inner plexiform layer (IPL) contains the synaptic connections between 
cells of the inner nuclear layer and the ganglion cells of the innermost retinal 
layer. 
The ganglion cell layer (GCL) contains displaced amacrine cells and ganglion 
cells which form the output from the retina to the brain via the optic nerve. The 
nerve fibers (axons) curve to the optic nerve forming the nerve fiber layer (NFL) 
which is separated from the vitreous by the inner limiting membrane (ILM) 
formed by astrocytes and the end feet of Müller cells.  
1.1.1.2 Retinal pigment epithelium 
The retinal pigment epithelium (RPE) is a monolayer of multifunctional, cuboidal 
epithelial cells located between the neurosensory retina and the choroidal 
vasculature (figure 1.1A-B). RPE cells are densely pigmented and form high 
columns at the posterior pole of the eye and become flatter, wider and less 
pigmented towards the periphery. Near the apex RPE cells are joined together 
by attachment girdles of tight junctions, which restrict aqueous diffusion across 
the layer contributing to the outer blood-retinal barrier. The basement membrane 
of RPE cells faces the choroid and contributes to Bruch’s membrane. The RPE 
plays a critical role in the eye providing much of the trophic support which is 
required for development and maintenance of photosensitive retinal cells. In 
addition, RPE cells phagocytose photoreceptor outer segments, allowing them 
to be turned over and re-synthesised, and contribute to the visual cycle by 
uptake and recycling of by-products of the phototransduction cascade. 
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Figure 1.1 Anatomy of the human retina. Histology (A) and corresponding schematic (B) of 
the human retina. NB: The flat detachment above the RPE is a fixation artifact. ILM = inner 
limiting membrane; NFL = nerve fiber layer; GCL = ganglion cell layer; IPL = inner plexiform 
layer; INL = inner nuclear layer; OPL = outer plexiform layer; ONL = outer nuclear layer; OLM = 
outer limiting membrane; IS/OS = Inner and outer segments; RPE= retinal pigment epithelium. 
Images adapted from www.atlasofophthalmology.com (A) and from Mikroskopische Anatomie 
der Organe - Auge und Retina; H.-J. Wagner (B). 
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1.1.2 Anatomy of the retinal vasculature 
The retinal layers are supplied by two discrete vascular networks – the retinal 
circulation composed of superficial and deep networks, and the choroidal 
circulation located under the retinal pigment epithelium (figure 1.1A, B). 
1.1.2.1 The retinal vasculature 
The central retinal artery is the first branch of the ophthalmic artery and enters 
the optic nerve approximately 1 cm posterior to the globe (figure 1.2A). Inside 
the eye, it emerges from the optic nerve head and divides into the superior and 
inferior papillary arteries, which in turn divide into nasal and temporal quadrantic 
branches (figure 1.2B). The retinal arteries are surrounded by a capillary free 
zone due to a sufficient oxygen supply through transarterial diffusion (figure 
1.2C) (Pournaras et al., 2008). The branches of the superiortemporal and 
inferotemporal arteries give rise to a two-layered peri-macular vessel ring 
creating a foveal capillary-free zone which allows light to pass directly to the 
fovea without obstruction. From the inner surface of the retina arterioles extend 
into deeper layers forming distinct capillary networks. Depending on the 
thickness of the retina, this capillary meshwork can vary from three layers at the 
posterior pole to one layer in the periphery (Shimizu K and Kazuyoshi U, 1978). 
At the posterior pole the arterial branches supply the superficial radial 
peripapillary capillaries in the nerve fiber layer (RPCs), the inner capillary 
network located in the ganglion cell layer and the deep capillary network in the 
inner nuclear layer. The postcapillary venules drain through the corresponding 
venous system to the central retinal vein.  
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Retinal capillaries are 5–6µm in diameter and consist of non-fenestrated 
endothelial cells that are surrounded by pericytes in a 1:1 ratio. The retinal 
capillary endothelial cells possess numerous tight junctions and are the major 
component of the inner blood-retinal barrier. Retinal pericytes contain contractile 
proteins such as actin and myosin which can constrict or dilate depending on the 
vascular microenvironment and are directly involved in the local control of retinal 
blood flow (autoregulation).  
1.1.2.2 Choroidal vasculature 
The choroid is a highly vascularised tissue layer located between the retina and 
sclera. It is separated from the RPE by Bruch’s membrane, from the sclera by 
the lamina fusca. The choroidal vasculature is nourished by 10 to 20 short 
posterior ciliary arteries (SPCA) that arise from the ophthalmic artery and pierce 
the posterior pole of the sclera to enter the choroid and supply the posterior 
portion of the choriocapillaris up to the equator. In addition, long posterior ciliary 
arteries (LPCA) nourished by the ophthalmic artery pierce the sclera and course 
anteriorly in the suprachoroidal space to their branch point near the ora serrata, 
sending branches posteriorly to supply the choriocapillaris up to the equator. 
The thickness of the choriocapillaris gradually decreases from 0.2 mm at the 
posterior pole to 0.1 mm at the ora serrata. Whereas the capillary network is 
dense and alveolar at the posterior pole (lobular pattern), the intercapillary 
spaces are widened and lobules become more polygonal and elongated at the 
equator (spindle pattern). In the far periphery choroid branching is less frequent 
and radial capillary orientation predominates (ladder pattern). Unlike most 
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vascular systems in the body the choroidal arteries and veins do not run parallel. 
Postcapillary venules form afferent veins that converge around the inner sclera 
of the four quadrants to vortex veins that pierce the sclera and drain into the 
superior and inferior ophthalmic veins (figure 1.2. A,D,E). 
Choroidal vessels are surrounded by smooth muscle cells and controlled by a 
perivascular nervous plexus comprising both divisions of the autonomic nervous 
system (Bill and Sperber, 1990; Lutjen-Drecoll, 2006). The wall of the 
choriocapillaris facing Bruch’s membrane is fenestrated with circular openings 
(fenestrae) measuring approximately 80 nm, Even though choroidal capillaries 
contain fenestrated endothelium and have no tight junctions, their adjacency to 
Bruch’s membrane and the RPE with its intercellular junctions secure a tight 
blood-retinal barrier. 
 
 
30 
 
 
Figure 1.2 Retinal and choroidal vasculature. A) Cutaway drawing of the human eye. The 
view is from a superior position over the left eye and the horizontal section passes through both 
the optic disk and the fovea. B,C) Funduscopic view and histology of the retinal vasculature. 
D,E) Funduscopic view and vascular cast of the choroidal vasculature. Drawing by Dave 
Schumick. Images adapted from (Anand-Apte B and Hollyfield J K, 2010) and 
www.atlasofophthalmology.com. 
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1.1.3 Anatomy of the murine retina  
As many of the experiments presented in this thesis deal with the retina of mice, 
some remarks on the development and anatomy of the murine retina are 
necessary. Even though the basic functional organisation of the murine retina is 
similar to the human retina, there are some differences:  
The mouse has a relatively small eye and measures 3.4 mm from the centre of 
the cornea to the posterior pole. It is characterised by a relatively large cornea 
and lens, the latter accounting for 60% of the axial length (Remtulla and Hallett, 
1985). As in other nocturnal mammals, rods greatly outnumber cones in the 
murine photoreceptor population at a ratio of 30:1. As in all mammals except the 
primates the mouse retina does not have a macula although the density of rods 
and cones peaks in the area centralis and decreases more peripherally. 
In contrast to the human, mice are born with an avascular retina reflecting the 
fact that they are born at an earlier developmental stage. During the first week 
after birth the superficial layer of the retinal vasculature sprouts from the optic 
nerve head to the peripheral retina. Over the following two weeks three parallel 
vascular networks are established within different layers of the retina.  
In adult mice multiple retinal arteries arise from the central retinal artery and 
radiate away from the optic nerve head across the vitreous surface of the retina 
feeding different regions of the mouse retina. Venous drainage follows the 
retinal arteries back to the optic nerve head and leaves the eye through the 
central retinal vene (Watson et al., 2012). 
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1.2 Development of the eye 
1.2.1 Development of the optic cup and the retina 
The vertebrate eye develops from three different germ layers: the 
neuroectoderm of the diencephalon, the surface ectoderm of the epithelium and 
the intervening neural crest/mesoderm (figure 1.3A). During the third week of 
human gestation the primitive forebrain sprouts on either side to form two optic 
stalks and vesicles which are surrounded by mesoderm, the primordium of the 
vascular (arachnoida and choroidea) and fibrous layer (dura mater and sclera). 
During the fourth week of gestation, the optical vesicle comes into contact with 
the surface ectoderm which thickens and invaginates together with the 
underlying neuroepithelium of the optic vesicle to form the lens placode (figure 
1.1 B,E). The lens differentiates and invaginates until it pinches off from the 
epithelium. The optic vesicle is converted into a double-layered optic cup by 
invagination of its distal and inferior wall (figure 1.1C,F). The outer layer of this 
cup will form the sclera, choroid and pigment epithelium, the inner layer will 
become the neuroepithelium (figure 1.1 D,G). The periphery of the optic cup, 
including the presumptive RPE, contributes to the formation of the ciliary body 
and iris anteriorly. The invagination, which also involves the optic stalk, allows 
axons to exit from the ganglion of the invaginated layer (i.e. the later 
neuroepithelium) via the optic nerve and also enables the entry of choroidal 
vessels. The periocular mesenchyme and cranial neural crest cells migrate in 
during formation of the optic cup and contribute to the development of the 
cornea, iris, ciliary body, sclera and blood vessels of the eye.   
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Figure 1.3 Development of the eye. At early stages of eye development, the optical vesicle 
induces thickening of the ectoderm and invagination of both epithelium (surface ectoderm) and 
underlying optic vesicle (neuroectoderm, A-B,E-F). The inner layer of the bilayered optic cup 
gives rise to the neural retina, the outer layer forms the sclera, choroid and retinal pigment 
epithelium (RPE, C,G). The mature neural retina comprises three cellular layers: photoreceptors, 
interneurons (horizontal, amacrine and bipolar cells), and retinal ganglion cells (D). Adapted 
from (Ali and Sowden, 2011) and http://isc.temple.edu/neuroanatomy/lab/. 
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1.2.2 Development of the retinal vasculature 
The development of the eye depends on the formation of a vascular system to 
provide nutrients and oxygen for the ocular tissues at the time of their active 
differentiation. During embryogenesis, this involves the de novo formation of 
blood vessels by differentiation of endothelial precursors to form the primary 
vascular network (vasculogenesis), and the formation of new blood vessels that 
branch off from existing vessels (angiogenesis) (Carmeliet, 2000). The brain and 
the eye are thought to be predominantly vascularised by angiogenesis (Fruttiger, 
2007). However, there is accumulating evidence that the primary inner vascular 
plexus in the retina is formed by vasculogenesis (Chan-Ling et al., 2004). During 
the initial development of the eye, the oxygenation of the retina is ensured by 
the choroidal vessels and the hyaloid system. The vascularisation of the retina 
itself occurs only during the late gestation and is restricted to the inner part of 
the retina, with the outer retina completely avascular to avoid disturbance of light 
perception. 
1.2.2.1 Development of the choroidal vasculature 
The choroidal circulation develops at the same stage as the invagination of the 
optic vesicle and uveal development (Saint-Geniez and D'Amore, 2004). At the 
fourth week of gestation, the undifferentiated mesoderm surrounding the optic 
cup starts to differentiate into endothelial cells and a large plexus of primitive 
vessels adjacent to the RPE. The initial choriocapillaris develops by haemo-
vasculogenesis, a process in which blood cells and blood vessels differentiate 
from a common precursor, the haemangioblast (Luty 2010). By the second 
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month of development the primitive vascular plexus envelops the entire exterior 
of the optic cup and the choriocapillary vessels begin to develop a basal lamina 
which, together with the basement membrane of the RPE, forms the initial 
Bruch’s membrane, separating the neural retina from the choroid. In the third 
month of gestation the intermediate choroidal vasculature, the large choroidal 
vessels and anastomosis betwenn the vascular layers develop by angiogenesis 
(Luty 2010). The choroidal capillary network becomes almost completely 
organised by the twelfth week of gestation with connections to the posterior 
ciliary arteries and to rudimentary vortex veins that develop in all four quadrants 
of the eye. By the fourth month of gestation most of the choroidal vasculature 
matures (Anand-Apte B and Hollyfield J K, 2010). 
Although the molecular mechanisms underlying the formation of the choroidal 
vasculature have not been fully defined, it is largely accepted that it depends on 
the presence of differentiated RPE cells and the production of inductive signal 
molecules such as VEGF, fibroblast growth factor (FGF)-9 and b-FGF (Saint-
Geniez and D'Amore, 2004). 
1.2.2.2 Development of the hyaloid vasculature 
The process of intraocular vascularisation begins around the first gestational 
month with the entry of the hyaloid artery into the optic cup through the fetal 
fissure. The hyaloid artery extends through the primitive vitreous and reachs the 
posterior pole of the forming lens where it branches intensively to form a dense 
capillary network over the lens surface, the so called tunica vasculosa lentis 
(figure 1.4A). The hyaloid system is characterised by the absence of veins and 
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all hyaloid arterial vessels drain into the choroidal veins. As the lens develops, 
the tunica vasculosa lentis expands to reach the anterior part of the lens and 
forms the pupillary membrane. In later stages, in human during the second 
month of gestation, the hyaloid vasculature regresses and a vascular plexus 
emerges from the optic nerve head giving rise to the retinal vasculature (figure 
1.4.B-C). The occlusion of the regressing capillaries has been suggested to 
depend on macrophages and on the levels of secreted growth factors such as 
Vegf and Angiopoietin 2 (Saint-Geniez and D'Amore, 2004). 
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Figure 1.4 Development and remodeling of the hyaloid and retinal vasculature. Early in 
development, the hyaloid artery supplies the hyaloid vasculature, the tunica vasculosa lentis and 
the pupillary membrane; the venous drain is accomplished by the choroidal veins (A). As the 
primary plexus grows into the retina, the hyaloid vasculature regresses (B) and the deeper 
plexus of the retinal vasculature develops from veins in the primary plexus (C). NB the choroidal 
vasculature is not shown in B and C. Adapted from (Fruttiger, 2007).  
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1.2.2.3 Development of the inner retinal vasculature 
During early development the inner retina is metabolically supported by the 
hyaloid vasculature and remains avascular until the fourth month of gestation 
(figure 1.4A). As the retina matures and grows, the demand for oxygen and 
nutrition increases which necessitates the formation of a retinal vascular bed 
(Chan-Ling et al., 1995; Stone et al., 1995). Primitive retinal vessels emerge 
from the optic disc at the base of the hyaloid artery and spread to the periphery 
of the retina forming a primitive central retinal arterial system (figure 1.4B). The 
initial intense angiogenic process is followed by a process called pruning which 
describes the eradication of part of the vessels, in order to adapt the blood flow 
to the needs and physiologic characteristics of the differentiated tissues. Pruning 
occurs via selective endothelial cell death (Ishida et al., 2003) or via migration 
and relocalisation of endothelial cells (Hughes and Chang-Ling, 2000) and is 
particularly evident in the vicinity of arteries where capillary free zones emerge 
due to high oxygen tension present in arteries (Riva et al., 1986). Over time, as 
more vessels are added in the periphery, the primitive plexus is remodeled and 
starts to mature into a hierarchical vascular tree with clearly defined arteries, 
capillaries and veins. The primary vessel plexus at the inner retinal surface 
subsequently remodels into two parallel but inter-connected networks, located in 
the nerve fiber layer and the inner plexiform layers (figure 1.4C). These vascular 
beds are further remodelled by proliferation and apoptosis of endothelial cells 
which is closely controlled by hypoxia and Vegf gradients (Chan-Ling et al., 
1995; Stone et al., 1995). The retinal vasculature in humans is fully mature at 
birth and remains quiescent unless the balance of angiogenic inhibitors is tipped 
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in favour of angiogenic activators (termed ‘angiogenic switch’) during hypoxia 
and ischaemia associated retinal disease (Carmeliet, 2000). 
1.3 Perfusion and oxygenation of the retina 
The retina is one of the most metabolically active tissues in the human body, 
consuming more oxygen per mg tissue than many other organs including the 
brain (Alm and Bill, 1972; Ames, III, 1992; ANDERSON, Jr. and SALTZMAN, 
1964). Oxygen is transported to the retina by two independent physiologically 
different vascular circulations - the retinal circulation composed of superficial 
and deep capillary networks, and the choroidal circulation located under the 
retinal pigment epithelium (figure 1.5A).  
1.3.1 Perfusion of the retina 
The retinal circulation supplies oxygen mainly to the inner retina (Provis, 2001) 
and has a relatively low blood flow and high oxygen extraction (8 ml oxygen per 
100 ml) compared to other tissues, resulting in a high arteriovenous oxygen 
saturation difference and low venous oxygen tension (Hickam et al., 1959; 
Hickam and Frayser, 1965). The retinal circulation has the capacity to 
autoregulate blood flow which helps to maintain oxygen homeostasis (Harris et 
al., 1998). Both endothelial and retinal cells release factors, such as nitric oxide 
(NO) and endothelin which modulate arterial tone, blood flow and oxygen 
delivery (Pournaras et al., 2008).  
The choroidal circulation nourishes the outer retina including the retinal pigment 
epithelium and the photoreceptors. It has a 20-fold greater blood flow and a very 
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low rate of oxygen extraction compared with the retinal circulation resulting in a 
low arteriovenous difference and high reserve of oxygen transport capacity 
(Wangsa-Wirawan and Linsenmeier, 2003). The fenestrae of the choriocapillaris 
allow easy movement of large macromolecules into the extracapillary 
compartment. Oxygen, fluid and molecules escaping from these leaky vessels 
percolate through Bruch’s membrane and have access to the basal side of the 
RPE. Whereas macromolecules are blocked from diffusing to the subretinal 
space by the outer blood-retinal barrier, oxygen can diffuse freely through the 
RPE and reach the photoreceptors (Anand-Apte B and Hollyfield J K, 2010). 
1.3.2 Oxygenation of the retina 
Inner retinal oxygenation has been measured directly using polarographic 
electrodes in several species including guinea pigs (Pournaras et al., 1989), cats 
(Linsenmeier, 1986), rats (Yu et al., 1994) and macaque (Ahmed et al., 1993) 
(figure 1.5B). In cats, rats and macaques, oxygen tension peaks in the inner and 
outer plexiform layers corresponding to the superficial and deep retinal vascular 
networks (figure 1.5C). The mean oxygen tension in the inner retina of the cat 
during dark adaptation is 18.5 mmHg (Linsenmeier and Braun, 1992) which is 
consistent with measurements of preretinal oxygen tension in cats of 18.9 
mmHg (Alm, 1972). Although some studies reported no difference in oxygen 
consumption between darkness and steady illumination (Alder and Cringle, 
1990; Medrano and Fox, 1995), the oxygen tension in the inner retina is slightly 
reduced in light adaptation compared with darkness (Linsenmeier and Braun, 
1992). Retinal oxygen tensions are highest at the level of the choroid and drop 
41 
 
steeply between the choriocapillaris and the outer plexiform layer under light-
adapted conditions. Mathematical modeling suggests that oxygen consumption 
is maximal in the inner segments of photoreceptor cells, amounting to 15 to 20 
ml per 100 g of tissue per minute in the dark which reflects the metabolic 
demand of tightly packed mitochondria in this region (Haugh et al., 1990). In 
darkness, the partial pressure in the outer retina is considerably lower reaching 
0 mmHg at the outer nuclear layer while the partial pressure in the choroid is 
unchanged (Ahmed et al., 1993; Linsenmeier, 1986). This finding reflects the 
increased oxygen consumption by photoreceptors in darkness which is needed 
for ATP production and maintenance of the dark current, in which Na+ ions are 
actively transported extracellularly by a Na+/K+ ATPase pump (Kimble et al., 
1980). The low oxygen tension in the outer retina in darkness results in a 
reversed oxygen gradient and oxygen diffusion from the inner retinal circulation 
to the outer retina (Wangsa-Wirawan and Linsenmeier, 2003). The direct 
measurement of oxygen tension within the human retina has not been reported 
as it would present a significant risk of adverse effects.  
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Figure 1.5 Perfusion and oxygenation of the retina. A) Schematic of the healthy retina and its 
vascular supply. NB: The vasculature is colour coded according to its oxygen saturation (Alm 
and Bill, 1970; Hardarson and Stefansson, 2010). RPE = retinal pigment epithelium; OS = outer 
segments; IS = inner segments; ONL= outer nuclear layer; OPL = outer plexiform layer; INL= 
inner nuclear layer; IPL= inner plexiform layer; GCL= ganglion cell layer; NFL= nerve fiber layer. 
Adapted from Mikroskopische Anatomie der Organe - Auge und Retina; H.-J. Wagner. B,C) 
Intraretinal oxygen tensions under light and dark adapted conditions in cats using an oxygen 
sensing microelectrode (Linsenmeier, 1986).  
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1.4 Oxygen sensing in the retina  
Retinal hypoxia can be caused by systemic cardio-respiratory failure or local 
vascular insufficiency affecting the carotid, ophthalmic, retinal and/or choroidal 
circulations. The functional reserve of oxygen in the human retina lasts for only 
seconds and even transient localised oxygen deficits can produce irreversible 
cellular damage. Maintenance of normal retinal function therefore depends on a 
continuous supply of oxygen and the capability to detect and respond rapidly to 
local oxygen deficiency (Pournaras et al., 2008). 
 
Systemic hypoxia is sensed by central chemoreceptors located near the 
respiratory centres in the brainstem medulla, and in the aortic and carotid bodies 
located on the aortic arch and at the bifurcation of the common carotid artery 
respectively (figure 1.6A-C). The mechanisms of hypoxia sensing in 
chemoreceptors involves hypoxia-induced depolarisation of mitochondrial 
membranes or suppression of K+ channels, resulting in membrane 
depolarisation, calcium influx and secretion of neurotransmitters such as 
adenosine and dopamine (Lahiri et al., 2006). The release of these factors 
activates afferent nerve fibers in the glossopharyngeal (carotid body) or the 
vagus nerve (aortic bodies) projecting to the nucleus tractus solitarius in the 
medulla. In close coordination with other brainstem mechanisms including 
baroreceptor stimulation, activation of sympathetic efferent pathways induces 
adaptive cardio-respiratory responses to hypoxia that include increased 
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respiratory and cardiac rates, and modulation of regional blood flow by changes 
in vascular tone (Weir et al., 2005).  
 
In addition to these systemic and regional responses, several mechanisms 
mediate adaptive responses to hypoxia within tissues at the cellular level. 
Mechanisms of oxygen sensing in the retina include acute changes in 
transmembrane ion permeability and stabilisation of key transcription factors 
which orchestrate multiple adaptive pathways to maintain oxygen homeostasis. 
 
 
 
Figure.1.6 Systemic oxygen sensing. A) Structures and circuits involved in oxygen sensing at 
the systems level. B) Regulatory centres in the brainstem. C) Oxygen sensing at the carotid 
level. 
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1.4.1 Oxygen dependent ion channels 
The literature on changes in ion permeability of the retinal vasculature cells upon 
hypoxia is sparse. Most of our understanding on these acute responses to 
hypoxia is based on the investigation of the microvasculature of the central 
nervous system. Since the microvasculature of the CNS and the retina share 
many similarities it is reasonable to deduce indirect evidence from these results 
for the retina. The resting membrane potential and the contractile status in 
smooth muscle cells and pericytes surrounding endothelial cells depend upon 
the balance of K+, Ca2+ and Cl− channel activity. In recent years, different 
oxygen sensitive ion channels have been suggested to function as oxygen 
sensors and to contribute to relaxation of vascular smooth muscle under hypoxic 
conditions. These channels are stimulated by low oxygen itself or by secondary 
changes to hypoxia, including reduced ATP levels, increased ADP levels and 
reduced intracellular pH (Lopez-Barneo et al., 1997). ATP-gated K+ channels 
(KATP) in smooth muscle cells have been proposed to be a critical link between 
hypoxia and vasodilatation in coronary and cerebral arterioles during hypoxia. 
Under normoxic condition KATP channels are inhibited by intracellular ATP. 
During hypoxia, a lack of ATP results in increased transmembrane K+ flux which 
is followed by cell hyperpolarisation, closure of voltage-dependent Ca2+ 
channels and a reduction in intracellular Ca2+ levels, resulting in vasorelaxation 
and dilatation (Daut et al., 1990; Standen et al., 1989). Furthermore, hypoxia 
has been shown to decrease Ca2+ flux in smooth muscle cells by a direct effect 
on Ca2+ channels or indirectly by changes in ATP, pH, Ca2+ and Mg2+ (Ohya and 
Sperelakis, 1989; Okashiro et al., 1992; Rekalov et al., 1997). The extent to 
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which such changes in ion permeability upon hypoxia also occur in retinal and 
choroidal arteriolar smooth muscle cells and pericytes is currently not well-
defined. 
1.4.2 Oxygen dependent transcription factors 
 A major advance in the field of oxygen sensing has been the discovery of the 
family of hypoxia-inducible transcription factors (HIFs). HIFs are heterodimeric 
transcription factors, each composed of one of the 3 oxygen-sensitive HIFalpha 
subunits (HIF1alpha, HIF2alpha and HIF3alpha) and the oxygen-insensitive and 
constitutively expressed HIFbeta subunit (ARNT, figure 1.7).  
1.4.3.1 Oxygen-dependent regulation of HIF  
In normoxic condition HIFs are continuously and rapidly hydroxylated by 3 
different catalyzing prolyl-4-hydroxylase isoforms (PHD 1-3) in a reaction that 
has an absolute requirement for molecular oxygen as a co-substrate (figure 
1.7)(Bruick and McKnight, 2001). Hydroxylation of proline residues changes the 
conformation of HIF1a and increases its affinity for the von Hippel Lindau protein 
(pVHL) and other factors including elongin B and elongin C (Kibel et al., 1995), 
Cullin 2 (Pause et al., 1997) and RBX1 (Iwai et al., 1999) which results in 
proteasomal proteolysis of HIF1a by the ubiquitin-proteasome pathway (Ivan et 
al., 2001; Maxwell et al., 1999). Normoxia also stimulates binding of ARD1 to 
HIF1a (Jeong et al., 2002) which acetylates lysine 532 in the oxygen-dependent 
degradation domain of HIF1a and thereby increases the interaction between HIF 
and VHL and promotes proteasomal degradation of HIF1a (Sharp and 
Bernaudin, 2004). In addition, HIF alpha subunits are hydroxylated at a specific 
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asparaginyl residue by another member of the 2-oxoglutarate-dependent-
oxygenase superfamily, which was originally identified as a protein that binds 
HIF and was named factor inhibiting HIF (FIH) (Mahon et al., 2001). This 
asparaginyl hydroxylation abrogates the interaction between HIF1 and the 
transcriptional co-activator p300/CBP and provides a second oxygen-regulated 
mechanism by which HIFa molecules that escape the prolyl-
hydroxylation/degradation pathway are prevented from activating gene 
transcription.  
 
Under hypoxic conditions in contrast, prolyl hydroxylation is suppressed and 
HIFa subunits escape pVHL mediated degradation (Bruick and McKnight, 2001). 
Consequently, the alpha unit accumulates to high levels and is translocated to 
the nucleus where it dimerises with the beta unit (figure 1.7). The HIF1a/HIF1b 
dimer binds to p300/CBP and activates the hypoxia response element in various 
hypoxia-responsive target genes. This triggers the transcription of many genes 
that facilitate adaptation to low oxygen conditions including those encoding for 
vascular endothelial growth factor (VEGF) (Forsythe et al., 1996), inducible 
nitric-oxide synthase (iNOS) (Melillo et al., 1995), erythropoietin (EPO) (Wang 
and Semenza, 1996), endothelin-1 (ET-1) (Hu et al., 1998) and many others 
(table 1.1) (Sharp and Bernaudin, 2004). Although the increase of HIF1a in 
hypoxia is mainly controlled by the inhibition of the VHL degradation pathway, 
hypoxia was also shown to increase HIF1a translation by stabilisation of HIF 
mRNA in certain cell types (Bergeron et al., 1999).  
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1.4.3.2 Oxygen-independent regulation of HIF1a  
Although originally named hypoxia-inducible factor, there is compelling evidence 
that HIFs can be activated by conditions other than hypoxia, such as ischaemic 
and inflammatory processes (Dalgard et al., 2004; Lu et al., 2002; Olson and 
van, V, 2011; Ren et al., 2011). HIF1a can be stabilised by lactate, pyruvate, 
and oxaloacetate independently of hypoxia (Dalgard et al., 2004; Lu et al., 2002; 
Ren et al., 2011). Moreover, nitric oxide was shown to stimulate HIF1a 
accumulation under normoxia by inhibition of prolyl-hydroxylases (Metzen et al., 
2003). The relationship between HIF1a and NO, however, is controversially 
discussed as NO has also been reported to induce an increase in prolyl-
hydroxylase-dependent degradation of HIF1a (Hagen et al., 2003). Furthermore 
various cytokines were reported to increase HIF1a levels, including insulin-like 
growth factor 1 (IGF1), interleukin-1ß (IL-1ß), transforming growth factor-ß 
(TGFß), tumour-necrosis factor- (TNF), insulin, and heregulin (Sharp and 
Bernaudin, 2004). The translation of HIF1a mRNA into protein is controlled by 
the phosphatidylinositol 3-kinase (PI3K)–AKT–FKBP12-rapamycin associated 
protein (FRAP) which is the mammalian target of rapamycin (mTOR) pathway 
and can be activated by various growth factors and cytokines (Treins et al., 
2002).  
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Figure 1.7 Oxygen dependent regulation and target genes of HIF1a. A) In normoxia, HIFa is 
hydroxylated by ‘factor inhibiting HIF’ (FIH-1) and prolyl-hydroxylase enzymes (PHD1-3). In 
addition, ARD1 acetylates lysine (L) 532 in HIFa to facilitate binding to the von Hippel Lindau 
protein (VHL) which promotes proteasomal degradation of HIF1a. B) Under hypoxic condition, 
hydroxylation of HIFa does not occur, which prevents VHL binding and HIFa degradation. HIFa 
accumulates in the cytosol and is translocated to the nucleus where it dimerises with HIF1b and 
activates hypoxia-response element in various target genes resulting in numerous adaptive 
responses to redress hypoxia. 
 
  
50 
 
1.4.3.3 Localisation and target genes of HIFa isoforms 
HIF1a and HIF2a are expressed in different cells or tissues, resulting in 
activation of different target genes with non-overlapping functions. Whereas 
HIF1a is ubiquitously expressed and participates in most of the chronic cellular 
responses to low oxygen levels, HIF2a was originally thought to be restricted to 
endothelial cells and therefore initially named endothelial PAS domain protein 1 
(EPAS, (Tian et al., 1997)). Recent work, however, has shown that HIF2a is 
more widely expressed than previously thought and is expressed in non-
endothelial derived tissues such as lung, kidney, olfactory epithelium and 
adrenal gland (Lofstedt et al., 2007). Both HIF1a (Iyer et al., 1998) and HIF2a 
knockout mice (Tian et al., 1998) die in mid-gestation, with multiple 
cardiovascular malformations and mesenchymal cell death, showing that each 
gene has critical and non-redundant functions. Although HIF1a and HIF2a 
subunits are structurally similar in their dimerisation domains and DNA binding 
sites, they differ in their transactivation domains, which results in specific target 
gene regulation (Hu et al., 2007). Whereas HIF1a specifically regulates 
glycolytic genes (Hu et al., 2003; Wang et al., 2005) as well as carbonic 
hydrase-9 (Grabmaier et al., 2004) and BNIP3 (Raval et al., 2005), HIF2a 
exclusively regulates other factors such as the transcription factor Oct-4, cyclin 
D1, and TGF-α (Gunaratnam et al., 2003). Other hypoxia-inducible genes, such 
as vascular endothelial growth factor (VEGF), facilitated glucose transporter-1 
(GLUT1), adipose differentiation-related protein, adrenomedullin are regulated 
by both HIF1a and HIF2 (Hu et al., 2003). The role of HIF3a is poorly 
understood, but may regulate the activity of other HIFa isoforms as a dominant 
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negative regulation of HIFmediated control of gene expression (Makino et al., 
2001). 
1.4.3.4 HIF activation in the retina 
Hypoxia-inducible transcription factors are activated in the retina both in 
development and disease. During retinal vascular development Hif1a is co-
localised with Vegf in ganglion cells and cells along the inner border of the 
neuroblastic layer of mice which is consistent with a role in hypoxia, Vegf 
expression and physiological angiogenesis (Kurihara et al., 2010; Ozaki et al., 
1999). Conditional inactivation of Hif1a in the peripheral retina results in arrested 
formation of the intermediate vascular plexus in the peripheral retina (Caprara et 
al., 2011), whereas an increase of Hifs in the neuroretina leads to dysmorphic 
retinal vascular development and persistence of embryonic vascular structures 
into adulthood (Kurihara et al., 2010; Lange et al., 2011). In healthy human and 
rat retina, HIF1a is detectable in the ganglion cell layer, inner nuclear layer, and 
outer nuclear layer suggesting that active HIF1a signalling occurs constitutively 
and has a physiological role in the human retina (Hughes et al., 2010). In 
addition to the physiological functions of Hifs in the retina there is accumulating 
evidence that HIFs also play a critical role in the pathogenesis of hypoxia 
associated retinal vascular disease (see chapter 1.6).  
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Role  HIF target genes  Reference 
Vasomotor control      
 Adrenomedullin (ADM)  (Cormier-Regard et al., 1998) 
 Nitric oxide synthase 2 (eNOS)  (Palmer et al., 1998) 
 Nitric oxide synthase 3 (iNOS)  (Melillo et al., 1995) 
 α1B adrenergic receptor  (Eckhart et al., 1997) 
 Endothelin 1 (ET1)  (Hu et al., 1998) 
 Tyrosin Hydroxylase (Millhorn et al., 1997) 
  Atrial natriuretic peptide (Chun et al., 2003) 
Angiogenesis      
 Vascular endothelial growth factor (VEGF)  (Forsythe et al., 1996) 
 FLT1 (VEGF receptor 1, VEGFR1)  (Gerber et al., 1997) 
 Platelet-derived growth factor B (Kelly et al., 2003) 
  Plasminogen-activator inhibitor-1 (Kietzmann et al., 1999) 
 Apelin (Ronkainen et al., 2007) 
Hormonal regulation/ Erythropoiesis     
 Connective tissue growth factor (CTGF) (Higgins et al., 2004) 
  Erythropoietin (EPO)  (Wang and Semenza, 1993) 
Iron metabolism      
 Transferrin  (Rolfs et al., 1997) 
 Transferrin receptor  (Tacchini et al., 1999) 
  Ceruloplasmin  (Mukhopadhyay et al., 2000) 
Cell cycle control     
 DMT1 (Wang et al., 2010) 
 p21 (WAF1/CIP1)  (Carmeliet et al., 1998) 
 Insulin-like growth factor 2 (IGF2)  (Feldser et al., 1999) 
 IGFBP1, IGFBP2, IGFBP3 (Tazuke et al., 1998) 
 Endoglin (Sanchez-Elsner et al., 2002) 
 Wilms’ tumour suppressor (Wagner et al., 2003) 
  α-Fetoprotein (negative regulation) (Mazure et al., 2002) 
Cell death      
 Calcitonin-receptor-like receptor (Nikitenko et al., 2003) 
  NIP3, NIX  (Bruick, 2000) 
 P53 (An et al., 1998) 
Cell migration     
  CXCR4 (Staller et al., 2003) 
Energy metabolism      
 Glucose transporters 1 and 3 (GLUT1, GLUT3) (Ebert et al., 1995) 
 Prolyl-4-hydroxylase α1  (Takahashi et al., 2000) 
 Phosphofructokinase  (Semenza et al., 1994) 
 Lactate dehydrogenase A  (Semenza et al., 1994) 
 Aldolases A and C (Semenza et al., 1994) 
 Pyruvate kinase M  (Semenza et al., 1994) 
 Enolase 1  (Semenza et al., 1994) 
 Hexokinases 1 and 2  (Iyer et al., 1998) 
 Pyruvate dehydrogenase kinase (Kim et al., 2006) 
 Monocarboxylate transporter 4 (Ullah et al., 2006) 
 Cytochrome oxidase isoform 2 (Fukuda et al., 2007) 
 Glyceraldehyde phosphate dehydrogenase  (Graven et al., 1999) 
  6-phospho-2-kinase/fructose 2,6 bisphosphatase (Minchenko et al., 2003) 
Miscellaneous      
 Plasminogen activator inhibitor (PAI1) 38 (Kietzmann et al., 1999) 
 Transforming growth factor β3 (TGFβ3) (Schaffer et al., 2003) 
 Haem oxygenase 1  (Lee et al., 1997) 
 Adenylate kinase 3  (O'Rourke et al., 1996) 
 Phosphoglycerate kinase 1  (Semenza et al., 1994) 
 Carbonic anhydrase 9  (Kaluz et al., 2002) 
 Leptin (Grosfeld et al., 2002) 
 Rab20 (Hackenbeck et al., 2011) 
Table 1.1 HIF target genes. 
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1.5 Adaptive responses to hypoxia in the retina 
Retinal hypoxia can cause retinal degeneration and neuroretinal dysfunction that 
lead directly to vision loss. The oxygen sensing mechanisms described above 
control adaptive responses that can help protect against ischaemic injury and 
redress hypoxia. These responses comprise rapid compensatory changes in 
blood flow and expression of numerous genes (table 1.2) that activate adaptive 
molecular and cellular mechanisms.  
1.5.1 Hypoxia-induced retinal vasodilatation 
The inner retinal vasculature responds promptly to acute hypoxia by increasing 
vessel diameter and blood flow and thereby oxygen supply to the inner retina 
{Papst, 1982 527 /id;Linsenmeier, 1992 442 /id;Frayser, 1974 684 /id}. In 
humans, hypoxia leads to dilatation of retinal arterioles and venules by 8-9% 
within minutes (Brinchmann-Hansen et al., 1989). Prolonged hypoxia, in humans 
at high altitude, can increase retinal vessel diameter by 24% (Rennie and 
Morrissey, 1975); retinal blood flow can increase by 89% within 2 hours and by 
174% after 7 weeks (Frayser et al., 1974). Choroidal blood flow is not 
significantly affected by moderate hypoxia suggesting that the choroidal 
circulation has excess capacity (Bosch et al., 2009; Kergoat et al., 2005). 
However, a substantial drop in venous oxygen saturation, such as can occur at 
prolonged high altitude, can induce increased choroidal blood flow that promotes 
oxygen delivery to the outer retina (Bosch et al., 2009).  
The mechanisms that underlie hypoxia-induced vasodilatation involve changes 
in ion permeability in vascular smooth muscle cells and local generation of 
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vasoactive mediators (Pournaras et al., 2008). Various vasoactive compounds 
such as nitric oxide, hydrogen oxide, K+, adenosine, GABA, adrenomedullin, 
excitatory amino acids and many others have been suggested as potential 
mediators of hypoxia-induced vasodilatation. Furthermore, it has been shown 
that hypoxia stimulates glial cells to release a ‘retinal relaxing factor’ that 
induces retinal vasodilatation independent of NO by activating a membrane 
bound Ca2+/ATPase (Maenhaut et al., 2009). The direct link between hypoxia 
and the secretion of these factors has not been identified yet but may depend on 
changes in ATP levels and ion currents in hypoxic glial cells (Pournaras et al., 
2008).  
1.5.2 Hypoxia-induced retinal angiogenesis 
A causative association between retinal hypoxia and angiogenesis was first 
suggested by Michaelson and further explored by Wise who speculated that a 
hypoxia-induced growth factor “factor X” was responsible for inducing retinal 
neovascularisation (Michaelson et al., 1954; Wise, 1956). Many candidate 
mediators have since been identified and VEGF has emerged as a particularly 
powerful proangiogenic growth factor (Aiello et al., 1994).  
1.5.2.1 VEGF 
VEGFs are a family of growth factors, expressed as a number of splice isoforms 
that vary in length and affinity to heparin (Holmes and Zachary, 2005). VEGFs 
bind to 2 high affinity receptors, VEGFR1 (de et al., 1992) and VEGFR2 
(Millauer et al., 1993), promoting vascular permeability and proliferation of 
vascular endothelial cells in the eye (Miller et al., 1994), and facilitating the 
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migration of vessels by inducing the production of matrix metalloproteinases 
(Yancopoulos et al., 2000). VEGF signalling is essential for normal development 
of the retinal and choroidal vasculature (Marneros et al., 2005) and plays a 
central role in the pathogenesis and progression of common blinding disorders 
including diabetic retinopathy and age-related macular degeneration (AMD). 
Expression of VEGF and VEGFR1 is upregulated by activation of HIF1a in 
human retinal glial cells and RPE cells upon hypoxia (Liu et al., 2006; Zhang et 
al., 2007b). Hypoxia-induced upregulation of VEGF expression is inhibited by 
siRNA against HIF1a (Zhang et al., 2007b) and in retinal ischaemia by 
hyperoxia, presumably by promoting VHL-induced prolyl hydroxylation of HIFa 
(Pournaras et al., 1997). In the retina, increased levels of HIF1a precede VEGF 
upregulation and correlate both spatially and temporally with the development of 
retinal neovascularisation (Mowat et al., 2010). 
1.5.2.2 Other HIF dependent angiogenic growth factors 
In addition to mediating upregulated expression of VEGF and VEGFR1, HIFs 
promote the expression of several other proangiogenic factors in hypoxia, 
including adrenomedullin (ADM) (Cormier-Regard et al., 1998), plasminogen 
activator inhibitor (PAI) (Kietzmann et al., 1999), connective tissue growth factor 
(CTGF) and platelet-derived growth factor B (PDGFB)(Kelly et al., 2003). ADM 
is a ubiquitously expressed peptide initially isolated from phaechromyctoma 
(Kitamura et al., 1993) that protects endothelial cells against apoptosis (Ribatti 
et al., 2005). It is secreted from cultured human RPE in hypoxia (Udono et al., 
2000) and associated with attenuation of ischaemia-induced injury (Zhu et al., 
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2008). Platelet-derived growth factor B (PDGFB) is a potent mitogen for cells of 
mesenchymal origin. PDGFB elicits a variety of cellular responses including the 
migration, differentiation and function of a variety of specialised mesenchymal 
and migratory cell types, both during development and in the adult animal (Hoch 
and Soriano, 2003). Intraocular injection of adenovirus expressing a 
constitutively active form of HIF1a results in increased levels of PDGF-B in the 
eye which is associated with the formation of retinal neovascularisation (Kelly et 
al., 2003). CTGF controls growth, adhesion and survival of vascular endothelial 
cells (Perbal, 2004). Plasminogen activator inhibitor is the principal inhibitor of 
fibrinolysis and has been associated with promoting angiogenesis (Agirbasli, 
2005). Both CTGF and PAI-1 levels are upregulated by hypoxia in cultured 
human RPE cells via HIF1a (Fuchshofer et al., 2009). The in vivo function of 
these molecules in the retina, however, is not well-defined and further studies 
will be necessary to elucidate their role in hypoxia driven physiological and 
pathological angiogenesis.  
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Increased retinal activity upon hypoxia  
Proteins species reference 
HIF1a rat (Kaur et al., 2006) 
HIF2a mouse (Thiersch et al., 2008) 
NMDAR1 rat (Kaur et al., 2006) 
NMDAR2D rat (Crosson et al., 2009) 
NMDAR2C rat (Crosson et al., 2009) 
CCR2 rat (Sivakumar et al., 2011) 
GluR2 rat (Kaur et al., 2006) 
GluR3 rat Kaur et al., 2006) 
VEGF rat (Kaur et al., 2009) 
IGF-I  rat (Sivakumar et al., 2008) 
IGF-II rat (Sivakumar et al., 2008) 
Ang-2 rat (Sivakumar et al., 2008) 
nitric oxide rat (Kaur et al., 2006) 
iNOS rat (Kaur et al., 2006) 
eNOS rat (Kaur et al., 2006) 
nNOS, rat (Kaur et al., 2006) 
iNOS  rat (Kaur et al., 2006) 
Flk1 rat Crosson 2009 
Erythropoietin rat Crosson 2009 
TNF-α rat (Sivakumar et al., 2011) 
TNF-receptor 1 rat (Sivakumar et al., 2011) 
IL-1β, rat (Sivakumar et al., 2011) 
IL-1 receptor 1 rat (Sivakumar et al., 2011) 
MCP-1 rat (Sivakumar et al., 2011) 
   
Decreased retinal activity upon hypoxia 
PEDF rat (Sivakumar et al., 2008) 
 
Table 1.2 Hypoxia-induced molecular mediators in the retina. 
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1.5.3 Hypoxia-induced neuroprotection 
1.5.3.1 Erythropoietin 
Accumulating evidence indicates that HIFdependent expression of erythropoietin 
(EPO) can protect the retina against ischaemic injury. EPO is a glycoprotein 
produced in hepatocytes during development and by renal interstitial fibroblasts 
in the adult, in an oxygen-dependent manner controlled by HIF1a (Wang and 
Semenza, 1993). It acts as a hormone to regulate production of red blood cells 
in the bone marrow by preventing apoptosis of erythroid progenitor cells. In 
addition to its known function of stimulating haematopoiesis, EPO is expressed 
in many other adult tissues, including the spleen, the brain and the retina 
indicating a paracrine function (Fandrey, 2004). EPO and its receptor are 
expressed in the human retinal pigment epithelium and to some extend in the 
neuroretina (Garcia-Ramirez et al., 2008). Hypoxia-induced stabilisation of both 
HIF1a and HIF2a is associated with increased EPO expression in the eye 
(Grimm et al., 2002; Mowat et al., 2010). Activation of EPO receptors, which are 
expressed in photoreceptors (Grimm et al., 2002) and in the ganglion cell layer 
in rodents (Zhong et al., 2008), lead to autophosphorylation and activation of 
multiple signal transduction pathways including the Jak/STAT5 and AKT 
pathways that have multiple effects on gene transcription, caspase activation 
and inflammation (Li et al., 2004). EPO protects neuronal cells in vitro and in 
vivo by reducing nitric oxide-induced free radical damage (Sakanaka et al., 
1998). Endogenous EPO is implicated in hypoxic preconditioning that protects 
photoreceptors against light-induced apoptosis (Grimm et al., 2002; Junk et al., 
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2002) and can protect the retina against ischaemia-induced dysfunction (Mowat 
et al., 2010). Systemic EPO supplementation protects ganglion cells against 
ischaemia (Junk et al., 2002) and can protect the retinal vasculature against 
oxygen-induced vaso-obliteration (Chen et al., 2009). Reduction in local EPO by 
inhibition of HIF1a using the drug YC-1 (3-5'-hydroxymethyl-2'-furyl-1-
benzylindazole) is associated with inhibition of retinal neovascularisation 
(DeNiro et al., 2010).  
1.5.4 Hypoxia-induced adaption of retinal metabolism 
1.5.4.1 Glucose metabolism  
A critical adaptation to hypoxia is the ability of cells to utilise glucose by means 
other than mitochondrial oxidative phosphorylation, for which oxygen is an 
absolute requirement. Hypoxic activation of HIF1a shifts energy production from 
mitochondrial to glycolytic sources by inducing a wide range of genes involved in 
glucose metabolism (table 1.1) including GLUT1 that promotes glucose 
transport into the hypoxic cell (Badr et al., 1999; Ebert et al., 1995). In addition, 
HIF1a promotes expression of enzymes responsible for the glycolysis of 
intracellular glucose such as aldolase A (Iyer et al., 1998), hexokinases 1 and 2, 
phosphofructokinase 1 (Brahimi-Horn et al., 2007; Denko, 2008) and lactate 
dehydrogenase A. Under normoxic conditions pyruvate can be metabolised by 
oxygen-dependent mitochondrial oxidative phosphorylation to generate ATP 
efficiently. In hypoxia, however, pyruvate is converted by lactate dehydrogenase 
to lactate with less efficient generation of ATP. Hypoxic activation of HIF1a also 
downregulates mitochondrial function and oxidative phosphorylation by 
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promoting the expression of genes such as pyruvate dehydrogenase kinase 1 
(Papandreou et al., 2006) and MAX interactor 1 (Zhang et al., 2007a) ultimately 
leading to reduced oxygen demand and consumption. The effect of these 
mechanisms is to compensate for hypoxia by reducing the oxygen demand 
while maintaining a supply of energy. In the retina, hypoxia induces an increase 
in extracellular concentration of lactate and increased utilisation of glucose 
(Doberstein et al., 1994). Lactate and glucose accumulates in the vitreous in 
proliferative diabetic retinopathy (Barba et al., 2010) and induction of hypoxia-
responsive genes by cobalt chloride increases the expression of GLUT1 in the 
neuroretina.  
 
1.6 Clinical significance of hypoxia in the retina 
Retinal hypoxia has been associated with major causes of blindness including 
diabetic retinopathy, vascular occlusive disease, age-related macular 
degeneration and retinopathy of prematurity (Fulton et al., 2009; Stefansson, 
2006; Stefansson et al., 2010). A common sequela to retinal hypoxia is the 
formation of aberrant new vessels which can lead to visual loss by increased 
vascular permeability causing retinal oedema, vascular fragility leading to 
haemorrhage, or fibrovascular scarring resulting in retinal detachment (Dorrell et 
al., 2007).  
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1.6.1 Age-related macular degeneration 
Age-related macular degeneration (AMD) is the leading cause of blindness in 
people over the age of 60 in the western world (Congdon et al., 2003) and has 
been estimated to affect 18.5% among those 85 years or older (Mitchell et al., 
1995). The etiology of AMD involves a complex interaction of genetic 
susceptibility, oxidative stress, environmental influences and inflammatory 
processes (Ding et al., 2009). Early signs of AMD include the presence of 
drusen and alterations of the RPE which can be followed by RPE atrophy (figure 
1.10A), central retinal degeneration and a chronic, slow progressing loss of 
central vision. Approximately 10%–15% of all AMD patients convert to the 
exudative form of AMD which is defined by the development of choroidal 
neovascular membranes that result in the formation of subretinal fluid, 
haemorrhage and acute visual loss (figure 1.10B) (Tielsch et al., 1995). Current 
treatment options include laser photocoagulation, photodynamic therapy and 
anti-VEGF agents such as pegaptanib sodium and ranibizumab which have 
been approved for the treatment of neovascular AMD (Chiang and Regillo, 
2011). 
Accumulating evidence indicates that hypoxia is involved in the development 
and progression of age-related macular degeneration (Stefansson et al., 2010). 
Individuals with AMD are more likely to have reduced choroidal perfusion 
(Grunwald et al., 1998; Grunwald et al., 2005; Metelitsina et al., 2008) or 
watershed perfusion defects (figure 1.10C) (Chen et al., 2001) which is 
associated with a dropout of choroidal capillaries adjacent to active choroidal 
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neovascularisation (figure 1.10D) (McLeod et al., 2009). Thickening of Bruch’s 
membrane and the formation of subretinal drusen increase the distance 
between the choroid and photoreceptors and may further limit oxygen availability 
(Bird, 1993; Stefansson et al., 2010). Hypoxia-induced expression of VEGF 
might paradoxically even exacerbate hypoxia by inducing accumulation of 
subretinal fluid which further increases the distance between the photoreceptors 
and the choroid (Stefansson et al., 2010). Hypoxia-induced activation of HIF 
signalling in the RPE and photoreceptors has been proposed to promote 
choroidal neovascularisation in AMD (figure 1.10E). HIF1a, HIF2a and VEGF 
expression was shown to be evident in RPE and CNV membranes (Inoue et al., 
2007; Sheridan et al., 2009), with activation of HIF2a particularly prominent 
(Sheridan et al., 2009). However, little is known about the consequences of HIF 
activation in the RPE on the retina and its vasculature in vivo. This work 
therefore aims to study the function of Vhl and Hif1a in the RPE and to 
determine the consequence of Hif activation in the RPE using a tissue-specific 
conditional-knockout approach in mice. 
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Figure 1.10 Clinical features of age-related macular degeneration. Color fundus images 
showing a large area of choroidal and pigment epithelial atrophy (A) and a subretinal 
haemorrhage from submacular neovascular fronds (B). ICG angiography demonstrating a 
central watershed zone with decreased choroidal perfusion (C) which is associated with a 
choroidal neovascularisation in its center (D, late phase). E) Schematic demonstrating the 
postulated role of hypoxia and HIF signalling in the progression of AMD (Stefansson et al., 
2010). Images adapted from www.atlasofophthalmology.com. 
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1.6.2 Diabetic retinopathy 
Diabetic retinopathy (DR) is one of the most frequent and severe complications 
of diabetes mellitus with an estimated 30-45% prevalence of all diabetics 
worldwide (International Diabetes Federation). Diabetic retinopathy is the most 
common cause of blindness in middle-aged subjects accounting for at least 
12.000 new cases in the US (Congdon et al., 2003) and for 1.500 new cases in 
the UK per year (Cormack et al., 2001). Diabetic retinopathy is caused by 
prolonged high blood glucose levels which can result in pericyte loss, oxidative 
stress and microvascular occlusion that commonly lead to hypoxia and 
ischaemia restricted to the inner retina. Early clinical signs of diabetic 
retinopathy include increased capillary permeability, haemorrhages and the 
formation of microaneurysms and capillary dilatation adjacent to areas of 
capillary nonperfusion (Pfister et al., 2008). As the disease progresses, the 
development of macular oedema, preretinal neovascularisation, haemorrhages, 
tractional retinal detachment can cause severe visual loss (figure 1.8). To this 
date the only approved therapy to prevent the development and progression of 
DR is a good glycemic control (UKPDS group, 1998). In more severe cases, 
such as advanced non-proliferative diabetic retinopathy and proliferative diabetic 
retinopathy, argon-laser retinal photocoagulation may be indicated which can 
result in a regression of the newly formed vessels (DRSR group 1981). Although 
effective, panretinal photocoagulation can cause severe adverse effects 
including decreased night vision, constricted visual field, persistent dilation of the 
pupil, or transient oedema of the retina. Refractory cases with PDR frequently 
require surgical intervention by pars plana vitrectomy which results in a 
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reduction of macular oedema and neovascularisation (Tachi and Ogino, 1996). 
Insight into the molecular mechanisms of neovascular eye disorders has 
provided new approaches for pharmacological treatment, i.e. the intravitreal 
application of antiangiogenic substances. Even though several antiangiogenic 
drugs such as the VEGF binding aptamer pegaptanib (Adamis et al., 2006; 
Cunningham, Jr. et al., 2005), the VEGF binding antibody bevacizumab (Avery 
et al., 2006; Jiang et al., 2008; Mason, III et al., 2008; Moradian et al., 2008; 
Simo and Hernandez, 2008; Thew, 2009) or its fragment ranibizumab (Chun et 
al., 2006) have promising effects and are already in clinical trials (e.g. 
NCT00407381, NCT00545870), an ideal pharmaceutical therapy to treat PDR 
has not yet been found.  
Substantial evidence indicates important roles for HIF signalling and hypoxia in 
the pathogenesis and progression of diabetic retinopathy. Hif1a is upregulated 
by hyperglycemia in rodents (Li et al., 2006; Lin et al., 2011), and Hif2a is 
upregulated in the retina of mice with diabetes (Wright et al., 2010). In humans, 
the concentrations of both HIF1a and VEGF are increased in the vitreous of 
patients with proliferative diabetic retinopathy and correlate with disease activity 
(Wang et al., 2009). Other HIF1a-dependent downstream molecules such as 
EPO (Inomata et al., 2004), soluble VEGF receptor (Matsunaga et al., 2008) and 
CTGF (Kuiper et al., 2008) are increased in the vitreous of subjects with 
proliferative diabetic retinopathy. Furthermore, immunohistochemistry studies 
demonstrated a strong staining for HIF1a on surgically excised fibrovascular 
membranes from subjects with proliferative diabetic retinopathy (bu El-Asrar et 
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al., 2007; Lim et al., 2010). Taken together, these findings strongly suggest that 
HIFs are involved in the pathogenesis and progression of diabetic retinopathy by 
promoting adaptive responses to tissue hypoxia including the secretion of 
proangiogenic factors such as EPO, CTGF and VEGF.  
The cellular origin of proangiogenic cytokines and their upstream regulators in 
DR, however, is still poorly understood. Increasing evidence suggests that 
activated myeloid cells, such as macrophages and microglial cells, accumulate 
in the inner retina of early DR and contribute to the development of retinal 
neovascularisation (Zeng et al., 2008a). Systemic depletion of macrophages by 
clodronate liposomes significantly reduces VEGFA levels as well as the 
development of retinal neovascularisation in mouse models of oxygen-induced 
retinopathy (OIR) (Kataoka et al., 2011). These data raised the possibility that 
myeloid cells are activated in DR and promote the development of retinal 
neovascularisation by releasing angiogenic factors such as VEGFA. Yet, the 
role of Hif1A and its contribution to Vegfa expression in myeloid cells recruited to 
sites of retinal neovascularisation has not been defined. This work therefore 
aims to explore the roles of myeloid cell derived Hif1a and Vegf in the 
development of retinal neovascularisation in the OIR mouse model by studying 
transgenic conditional knockout mice (see chapter 4).  
Areas of capillary nonperfusion and decreased retinal blood flow detected by 
fluorescein angiography in early diabetic retinopathy (Kawagishi et al., 1995; 
Konno et al., 1996) have led to the current hypothesis that inner retinal hypoxia 
is a critical component in the pathogenesis and progression of diabetic 
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retinopathy (D'Amore, 1994; WISE, 1956). Direct evidence of tissue hypoxia in 
human diabetic retinopathy, however, is sparse and most of our knowledge is 
derived from experiments using diabetic animal models. Inner retinal oxygen 
tension is reduced by half in cats with long-term diabetes before capillary 
dropout is evident, suggesting that inner retinal hypoxia is preceding 
morphological changes (Linsenmeier et al., 1998). Furthermore hypoxia is 
evident in diabetic rats on magnetic resonance imaging (Trick and Berkowitz, 
2005) and in diabetic mice on immunohistochemistry using the oxygen-
dependent chemical probe pimonidazole (de Gooyer et al., 2006). Indirect 
evidence of the role of hypoxia in early diabetic retinopathy in man includes 
hyperoxia-induced reversal of electroretinographic changes (early oscillatory 
potential reduction) (Drasdo et al., 2002), ameliorated contrast sensitivity deficit 
(Harris et al., 1996) and reduced macular oedema (Nguyen et al., 2004). 
Oxygen tension measured using an optical oxygen probe in humans with 
diabetes is reduced in the mid-vitreous, a site which is believed to reflect global 
oxygenation of the retina (Holekamp et al., 2005). The distribution of oxygen 
across the human vitreous and retina and its relation to vitreous HIF1a and 
cytokine levels in PDR, however, is not well defined and will be further explored 
in this thesis.  
 
. 
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Figure 1.8 Clinical features of proliferative diabetic retinopathy. Color fundus images (A,C), 
fluorescein angiograms (B,D) and histological sections (D,E) showing preretinal 
neovascularisation (*) that typically occur at the disc and along the arcades close to ischaemic 
areas (**). Images adapted from www.atlasofophthalmology.com. 
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1.6.3 Vascular occlusive disease 
Retinal vascular occlusive diseases develop when terminal veins or arteries are 
blocked resulting in hypoperfusion and hypoxia of the inner retina. Central retinal 
vein occlusion (CRVO) and branch retinal vein occlusion (BRVO) are found in 
individuals over 50 years old and are associated with common cardio-metabolic 
risk factors such as diabetes mellitus, systemic hypertension and atherosclerotic 
cardiovascular disease (Rodriguez et al., 2010). Central and branch retinal vein 
occlusion are caused by a thrombus which blocks retinal perfusion (Laatikainen, 
1976). The ischaemic forms of central retinal vein occlusion, hemi-central retinal 
vein occlusion and branch retinal vein occlusion all frequently lead to the 
formation of retinal neovascularisation and a poor visual outcome (figure 1.9A-B) 
(Hayreh et al., 1983; Hayreh and Podhajsky, 1982). Arterial occlusions cause an 
abrupt reduction in retinal blood flow and occur mostly as a result of 
atherosclerosis or an embolic event. The most common site of obstruction is the 
central retinal artery behind the lamina cribrosa (figure 1.9C-D). Whereas central 
retinal artery occlusion causes a widespread loss of vision, branch retinal artery 
occlusion causes a segmental loss of vision. Nonperfusion of the inner retinal 
vasculature compromises the energy and oxygen supply to the retina, which, if 
prolonged, leads to permanent retinal degeneration. The prognosis for vision is 
poor, as even after restoration of perfusion, recovery of vision is minimal 
(Hayreh et al., 1983). 
Both central and branch retinal vein occlusion have been associated with a 
variable degree of capillary nonperfusion on fluorescein angiography (Hayreh, 
70 
 
2005; Laatikainen, 1976) and tissue hypoxia in the inner retina (Hardarson and 
Stefansson, 2010; Yoneya et al., 2002). Experimental retinal vascular occlusion 
in animal models results in inner retinal ischaemia and hypoxia (Bardy and 
Tsacopoulos, 1978; Pournaras et al., 1985; Pournaras et al., 1990a; Stefansson 
et al., 1981) resulting in anoxic cell death (Donati et al., 2008) and a rapid failure 
of neuroretinal function (Zhang et al., 2008). In some animal models retinal 
hypoxia was followed by the formation of retinal neovascularisation and 
extracellular oedema similar to the one observed in human (Pournaras et al., 
1990a). In humans, central retinal vein occlusion is associated with reduced 
mid-vitreous oxygen levels (Williamson et al., 2009); while venular oxygen 
saturation is reduced arteriolar saturation can be relatively spared (Hardarson 
and Stefansson, 2010). In central retinal vein occlusion, hypoxia and vitreous 
upregulation of VEGF (Noma et al., 2011) and EPO (Stahl et al., 2010), are 
consistent with retinal activation of the HIF pathway. 
To date there is no known effective medical treatment available for either the 
prevention of or the treatment of vascular occlusive disease. Fibrinolytic therapy 
is of limited use in the treatment of these diseases as emboli are frequently not 
fibrin based (Hayreh, 2005). Current treatment options for retinal 
neovascularisation in vascular occlusive disorders include panretinal laser 
photocoagulation or in severe cases pars plana vitrectomy. New approaches for 
pharmacological treatment include the intravitreal application of antiangiogenic 
substances, such as anti-VEGF or corticosteroids to reduce retinal oedema 
(Rehak and Wiedemann, 2010). Even though several antiangiogenic drugs 
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seem to have promising effects and are already in clinical trials (e.g. 
NCT01028248) an ideal pharmaceutical therapy to treat vascular occlusive 
disease has not yet been found. 
 
 
 
  
Figure 1.9 Clinical features of retinal vascular occlusive disease. Color fundus images (A,C) 
and correspondent fluorescein angiograms (B,D) of a branch retinal vein occlusion (A,B) and a 
central artery occlusion (C,D) showing areas of retinal neovascularisation (**) and nonperfusion 
(*). NB Perfused cilioretinal artery (D) which is present in 33% of eyes and nourished by the 
short posterior ciliary artery independent of the central artery. Images adapted from 
www.atlasofophthalmology.com. 
  
72 
 
1.6.4 Retinopathy of prematurity 
Retinopathy of prematurity (ROP) is a major cause of blindness in children in the 
developed and developing world (Gilbert, 2008). It was first identified by Terry in 
1942 and associated with premature birth and slightly later with oxygen 
supplementation in premature infants (Terry, 1944). Following the advent and 
progress of neonatology, infants with very low birth weight survive today and 
account for the substantial number of new cases of ROP in recent years 
(Palmer, 1996). Retinopathy of prematurity is a biphasic disease consisting of an 
initial phase of vessel growth cessation followed by a second phase of vessel 
proliferation. The first phase of ROP occurs from birth to postmenstrual age of 
30-32 weeks. As the human retina is vascularised in the final trimester of 
gestation, the retina of prematurely born infants is incompletely vascularised 
with an avascular periphery. In this phase prematurely born babies are exposed 
to hyperoxia for pulmonary reasons which can cause growth retardation of 
retinal vessels. As the infant matures, the retina becomes increasingly 
metabolically active resulting in tissue ischaemia and hypoxia in the avascular 
periphery. The second phase of ROP begins around 32-34 weeks postmenstrual 
age and is associated with hypoxia-induced formation of retinal 
neovascularisation which can extend into the vitreous causing tractional retinal 
detachment and severe visual complications (Patz, 1968). For prognostic and 
therapeutic reasons staging of the disease was proposed based on the 
presence of a demarcation line (stage 1), the formation of an elevated ridge at 
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the demarcation (stage 2), preretinal fibrovascular proliferation (stage 3) and 
retinal detachment (stage 4, figure 1.11 A-H (ICROP, 2005))  
Substantial evidence indicates an important role for HIF and its downstream 
factors VEGF and EPO in ROP. In the murine ROP model, both Hif1a and Hif2a 
signalling is increased in the avascular area (Mowat et al., 2010) and inhibition 
of Hif1a results in reduced Vegf and Epo levels which are associated with 
reduced retinal neovascularisation (DeNiro et al., 2010). 
To date, the only approved treatment for ROP is laser photocoagulation of the 
non-vascularised peripheral retina (Ng et al., 2002). Although this treatment can 
reduce the incidence of blindness by approximately 25% in infants with ROP, it 
is associated with poor visual acuity after treatment and significant risks 
including corneal oedema, intraocular haemorrhage and cataract formation 
(Chen et al., 2011). Because of the significant role of VEGF in inducing retinal 
neovascularisation in ROP (Sato et al., 2009), anti-VEGF treatment has been 
suggested as a promising treatment option for ROP (Mintz-Hittner et al., 2011). 
Recent advances in angiogenesis research have also suggested a number of 
new ways to potentially treat ROP, such as targeting IGF1 signalling (Hellstrom 
et al., 2001) and dietary supplementation with omega-3 polyunsaturated fatty 
acids (Stahl et al., 2011).  
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Figure 1.11 Clinical features of retinopathy of prematurity. Fundus photography 
demonstrating a demarcation line in ROP stage 1 (A), the ridge between vascularised and 
avascular retina (single long arrow) and small isolated vascular tufts (“popcorn”, short arrows) 
typical for ROP stage 2 (B), beginning fibrovascular infiltration of the vitreous (stage 3, C) and 
retinal detachment (stage 4, D). E-H) Corresponding drawings illustrating the key features of 
ROP stage 1-4. Adapted from (ICROP, 2005; J J Kanski, 1999).  
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1.7 Animal models of retinal hypoxia and neovascularisation 
Animal models of retinal ischaemia and hypoxia are used to learn more about 
disease mechanisms, its diagnostics and potential treatments. They include 
models of diabetic retinopathy, vaso-occlusive disease, retinopathy of 
prematurity and choroidal neovascularisation.  
1.7.1 Models of diabetic retinopathy 
Diabetes in animals can occur spontaneously in the context of obesity, 
hyperinsulinaemia and insulin resistance or can be induced by a variety of 
experimental procedures, e.g. by means of surgery, viral infection or the 
administration of hormones and chemical agents (Mordes and Rossini, 1981). A 
number of rodent models exhibit clinicopathological features of human diabetic 
retinopathy, such as streptozotocin induced rats (Hammes et al., 1998), 
galactose fed rodents (Kern and Engerman, 1996; Roy et al., 2003) and 
genetically modified mice (Cohen et al., 2008; Shinohara et al., 2000). Many of 
these rodent models develop pre-proliferative retinal disease such as increased 
vascular permeability, capillary basement membrane thickening, microaneurysm 
formation, functional abnormalities and neuronal loss (Aizu et al., 2002), and are 
used to study the biology and treatment of early diabetic retinopathy. Despite 
many attempts to develop suitable models that accurately reflect human diabetic 
eye disease, very few animal models develop the severe vasoproliferative forms 
of diabetic retinopathy (Kador et al., 1995; Yamada et al., 2005). This is likely to 
relate to the short duration of diabetes in rodent models in comparison with 
diabetes in humans.  
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1.7.2 Models of retinal vascular occlusions  
Retinal vascular occlusion can be induced in various rodent models by 
intravenous injection of a photoactive dye that is activated by laser exposure. 
Several models of retinal arterial (Braun and Linsenmeier, 1995; Yu et al., 2005) 
and venous (Miller et al., 1994; Yu and Cringle, 2001a) occlusions have been 
reported and were associated with increased inner retinal hypoxia, rapid 
neuronal degeneration and necrosis (Osborne et al., 2004). The induction of 
reproducible ischaemia and downstream abnormalities in these models, 
however, is difficult to attain and neovascularisation occurs only in a few models 
as a very late consequence of ischaemia (Tamura, 2001). Experimental models 
of vascular occlusion are therefore limited to examine retinal hypoxia and its 
downstream effects. 
1.7.3 Models of oxygen.-induced retinopathy 
Oxygen-induced retinopathy in the mouse and rat is a short term and 
reproducible model of hypoxic and ischaemic retinopathy (Penn et al., 1994; 
Smith et al., 1994). Exposure of neonatal animals to high concentrations of 
oxygen in the early postnatal period results in the development of central 
capillary vaso-obliteration which is associated with increased inner retinal 
hypoxia (Mowat et al., 2010) and the formation of retinal neovascularisation 
(Lange et al., 2007). The most commonly used mouse OIR model, the “75 
model” (Smith et al., 1994), involves exposure to 75% oxygen from p7-p12. This 
mouse model demonstrates central retinal vaso-obliteration in contrast to a 
peripheral location in human ROP and rat OIR (Smith et al., 1994). This may be 
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because sufficient oxygen is supplied from the choroid at the thinner peripheral 
retina alongside the contribution of the hyaloid to peripheral retinal perfusion. In 
rodent OIR, neovascularisation can be quantified either by quantifying the area 
of neovascularisation and vaso-obliteration on vessel stained retinal flatmounts 
(Gardiner et al., 2005) or by serial section analysis of intravitreal vessels (Smith 
et al., 1994).  
1.7.4 Models of choroidal neovascularisation 
Models of choroidal neovascularisation include the laser-induced CNV model, 
models of injections of proangiogenic molecules and knockout or knockin 
transgenic mice. Based on the observation that choroidal neovascularisation can 
occur after argon laser photocoagulation in humans (Francois et al., 1975) 
Francois and Ryan (Ryan, 1979) developed a primate model to study the nature 
of choroidal neovascularisation. Since then the laser model has been adapted to 
monkeys, rabbits, (Kimura et al., 1995) rats, (Dobi et al., 1989) and mice 
(Balaggan et al., 2006; Dobi et al., 1989). In the laser-induced CNV model, 
argon laser photocoagulation of the posterior pole results in rupture of Bruch’s 
membrane and in CNV formation which is associated with an increased number 
of macrophages and the expression of proangiogenic factors (Sakurai et al., 
2003). Studies in monkeys have shown that the new vessels arise at the site of 
the laser and can infiltrate the subretinal space, or in a few instances enter the 
vitreous cavity (Archer and Gardiner, 1981b). Electron microscopy on laser-
induced CNV lesion has demonstrated that the new capillary sprouts are 
comprised of primitive endothelial tubes, pericytes, and a loose basement-
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membrane like material (Archer and Gardiner, 1981a). The laser-induced CNV 
model is by definition, more acute than age-related macular degeneration and 
does not reflect the pathogenesis of CNV formation in human AMD, although 
inflammation may play a role in each (Ryan, 1979). Despite many attempts to 
develop suitable models that develop spontaneous CNV formation, very few 
publications demonstrate convincing data. Okamoto et al. have reported the 
formation of retinal and subretinal neovascularisation in the rhodopsin-VEGF 
transgenic mice. The neovascularisation arose from the retinal vasculature 
rather than from the choroidal vasculature and this model may relate more 
closely to the human Retinal Angiomatous Proliferation (RAP), a variant of “wet” 
AMD (Okamoto et al., 1997). Lai et al. developed four human VEGF165 over-
expressing transgenic mouse lines driven by the rhodopsin promoter. The 
animals developed phenotypes ranging from mild to severe retinal 
neovascularisation but did not show any choroidal neovascularisation (Lai et al., 
2005). 
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1.8 Therapeutic intervention for retinal hypoxia 
1.8.1 Improving retinal perfusion and oxygen delivery 
Hypoxia resulting from disorders of retinal perfusion is addressed clinically by 
appropriately managing specific underlying causes. For example, 
endarterectomy is conventional management for carotid stenosis, and optimal 
management of blood glucose and blood pressure can slow progression of 
retinal vascular disease (Boscia, 2010; Rehak and Wiedemann, 2010). 
Experimental interventions for retinal vascular occlusions include radial optic 
neurotomy for CRVO, adventitial sheathotomy for BRVO, and embolectomy for 
BRAO. In addition to redressing perfusion deficits, the availability of oxygen to 
the retina may be enhanced by increasing supply or by reducing demand for 
oxygen itself. Increased oxygen delivery may be achieved by inhalation of 
hyperbaric or supplemental oxygen. Hyperbaric oxygen treatment is reported to 
ameliorate the blood-retinal barrier breakdown in diabetic retinopathy in rats 
(Chang et al., 2006). Supplemental inhaled oxygen for 3 months was associated 
with improved diabetic macular oedema (Nguyen et al., 2004). While these 
interventions are unlikely to provide practical treatment options, the findings 
provide further evidence of the importance of hypoxia in diabetic retinopathy.  
1.8.2 Improving inner retinal oxygenation by panretinal 
photocoagulation 
Panretinal photocoagulation (PRP) promotes regression of pathological retinal 
neovascularisation and is the conventional treatment for proliferative 
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retinopathies associated with chronic hypoxia. PRP causes thermal destruction 
of retinal pigment epithelial cells and adjacent photoreceptors, which are 
replaced by glial cells with relatively low oxygen consumption (Roider et al., 
1992; Thompson et al., 1996). Reduced local consumption of oxygen at sites of 
photocoagulation has been proposed to promote oxygen diffusion from the 
choroidal circulation to the inner retina and to relieve inner retinal hypoxia locally 
(Stefansson, 2006). Evidence supporting this hypothesis has been provided by 
studies in the cat (Stefansson et al., 1986), the pig (Pournaras et al., 1990b), the 
rabbit (Funatsu et al., 1997) and in the human (Stefansson et al., 1992). 
Application of PRP is followed by vascular constriction consistent with 
autoregulatory adaption to locally increased oxygenation (Gottfredsdottir et al., 
1993) and with reduction in VEGF and VEGF receptors levels in the vitreous 
(Aiello et al., 1994; Augustin et al., 2001). Although PRP offers a powerful 
technique to protect central vision against the consequences of retinal 
neovascularisation, conventional photocoagulation strategies cause predictable 
adverse impact on peripheral vision, contrast sensitivity and night vision, and 
safer alternative approaches are highly desirable. 
1.8.3 Improving inner retinal oxygenation by vitrectomy 
Vitrectomy can reduce retinal neovascularisation and macular oedema 
(Blankenship and Machemer, 1985; Hoerle et al., 2002) while increasing the rate 
of cataract formation and iris neovascularisation (Schachat et al., 1983; van 
Meurs et al., 1996). These clinical observations can be explained by changes in 
ocular oxygenation associated with the promotion of fluid currents in the vitreous 
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cavity (Stefansson, 2006). The vitreous gel has a relatively low oxygen tension, 
possibly maintained by a high ascorbate content that acts as an oxygen sink to 
protect the lens from oxidative damage (Shui et al., 2009). The removal of 
vitreous gel and its replacement with aqueous facilitates diffusion of both oxygen 
and growth factors. Vitrectomy results in increased oxygen tension in the mid-
vitreous and is associated with accelerated development of nuclear sclerotic 
lens opacity (Holekamp et al., 2006). Vitrectomy may promote diffusion of 
oxygen to the retina from the anterior segment and possibly from better-
perfused areas of the retina to areas of retinal hypoxia (Stefansson et al., 1981). 
Conversely, increased clearance of hypoxia-induced vasoactive growth factors 
such as VEGF from the eye following vitrectomy may account for iris 
neovascularisation and neovascular glaucoma (Stefansson, 2009). 
 
1.8.4 Improving inner retinal oxygenation by maintaining light-
adaptation 
Arden and colleagues have suggested that inner retinal hypoxia in diabetes may 
be aggravated by dark adaptation because the metabolically-demanding dark 
current of photoreceptor cells in the outer retina reduces availability of oxygen to 
the inner retina (figure 1.5C). He further postulated that progression of diabetic 
retinopathy may be controlled by minimising dark adaptation to promote retinal 
oxygen availability (Arden et al., 1998). Preliminary reports suggest that 
application of trans-lid retinal illumination during sleep to one eye of subjects 
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with non-proliferative diabetic retinopathy is associated with improved outcome 
(Arden et al., 2010). 
1.8.5 Targeting adaptive responses to hypoxia 
VEGF is an attractive target in hypoxic and ischaemic eye disease as VEGF-
induced neovascularisation is disorganised and leaky and contributes 
significantly to visual loss. In recent years, three major anti-VEGF treatments 
have been developed and applied to ocular neovascularisation in a number of 
clinical trials.  
Pegaptanib sodium (Macugen™) is an RNA oligonucleotide aptamer that 
selectively inhibits the VEGF165 isoform (Fine et al., 2005; Ng and Adamis, 
2006). Treatment with pegaptanib was reported to improve visual outcome in 
neovascular AMD (Gonzales, 2005; Singerman et al., 2008) and diabetic 
macular oedema (Cunningham, Jr. et al., 2005). These studies suggest that 
pegaptanib is likely to be a safe and effective therapy. Pegaptanib has been 
approved by the FDA for the treatment of neovascular AMD and large scale 
prospective clinical trials into its use in other ischaemic eye diseases are 
ongoing.  
Ranibizumab (Lucentis™) is a humanised anti-VEGF antibody fragment 
targeting all isoforms of VEGF (Lowe et al., 2007). It has been shown to be an 
effective antiangiogenic treatment for the treatment of neovascular AMD (Brown 
et al., 2006; Brown et al., 2009; Chang et al., 2007; Regillo et al., 2008). Side 
effects after intravitreal injection of Ranibizumab include increase in intraocular 
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pressure, inflammation and progression development of cataract (Rosenfeld et 
al., 2005) (Brown et al., 2009). Ranibizumab was licensed for the treatment of 
neovascular AMD by the FDA in 2006 and large scale prospective clinical trials 
into its use in diabetic retinopathy are ongoing. 
Bevacizumab (Avastin™) is a monoclonal antibody targeting all isoforms of 
VEGF and was originally developed as a cancer therapeutic. The use of 
Bevacizumab in the treatment of neovascular eye disease is currently 
unlicensed but provides a cost effective alternative to ranibizumab (Michels et 
al., 2005). Systemic use of Bevacizumab has been associated with hypertension 
(Cobleigh et al., 2003; Hurwitz et al., 2004; Yang et al., 2003) and increased risk 
of thromboembolism possibly related to the drug’s effect on enhancing 
inflammation (Ratner, 2004).  
The clinical trials published to date suggest that VEGF inhibition is a powerful 
and effective treatment option for hypoxia associated neovascular eye disease. 
However, treatment does not fully reverse blindness and repeated treatments 
are frequently required. The application of VEGF inhibitors which target all 
isoforms of VEGF should be carefully evaluated for intraocular and systemic 
safety before being approved for the treatment of other forms of hypoxic 
retinopathy. Furthermore, consideration should be made to the important role of 
VEGF isoforms in retinal vascular development (Chan-Ling et al., 1995; Feeney 
et al., 2003; Ng et al., 2001) and in neuroprotection (Nishijima, 2007; Saint-
Geniez et al., 2008) when applying VEGF inhibitors to the immature eye to treat 
neovascularisation associated with retinopathy of prematurity.  
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1.9 Aims of the project 
The purpose of the work presented in this thesis was to further elucidate the 
roles of hypoxia, hypoxia sensing mechanisms and downstream effector 
pathways in eye development and neovascular eye disease. Specifically, I 
focused on the following three interrelated topics: 
 
1) Activation of HIF in the RPE has been proposed to contribute to disease 
progression and promote choroidal neovascularisation in age-related macular 
degeneration. I therefore aimed to explore the consequences of Hif activation in 
the RPE on the retina and its vasculature using transgenic mice. As activation of 
Hif in the RPE surprisingly resulted in a dramatic and interesting early ocular 
phenotype, I focused on the role of Hif in the RPE during development. 
 
2) Activated myeloid cells, such as macrophages and microglial cells, have been 
shown to accumulate at sites of retinal hypoxia/ischaemia in neovascular eye 
disease and proposed to contribute to the development of neovascularisation. I 
therefore aimed to study the role of Hif1a and its downstream effector protein 
Vegf in myeloid cells in the development of retinal and choroidal 
neovascularisation in transgenic knockout mice.  
 
3) Hypoxia-induced activation of HIF and the expression of downstream 
cytokines have been suggested to contribute to disease progression and the 
development of neovascularisation in diabetic retinopathy. I therefore aimed to 
explore the distribution of oxygen across the human vitreous and retina and 
study its association to vitreous HIF1a and cytokine levels in PDR in man. 
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2. Material and Methods 
2.1 Buffers and reagents 
All reagents were obtained from Sigma Aldrich (Sigma-Aldrich Ltd. Gillingham, 
UK) unless otherwise stated. 
 
ELISA wash buffer: 0.05% Tween 20 in PBS, pH 7.2-7.4 (R&D Systems, UK, 
Cat No WA126) 
ELISA reagent diluent: 1% BSA in PBS, pH 7.2-7.4, 0.2 µm filtered 
ELISA stop solution: 2 N H2SO4  
ELISA substrate solution: 1:1 mixture of Colour Reagent A (H2O2) and Colour 
Reagent B (Tetramethylbenzidine, R&D Systems Cat no DY999) 
Immunohistochemistry block: 1% bovine serum albumin, 5% goat serum, 0.01% 
Tween-20 in PBS 
PBS: PBS tablets (Oxoid Ltd. Basingstoke UK): 1 tablet per 100ml distilled 
water, to make a 1l solution containing 8 g NaCl, 0.2g KCl, 1.15g Na2HPO4; 
0.2g KH2PO4. 
PBST: PBS 1x with 0.05% (v/v) Tween-20. 
Proteinase K buffer: 30mM Tris-HCl pH 8.0 0.5% (w/v) SDS. 
Protein medium for ELISA: 1% Proteinase inhibitor in RIPA buffer 
Serras fixative: 60% (v/v) ethanol, 30% (v/v) saturated formaldehyde, 10% (v/v) 
concentrated acetic acid. 
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2.2 Molecular biology 
2.2.1 Purification of genomic DNA and polymerase chain reaction for 
genotyping 
Genomic DNA was extracted from murine ear-clip samples by proteinase K 
(0.1mg/ml) digestion at 55˚C for 12 hours. The digest was spun at 14000 RPM 
for 10 minutes to eliminate any contaminations and the supernatant was added 
to 1ml of 100% of isopropanol to precipitate the DNA. After another spin at 
14000 RPE for 10min the DNA pellet was resuspended and washed in 70% 
ethanol and spun down again. The washed pellet was finally resuspended in 
sterile water on a heated shaker (55°C) for 30 minutes. Genomic DNA was 
stored short-term at 4˚C or long term at -20˚C. PCR reactions were performed 
using a commercially available master mix containing Taq polymerase (Thermo 
scientific 1.1 x ReadyMix PCR Master Mix 1.5 mM MgCl2, ABgene, Epsom UK). 
Routinely, a 25μl volume was used with 0.5μl of DNA, 0.075μl 100μM primers, 
with distilled water used to make up the volume to 25μl. PCR sequences and 
conditions, and expected product sizes are shown in Appendix 1. 
 
2.2.2 DNA electrophoresis 
After PCR amplification, DNA fragments were separated on a 2% (w/v) agarose 
gel. Ethidium bromide (1µl of 10mg/ml concentration per 50ml of gel) was added 
to visualise nucleic acid bands. Samples were loaded onto the gel using gel-
loading buffer (6x; 0.25 % (w/v) bromophenol blue in water). A 1 kb DNA ladder 
(Bioline Ltd., UK) was added and run at the same time to provide a standard 
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size marker. The voltage was set between 180V for 60 minutes. Finally, the gels 
were photographed on an ultraviolet transilluminator (G-Box, Syngene, 
Cambridge, UK). 
2.2.3 Purification of RNA, manufacture of cDNA and quantitative real-time 
PCR 
Real-time polymerase chain reaction (RT-PCR) was performed with the kind 
help of Anastasios Georgiadis (Department of Genetics, Institute of 
Ophthalmology, London, UK) who assisted with RNA isolation, cDNA 
manufacture and mRNA quantification. Eyes were homogenised and RNA was 
extracted using a commercial kit (RNeasy Mini Kit, Qiagen, UK). Purified RNA 
was stored in DEPC treated water (Invitrogen Ltd., Paisley, UK) at -80˚C until 
use. The amount of template RNA was measured using a small-volume 
spectrophotometer (Nanodrop ND-1000, ThermoScientific, Wilmington, DE 
USA). For each experiment, equal amounts of RNA were used for all samples 
as a template for cDNA manufacture. cDNA was made from template RNA using 
a commercial kit (Quantitect Reverse Transcriptase kit, Quiagen Ltd., UK) 
according to manufacturer’s instructions and stored at -20˚C until use. 
Real-time quantitative RT-PCR was performed using a commercial thermal-
cycler (Applied Biosciences 7900HT) with its associated software (Applied 
Biosciences SDS version 2.2.2). Real-time PCR reagents were obtained 
commercially (Roche Diagnostics Ltd., Burgess Hill, UK). The 5’ nuclease 
technique based on Taq-polymerase and FAM labelled hydrolysis probes was 
used for all real-time reactions using commercially designed primer/probe 
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combinations (Roche Universal Probe Library, sequences for all primers and 
probes are shown in Appendix 1). All reactions were performed in triplicate. For 
all test samples, the endogenous control β-actin was used to verify equal 
loading and to facilitate relative quantitation calculation. A water-only control 
sample was included for each primer/probe combination on each test plate to 
verify the lack of contaminants in the mixture. For each experiment, a suitable 
control sample was used to compare the test samples. The ΔΔ-Ct method of 
relative quantitation was used to compare data, and only data from samples in a 
single plate run at the same time were compared statistically. 
2.2.4 Protein isolation and quantification  
For quantification of protein in murine tissues, retinal or choroidal/RPE samples 
or whole eyes were collected and immediately snap frozen in liquid nitrogen. 
After homogenisation in sterile PBS with protease inhibitors (Sigma Aldrich, 
Gillingham, UK) using a glass homogeniser, the homogenate was spun at 
7000rpm for 10 minutes. The concentration of protein in each sample was 
measured using a Lowry-based colorimetric protein assay done in triplicate (DC 
protein assay kit, Bio-Rad, Hemel Hempstead UK) and compared to a bovine 
serum albumin standard curve. Samples were diluted in assay buffer to bring the 
concentration to within the linear portion of the standard curve (0.2 - 0.9mg/ml).  
 
For quantification of protein in human tissues, undiluted vitreous samples (0.3 - 
1ml) were obtained from the mid-vitreous of diabetic and non-diabetic individuals 
using a vitreous cutter at the start of vitrectomy, prior to intraocular infusion of 
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fluid. The vitreous was collected in EDTA coated Eppendorf tubes (Eppendorf 
UK Limited, Cambridge, UK) and stored on ice. Blood samples were obtained by 
venous puncture following surgery (5ml) and stored on ice. The vitreous and 
blood samples were transferred to the Institute of Ophthalmology for further 
processing within maximal 45 minutes. The vitreous was subsequently 
centrifuged at 500g for 10min, and the blood sample at 1500g for 15min, at 4°C 
to remove the cellular components. The supernatants were aliquoted and stored 
at -80°C. The protein concentration of each sample was determined using a 
Lowry-based colorimetric protein assay performed in triplicate (DC protein assay 
kit, Bio-Rad, Hemel Hempstead UK) as described above. 
2.2.4.1 ELISA for murine Vegf, Hif1a and Hif2a 
Murine Vegf, Hif1a and Hif2a protein levels were quantified using commercial 
available ELISA kits (Mouse Hif1a DuoSet, IC R and D Systems Europe 
Abingdon UK; Hif2a ELISA kit, antibodies-online, Germany; Mouse Vegf DuoSet 
ELISA development kit, R and D Systems Europe Abingdon UK) according to 
the protocol of the manufacture. Briefly, a 96-well plate was coated with 100µl of 
diluted capture antibody overnight and blocked with reagent diluent (1% BSA in 
PBS) for one hour. After a washing step with 200µl of wash buffer (00.05% 
Tween 20 in PBS), 50µl of murine protein samples were added in duplicates to 
the plate for two hours at room temperature. The wells were washed with 200µl 
of wash buffer (00.05% Tween 20 in PBS) and 100µl of detection antibody was 
added to each well for two hours at room temperature. The wells were washed 
again and covered with 100µl of Streptavidin-HRP for 20 minutes followed by 
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another wash step and incubation with substrate solution (1:1 mixture of Colour 
Reagent A (H2O2) and Colour Reagent B (Tetramethylbezidine), OptEIA
TM, BD 
Bioscience, CA, USA) for 20 minutes. Finally, 50µl of stop solution (2N H2SO4) 
was added to each well and the optical density of each well was immediately 
determined using a microplate reader set at 450nm with a reference at 650nm 
(Emax, Molecular Devices Ltd. Berkshire UK). The results of each sample were 
compared to a standard curve of known concentration. To correct for total 
protein levels, Vegf, Hif1a and Hif2a protein levels are presented per milligram 
of whole eye protein.  
2.2.4.2 ELISA for human HIF1a 
Human HIF1a protein was quantified in vitreous and plasma samples using a 
commercial available ELISA kit (Human HIF1a DuoSet IC R and D Systems 
Europe Abingdon UK) according to the protocol of the manufacture. Briefly, a 
96-well plate was coated with 100µl of diluted HIF1a capture antibody overnight 
and blocked with reagent diluent (1% BSA in PBS) for one hour. Vitreous and 
plasma samples were brought to room temperature and added in duplicate to 
the plate. After a washing step with 200µl of wash buffer (00.05% Tween 20 in 
PBS) 100µl of detection antibody was added to each well for two hours at room 
temperature. The wells were washed and covered with 100µl of Streptavidin-
HRP for 20 minutes followed by another wash step and incubation with 
substrate solution (1:1 mixture of Color Reagent A (H2O2) and Color Reagent B 
(Tetramethylbezidine) for 20 minutes. Finally, 50µl of stop solution (2N H2SO4) 
was added to each well and the optical density of each well was immediately 
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determined using a microplate reader set at 450nm with a reference at 650nm 
(Emax, Molecular Devices Ltd. Berkshire UK). The results of each sample were 
compared to a standard curve of known concentration.  
2.2.4.3 Cytometric bead array for human cytokines (CBA)  
Multiplex bead analysis was kindly performed by Chris Cox (Director of Clinical 
Services, BioAnaLab Limited, Oxford, UK) as previously described (Groer and 
Shelton, 2009). Both vitreous and plasma samples were analyzed using the 
Milliplex Human Cytokine Panel 1 (Catalog number MPXHCYTO-60K; Millipore 
UK Ltd) for the following 42 cytokines: EGF, Eotaxin, FGF-2, Fit-3L, Fractalkine, 
G-CSF, GM-CSF, GRO, IFNα2, IFN-γ, IL-1α, IL-1, IL-1Rα, IL-2, IL-3, IL-4, IL-5, 
IL-6, IL-7, IL-8, IL-9, IL-10, IL-12 (p40), IL-12 (p70), IL-13, IL-15, IL-17, IP-10, 
MCP-1, MCP-3, MDC, MPI-1α, MIP-1, PDGF-AA, PDGF-AB, sCD40K, sIL-
2Rα, RANTES, TGFα, TNFα, TNF and VEGF in a single sample. Samples 
were brought to room temperature and added in duplicate to 96-well filter-bottom 
plates. Antibody-coated capture beads were added to the wells and incubated 
on a plate shaker at 4° C overnight. After a washing step, beads were further 
incubated with biotin-labelled secondary antibody for 1 hour and then incubated 
with streptavidin-phycoerythrin for 30 minutes. 100 µl of sheath fluid was added 
to each well and samples were analysed using a bioassay analyzer (model 200; 
Luminex, Austin, TX). Cytokine concentrations were determined from standard 
curves prepared on each plate and expressed as picogram per milliliter (pg/ml). 
Concentrations below the detection limit of 3.2pg/ml are treated as having a 
value of 1.6pg/ml for the purposes of the analysis. 
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2.3 In vivo techniques in mice 
2.3.1 Animals and breeding 
2.3.1.1 Animals 
All animals were used with University College London ethics committee approval 
and under a UK Home Office project licence and personal licence (PIL 
70/22032). All procedures were performed in accordance with the Association 
for Research in Vision and Ophthalmology Statement for the Use of Animals in 
Ophthalmic and Vision Research. All mice in this study were maintained on a 
C57BL/6J background. 
 
Mouse lines used in the study include: 
- C57Bl/6J mice were obtained from Harlan UK Ltd. Bicester UK 
- Vhlflox/flox mice (Haase et al., 2001) were obtained from Patrick Maxwell (UCL 
Department of Medicine, London, UK) 
- Hif1aflox/flox mice (Ryan et al., 2000) were obtained from Patrick Maxwell (UCL 
Department of Medicine, London, UK)  
- Vhlflox/flox;HIF1aflox/flox mice were bred by myself in the Biological Resource 
Unit of the Institute of Ophthalmology, London, UK 
- trp-1 cre mice (Mori et al., 2002) were obtained from Pierre Chambon (Institute 
of Genetics, University of Strasbourg, France)  
- lysM cre mice (Clausen et al., 1999) were obtained from Christiana Ruhrberg 
(Department of Cell Biology, Institute of Ophthalmology, UCL, London) 
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2.3.1.2 Breeding 
Transgenic mice expressing cre recombinase under the control of the RPE cell-
specific tyrosinase-related protein 1 promotor, referred to as trp-1 (Mori et al., 
2002), were mated with Vhlfloxed/floxed mice (Haase et al., 2001), Hif1afloxed/floxed 
mice (Ryan et al., 2000), or double floxed Vhlfloxed/floxed;Hif1afloxed/floxed mice. 
Transgenic mice expressing cre recombinase under the control of the myeloid 
cell-specific lysozymeM promotor, referred to as lysM (Clausen et al., 1999), 
were mated with Vhlfloxed/floxed mice (Haase et al., 2001) and Hif1afloxed/floxed mice 
(Ryan et al., 2000). All experiments were controlled with age-matched 
littermates without the cre transgene (referred to as control). Genotyping was 
performed at weaning age or before using earclip genomic DNA. All procedured 
animals were genotyped at euthanasia for a second time to confirm their 
genotype.  
2.3.2 Anaesthesia 
If required, mice were anaesthetised using an intraperitoneal injection of a 
mixture containing medetomidine hydrochloride (1mg/ml, Domitor™ Pfizer 
animal health, Kent, UK), ketamine (100mg/ml, Fort Dodge Animal Health, 
Southampton UK) and sterile water in the ratio 5:3:42. Mice were recovered 
using an intraperitoneal injection of the reversal agent atipamezole 
hydrochloride (5mg/ml, Antisedan™ Pfizer animal health, Kent, UK) in sterile 
water (ratio 1:50). Mice were monitored in the recovery period and body 
temperature was maintained using a heat pad. Local anaesthesia using topical 
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0.5% amethocaine drops (Minims, Bausch and Lomb Ltd, Kingston-upon-
Thames, UK) was provided when necessary. 
2.3.3 Intraperitoneal injection 
Intraperitoneal injection (i.p.) was performed for fluorescein and indocyanin 
green (ICG) angiography and terminal procedures. A maximum volume of 
0.15ml was injected for pre-weaning mice, 0.25ml for adult mice. Injections were 
made at either side of midline (alternating for repeated injections) using a 30g 
hypodermic needle and a 1ml syringe.  
2.3.4 Macroscopical examination of mouse eyes  
In order to characterise the ocular development and eye growth, the eye 
diameter was assessed at different time points during development by 
measuring the distance from the optic nerve head to the center of the cornea 
using an electronic digital caliper. To further document the ocular development 
macroscopically, enucleated eyes were imaged at different time points during 
development using a digital camera (Lumix 12x, DMC-TZ7, Panasonic). 
2.3.5 Indocyanin green and fluorescein angiography 
To analyse the ocular vascular phenotype in mice in vivo, fluorescein (FA) and 
indocyanin green (ICG) angiography was performed. Mice were anaesthetised 
and injected with 0.2 ml of 1% fluorescein sodium (Akorn, Decatur, IL) or 0.2 ml 
of 5mg/ml ICG in dH2O in the peritoneum and fundus images were captured 
three minutes later using the autofluorescent channel of SpectralisTM HRA2 
digital angiography system (Heidelberg engineering, Heidelberg, Germany). In 
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vivo fluorescein angiography after laser CNV induction (see below) was 
performed without anaesthesia using a small animal fundus camera with 
appropriate filters (Kowa Genesis, Tokyo, Japan). 
2.3.6 The mouse model of oxygen-induced retinopathy (OIR) 
Pups and their nursing mothers were placed in a 75% oxygen supply chamber 
from postnatal day 7 to postnatal day 12 as previously described (Mowat et al., 
2010). A constant low flow of 80% oxygen and 20% nitrogen was provided to a 
closed perspex chamber. The oxygen level was monitored three times a day, 
and maintained at 75% ±2% O2. If necessary the oxygen levels in the chamber 
were increased by adding 100% of oxygen or decreased by opening the 
chamber. Mice were checked three times daily and the nursing mother was 
removed from the chamber to breathe room air (21% oxygen) for a minimum of 
2 hours a day to minimise lung toxicity associated with hyperoxia in adults. The 
mice were exposed to a standard 12 hour light-dark cycle and returned to 
constant room air (21% O2) at p12. Pups were weighed and culled at p12 or p17 
to assess the neovascular and vaso-obliterative fraction of the total retinal area. 
To ensure the validity of each experiment one animal per litter was culled at p12 
and the hyperoxia induced vaso-obliterative area was determined on a vessel 
stained flatmount. A vaso-obliterative area of 20-50% was considered as a result 
of a valid experiment.  
2.3.6.1 Imaging and analysis  
Retinal flatmounts were dissected and stained with TRITC-conjugated isolectin 
B4, collagen 4 or CD31 as described below. Retinal flatmounts were imaged 
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using a confocal laser scanning microscope (Leica DM5500Q, Wetzlar, 
Germany) at 5x magnification. Single x/y plane was taken from each quadrant of 
the retina and the central retina at 1024 x 1024 resolution. Composite images 
were produced and exported as a *.tiff file using the Leica imaging software 
(LAS AF, Leica, Wetzlar, Germany). Images were loaded into an image analysis 
program (Image J) and converted to 16bit grayscale images. The area of the 
total retina and the vaso-obliterative area were delineated using the freehand 
selection tool as previously described (Banin et al., 2006). Areas of 
neovascularisation were outlined, and the manual selection tool was used to 
highlight the bright neovascular areas only. The neovascular area and ischaemic 
area were quantified and represented as percentages of total retinal area. 
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Figure 2.1 Analysis of retinal ischaemia and neovascularisation 
Retinal vessels were labelled with fluorescent TRITC-conjugated BS lectin. 
Retinas were flatmounted and imaged (A, x5 magnification). Image analysis 
software (ImageJ) was used to delineate and measure the total retinal area (B), 
the area of central ischaemia (C) and neovascularisation (D). Ischaemia and 
neovascularisation were presented as a percentage of the total retinal area. 
Scale bar = 1mm 
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2.3.7 The mouse model of laser-induced choroidal neovascularisation 
Choroidal neovascularisation was induced by rupturing Bruch’s membrane using 
a slit-lamp-mounted diode laser system (wavelength 680nm; Keeler, UK) at 
210mW power, 100ms duration and 100μm spot diameter. These settings 
consistently generate a subretinal gas bubble which indicates an adequate 
laser-induced rupture of Bruch's membrane and successful induction of CNV. 
Only eyes in which laser-induced subretinal bubble formation occurred were 
included in the analysis. Eyes were also excluded if there was significant 
cataract or keratopathy formation which prevented good fundus view and could 
affect laser energy delivery or angiography. For subsequent assessment of CNV 
lesion size energy was targeted at 3 areas approximately 3-4 disc diameters 
from the optic nerve head at the 10 o’clock, 2 o’clock and 6 o’clock positions and 
avoiding any vessels.  
2.3.7.1 Imaging and analysis  
In vivo fluorescein angiography (FFA) was performed at 3 days, 1 and 2 weeks 
after laser injury. Images from the early (90 seconds after fluorescein injection) 
and late (7 minutes) phases were obtained using a small animal fundus camera 
with appropriate filters (Kowa Genesis, Tokyo, Japan). The pixel area of CNV-
associated hyperfluorescence was quantified for each lesion using image-
analysis software (Image J; National Institute for Health, US; free download from 
http://rsbweb.nih.gov/ij/) (Collins, 2007). The border of each lesion was 
delineated using the free-hand area selection tool and the pixels of each lesion 
was highlighted and automatically counted after adjusting for an appropriate 
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threshold level. Confluent lesions and lesions surrounded by retinal bleeding 
were excluded in all experiments.  
 
 
 
 
 
Figure 2.2 Analysis of laser-induced choroidal neovascularisation on fluorescein 
angiograms. A,B) Image analysis software (ImageJ) was used to delineate the borders 
of a choroidal neovascularisation on a fluorescein angiogram. C,D) The “threshold 
function” of ImageJ was used to highlight and automatically count the pixels of the 
choroidal neovascularisation. 
  
100 
 
2.3.8 Electroretinography 
Standard photopic and scotopic flash Ganzfeld electroretinography (ERG) were 
recorded from 2-3 month old mice in a standardised fashion. Following dark 
adaption overnight (>14 hours) mice were anesthetised with a single 
intraperitoneal injection as described above. The pupils were dilated using one 
drop each of 0.5% tropicamid (Minims, Bausch and Lomb, Kingston-upon-
Thames, UK) to each eye. Contact corneal platinum electrodes were placed on 
each eye and one reference electrode sublingually. The ground electrode was 
placed subdermally in the midline at the base of the tail. Water based ocular 
lubricant (Viscotears, Novartis Pharmaceuticals UK Ltd, Camberley, UK) was 
placed on each cornea to improve electrical contact with the electrode and to 
keep the eye moisturised during procedure. The head was placed in a 
standardised position in the Ganzfeld bowl and great care was taken to keep the 
electrodes impedance symmetrical and low (between 5-10kOhm). ERGs were 
recorded from both eyes simultaneously using the Espion ERG Diagnosys 
system (Diagnosys LLC, Cambridge, UK).  
 
For scotopic examination, single-flash recordings were obtained at increasing 
light intensities from 0.001 to 3 cd/m2 with an interstimulus interval of 30 (0.001–
1 cd/m2) and 60 (3 cd/m2) seconds. Following light-adaption for 10 minutes at 
10cd/m2 intensity, photopic single-flash recordings were obtained at increasing 
light intensities from 0.1 -10 cd/m2 with an interstimulus interval of 30 (0.001–1 
cd/m2) and 60 (3 cd/m2) seconds. Ten responses per intensity level were 
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averaged and the a- and b-wave amplitudes were analysed using an Espion 
software (Diagnosys LLC).  
2.3.8.1 Analysis of ERG data  
Measurements for amplitude were obtained from the trough of the a wave and 
the peak of the b-wave. The photopic a-wave was defined as the maximal 
negative amplitude after the onset of light exposure. The photopic b-wave was 
defined as the maximal positive amplitude after the onset of light exposure 
compensating visually for the waveforms of the oscillatory potentials. Statistical 
comparison was performed at the 1cd.s/m2 intensity which represents a mixed 
cone-rod response (Lei et al., 2006).  
 
2.4 In vivo techniques in humans 
2.4.1 Oxygen measurements in the human vitreous 
2.4.1.1 Study population 
The study on vitreous oxygenation in PDR was performed in accordance with 
the Declaration of Helsinki and approved by the Moorfields and Whittington 
Research Ethics Committee (REC reference number 07/Q0504/17). 14 
individuals having vitrectomy surgery for advanced proliferative diabetic 
retinopathy (PDR), and 14 control subjects having surgery for idiopathic 
epiretinal membranes or full-thickness macular hole were recruited in this study. 
Prior to entering the study, informed consent was obtained from all subjects. As 
previous intraocular surgery can change the intra-ocular distribution of oxygen 
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(Holekamp et al., 2005), individuals with any history of intra-ocular surgery 
including cataract surgery were excluded. In order to allow the surgeons the 
best possible view during the intraoperative oxygen measurements individuals 
with the presence of intraocular haemorrhage or inflammation were excluded. 
Because systemic hyperoxia can influence intraocular oxygen tensions (Yu and 
Cringle, 2001b), only patients having surgery under local anesthesia who 
maintained peripheral oxygen saturations of 95% minimum during surgery 
without supplementary inhaled oxygen were included in this study (table 2.1).  
 
 
Inclusion criteria Exclusion criteria 
• Patients listed for vitrectomy under local 
anaesthesia 
• Patients unable to give informed consent 
• Patients with PDR (study group), MH or ERM 
(control) 
• Hx of pulmonal disease (e.g. asthma or 
COPD) 
• Age > 16 years of age • Previous intraocular inflammation 
 
• Peripheral O2 saturation <95% during 
surgery 
 
• Previous intraocular surgery 
 
 
 
Table 2.1 Inclusion and exclusion criteria for the study on intraocular oxygen in PDR 
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2.6.1.2 Measurement of oxygen tension 
Intraocular oxygen measurements were kindly performed by Zdenek Gregor, 
Panagiotis Stavrakas and James Bainbridge (Vitreo-retinal service, Moorfields 
Eye Hospital, London, UK) using an Oxylab pO2 optical sensor (Oxford Optronix, 
Oxford, United Kingdom) set in fast mode (one measurement per second). Prior 
to measuring oxygen tensions in the eyes of human subjects, the effect of gas 
sterilisation and endoscopic illumination on the reliability of the sensor was 
determined in gas mixtures of known oxygen tensions (0-147.4mmHg). Oxygen 
probes were gas-sterilised (Sterrad 100Nx, Johnson&Johnson, USA) prior to 
use in human subjects. Using a 20-gauge 3-port pars plana technique the 
surgeons sited the infusion cannula in the inferotemporal port without turning on 
the intraocular infusion. The oxygen probe was introduced via a heavy liquid 
cannula through a second port into the vitreous cavity and an endoscopic light 
pipe was introduced through the third port. Oxygen tensions were measured by 
holding the sensor at specific sites in the eye for at least 35 seconds until the 
monitor recorded constant values. Oxygen tensions were measured in the 
anterior vitreous 3mm posterior to the posterior pole of the lens (1), the mid 
vitreous (2), at the retinal surface one disc-macula diameter temporal to the 
macula (3a), at the retinal surface superior to the superotemporal arcade (3b) 
and at the retinal surface in the mid-periphery (superior equator, 4). 
Furthermore, oxygen tensions were recorded at the retinal surface of tractional 
retinal detachments and above and between photocoagulated areas in subjects 
with proliferative diabetic retinopathy (figure 2.3). All preretinal measurements 
were taken with the probe in light contact with the retinal surface. To determine 
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the test-retest variability of the sensors in vivo, and to identify any artefactual 
disturbance of intraocular oxygen tension caused by the measurement 
technique itself the mid vitreous oxygen tension was measured at both the start 
and the completion of the measurements. Once the measurements were 
completed and the vitreous sample collected (see below), the intraocular 
infusion was turned on and the vitreous surgery was performed as planned. 
 
 
 
 
 
Figure 2.3 Sites of intraocular oxygen measurements. A) Intraocular oxygen tension was 
measured in the anterior vitreous (1) and in the mid vitreous (2). B) Preretinal oxygen 
tension were measured at the retinal surface superior to the superotemporal arcade 
(3a), one disc-macula diameter temporal to the macula (3b), in the mid-periphery 
(superior equator, 4), above and between photocoagulated areas (5,6) and above areas 
of tractional retinal detachments in subjects with proliferative diabetic retinopathy 
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2.5 Histology and immunohistochemistry 
2.5.1 Tissue processing on paraffin embedded tissue 
Animals were terminally anaesthetised with intraperitoneal injection of 
pentobarbital (Euthatal™ Merial Animal Health Ltd. Harlow, UK) and perfused 
via intracardiac puncture with ice-cold fixative (4% PFA). As standard, tissue 
was fixed for 12 hours in 4% PFA at 4˚C then embedded in paraffin. Tissues 
were processed in an automated machine (Leica TP1020) and embedded in 
paraffin blocks for sectioning. Sections were cut on a microtome (Shandon 
sledge, Runcorn, UK) routinely at 6μm, and mounted on polylysine coated slides 
(Thermofisher Loughborough, UK). Sections were stored at room temperature 
until staining.  
2.5.2 Immunohistochemistry on paraffin embedded tissue 
Sections were dewaxed in xylene and rehydrated though grades of alcohol 
(100%, 90% and 80% of ethanol) to distilled water. Sections were stained with 
haematoxylin (nuclei) and eosin (cytoplasm) and washed thoroughly. Next, 
sections were dehydrated for 5 minutes in 95% ethanol, 5 minutes in 100% 
ethanol and at the end for 15 minutes in xylene. The slides were coversliped 
using xylene based Permount (Fisher scientific, UK). A drop of Permount was 
placed on the slide using a glass rod, taking care to leave no bubbles. The 
coverslip was angled and let fall gently onto the slide. Slides were dried 
overnight in the hood. 
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2.5.3 Tissue processing on frozen tissue 
Fixation was dependent on the individual immunohistochemistry protocol used. 
Routinely, animals were terminally anaesthetised with pentobarbital (Euthatal™ 
Merial Animal Health Ltd. Harlow, UK) and perfused via intracardiac puncture 
with ice-cold paraformaldehyde (4% (w/v)) in PBS pH 7.4. Eyes were then post 
fixed in paraformaldehyde (4% (w/v)) for 5-10 minutes. Eyes were embedded in 
optimal cutting temperature medium (Tissue Tek OCT medium, Raymond Lamb, 
Eastbourne, UK) before freezing. Retinal cryosections were cut using a cryostat 
(Bright OTF 5000, Huntingdon, UK) in a sagittal direction at between 12-20μm 
thickness. Details of section thickness are given in specific chapter methods. 
Sections were collected onto polylysine coated slides (Thermofisher 
Loughborough, UK), air dried and stored at -20˚C until staining. 
2.5.4 Immunohistochemistry on frozen tissue 
Sections were defrosted for 10 minutes at room temperature, and rehydrated in 
PBS for 10 minutes at room temperature. Blocking solutions comprised PBST 
with 5% normal goat serum and 1% bovine serum albumin. All antibodies were 
incubated in blocking solution, antibody conditions varied depending on the 
primary antibody used. After intensive washing, sections were incubated with 
fluorescent secondary antibodies (Invitrogen Ltd., Paisley, UK) for 4 hours at 
room temperature and counterstained with blue fluorescent DAPI (1:1000, 
Invitrogen Ltd., Paisley, UK) for 10 minutes at room temperature. Where double 
immunohistochemistry was performed, it was ensured that primary antibodies 
from different host species were used to avoid potential cross reactivity. In all 
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immunohistochemical experiment, incubations omitting the primary antibody 
were performed as controls for non-specific secondary antibody binding.  
2.5.5 In situ hybridisation on frozen sections 
The in situ hybridisation experiments for Vegf were performed with the kind help 
of Michael Powner and Marcus Fruttiger (Department of Cell Biology, Institute of 
Ophthalmology, UCL London, UK).  
Eyes were fixed in 4% PFA in PBS for 24 hours at 4°C and cryoprotected in 
20% (w/v) sucrose in PBS overnight at 4°C. Eyes were embedded in OCT 
compound (Raymond and Lamb, Sussex, UK), frozen in liquid nitrogen and 
stored at -20°C until further use. Cryosections (15μm) were collected on 
Vectabond (Vector Laboratories, Burlingham, USA)-coated slides and air-dried 
for four hours. Digoxigenin-labelled probes against full length mouse Vegf 
mRNA (coding region and 3' UTR) were diluted in hybridisation buffer and 
applied directly to sections and hybridised overnight at 65°C. Subsequent 
visualisation of RNA hybrids was carried with alkaline phosphatase-conjugated 
anti-digoxigenin antibodies according to the manufacturer's instructions using 
NBT/BCIP as a colour reagent (Roche Diagnostics GmbH, Mannheim, 
Germany). Pigment in the RPE was subsequently bleached by incubating the 
sections first in KMnO4 (0.25% in H2O) for 10 min at RT and then in oxalic acid 
(1% in H2O) for 20 min at room temperature.  
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2.5.6 Tissue processing for retinal flatmounts 
For flatmount preparation, animals were routinely perfused with 4% (w/v) PFA, 
and eyes were fixed for 1 hour after enucleation. The cornea, lens and iris were 
dissected and four radial cuts were made through the RPE, choroid and retina. 
The RPE/choroid complex was carefully dissected from the retina and both 
unfolded on a plastic dish. Samples were postfixed with 4% PFA for 1 hour at 
4°C or in 100% methanol at -20°C until further use. Once staining was 
completed, retinas were mounted ganglion cell layer up in aqueous fluorescent 
mounting medium (Dako Ltd., Ely, UK) with a cover slip. 
2.5.7 Immunohistochemistry on retinal flatmounts 
Retinal and choroidal flatmounts were washed in PBS and incubated with 
primary antibodies (table 2.2) or 0.1mg/ml TRITC conjugated Bandeiraea 
simplicifolia (BS) lectin (Sigma Aldrich, Gillingham UK) diluted in blocking 
solution overnight at 4˚C. Flatmounts were thoroughly washed in PBS and 
incubated with fluorescent secondary antibodies (Invitrogen Ltd., Paisley, UK) 
for 4 hours at room temperature. Finally retinal and choroidal flatmounts were 
mounted with fluorescent aqueous mounting medium (Dako Ltd., Ely, UK) with 
the ganglion cell layer or RPE uppermost. 
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1° ab (host) cell type labelled company 1° ab 2° ab 
Caspase 3  
(rabbit) 
Apoptotic cells Abcam, US, ab 2302 
1:20, 
overnight, 4˚C 
1:200 4h 
RT 
Collagen IV  
(rabbit) 
Vascular 
endothelial cells 
AbD Serotec, Oxford, 
UK, 2150-1470 
1:300, 
overnight, 
4˚C 
1: 500 
4h RT 
Cre (rabbit) Cre recombinase 
Novagen, 69050, 
M00000463 
1:200, 
overnight, 4˚C 
1: 500 
4h RT 
GFAP  
(rabbit) 
Astrocytes, Mueller 
glia 
DAKO, Ref Z0334, Lot 
0006609 
1:500, 
overnight 4˚C 
1: 500 
4h RT 
Hif1a 
(rabbit) 
Hif1a 
Novus Biologicals, 
NB100-479, Lot P1 
1:1-200, 
overnight, 4˚C 
1: 500 
4h RT 
Otx2 
(rabbit) 
PR progenitors 
RPE (in adults) 
Abcam (ab21990) 
1:100, 4˚C 
overnight 
1: 500 
4h RT 
Pax6 
(rabbit) 
PR progenitors 
 
Covance (PRB-278P) 
1:300, 4˚C 
overnight 
1: 500 
4h RT 
P-histone 
H3 (rabbit) 
Proliferating cells 
Chemicon Milipore, 
MA, US E173 
1:500, 
overnight, 4˚C 
1:200 4h 
RT 
Ribeye/ 
CtBP2 
(mouse) 
Synapses 
BS Transduction 
Laboratories, 612044 
1:500, 
overnight, 4˚C 
1: 500 
4h RT 
Recoverin  
(rabbit) 
Photoreceptors 
Chemicon, Ref 
AB5585, Lot 
LV1480447 
1:1-2000, 
overnight, 4˚C 
1: 500 
4h RT 
Rhodopsin Rods 
Sigma Aldrich Ltd.,UK, 
cat#O4886, Clone 
RET-P1 
1:1000, 
overnight, 4˚C 
1:500, 
4h RT 
YFP (rabbit) YFP positive cells MBL, MA, US, code 
598 
1:500, 
overnight, 4˚C 
1: 200 
4h RT 
 
Table 2.2 Primary antibodies used on cryo sections. 
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1° ab (host) cell type labelled source 1° ab 
2° ab 
 
Collagen IV 
(rabbit) 
Vascular 
endothelial cells 
AbD Serotec, Oxford, 
UK, 2150-1470 
1: 200, 
overnight 
4 ˚C 
1:200, 
4h RT 
F4/80  
(rat) 
Macrophages. 
Microglia 
AbD Serotec, Oxford, 
UK, Cl:A3-1 
1:500 
1:200, 
4h RT 
Iba1 (rabbit) 
Macrophages, 
microglia 
WAKO, Japan, Code 
No. 019-19741 
1:500, 
overnight, 4˚C 
1: 200, 
4h RT 
Pecam 
(rabbit) 
Endothelial cells 
BD Pharmingen, CA, 
US, Code MEC 13.3 
1:200, 
overnight, 4˚C 
1: 200, 
4h RT 
TRITC 
conjugated 
BS lectin 
Vascular 
endothelial cells, 
monocytes 
Sigma Aldrich, L2140 0.1mg/ml N/A 
 
Table 2.3 Primary antibodies used on retinal and choroidal flatmounts.  
 
 
2.5.8 Imaging and analysis 
Fluorescence images were obtained using a confocal laser scanning 
microscope (Zeiss LSM 710, Hertfordshire, UK). Confocal sections were 
obtained using a 20x or 40x water immersion plan apochromat lens. Z-stacks 
were 3D reconstructed and surface rendered using Imaris software (Bitplane, 
Zurich, Switzerland). For quantification of proliferating and apoptotic cells, the 
number of cell nuclei stained with caspase 3 or phospho-histone H3 were 
counted in the iris, retina and RPE in 5 central cryosections 60μm apart. An 
average value per animal was calculated and used in subsequent analysis. 
Paraffin and semithin sections were imaged using a light microscope (Zeiss Axio 
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Observer Z1, NY, US). The number of RPE cells on semithins was quantified as 
described above. For ultrastructural imaging, a transmission electron 
microscope (TEM model 1010; JEOL, Tokyo, Japan) was used operating at 
80kV. All images were captured with a digital camera (QImaging micropublisher 
5.0 digital camera, QImaging, BC Canada) and exported as tiff files into Image J 
for quantification (developed by Wayne Rasband, National Institutes of Health, 
Bethesda, MD; available at http://rsb.info.nih.gov/ij/index.html).  
2.6 Graphical representation of data and statistical analysis 
All statistical analysis and graph composition was performed in a commercial 
program (GraphPad Prism version 5.00 for Windows, San Diego, USA). In all 
graphs, error bars indicate standard error of the mean (SEM) if not differently 
indicated. When comparing animals (for example when comparing the effect of 
genotype), all values were calculated or averaged on a per-animal basis, to 
ensure all data were independent. P values of p<0.05 were considered 
statistically significant. When comparing two normally distributed groups, a 
student’s t-test was used. Details of t-tests used are given in specific chapter 
methods. When comparing 3 or more groups, a repeated-measures analysis of 
variance (ANOVA) was performed. Suitable post-tests were performed to 
compare groups of interest, as detailed in specific chapter methods. Correlation 
of the in vitro oxygen measurements and the in vivo test-retest measurements 
were calculated using the Pearson correlation coefficient. Differences in 
intraocular O2 tensions between subjects with diabetes and controls, and in the 
concentrations of cytokines detected in more than 5 vitreous samples were 
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analyzed using a two tailed Mann-Whitney test and expressed as mean ± SEM. 
To correct for multiple univariate analyses, the Bonferroni correction algorithm of 
error I level was applied for the cytokine microarray analysis to retain the global 
error level at 5%. P values less than 0.0039 (=0.05/13) were considered 
statistically significant. Correlations between cytokine concentrations and 
intraocular oxygen tensions were determined using the non-parametric 
Spearman correlation coefficient. 
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3. The roles of Vhl and Hif1a in ocular and 
vascular development 
3.1 Introduction 
Molecular oxygen is essential for the development, growth and survival of 
multicellular organisms. Hypoxic microenvironments and oxygen gradients are 
generated physiologically during embryogenesis and organogenesis, including 
brain, heart and eye development (Caprara and Grimm, 2012; Patterson and 
Zhang, 2010; Trollmann and Gassmann, 2009). Tissue responses to local 
oxygen availability drive and coordinate the development of the blood, 
vasculature, the nervous system and other organs (Simon and Keith, 2008). In 
the eye, development of the retinal vasculature occurs in response to 
physiological hypoxia (Chan-Ling et al., 1995) generated by the increasing 
metabolic demand of differentiating neural cells (Stone et al., 1995). Hif 
signalling has been proposed to mediate this adaptive response to hypoxia 
during development and was shown to control normal retinal vascularisation and 
regression of the hyaloid vasculature in the developing neuroretina (Kurihara et 
al., 2010).  
The retinal pigmented epithelium (RPE) is critical for the development of the eye 
and its vasculature. It is developmentally derived from the outer layer of the 
bilayered optic cup and contributes together with the peripheral neuroretina to 
the formation of the ciliary body and iris anteriorly. Normal development of the 
RPE is important for subsequent development of the choroidal vasculature 
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(Bharti et al., 2006) as well as closure of the optic fissure, retinal neurogenesis 
and neuronal cell projections (Bumsted and Barnstable, 2000; Martinez-Morales 
et al., 2001; Raymond and Jackson, 1995; Scholtz and Chan, 1987). Genetic 
ablation of the RPE or disruption of RPE specification genes during 
development in the mouse eye results in RPE transdifferentiation to neuroretina, 
coloboma and microphthalmia (Bharti et al., 2006; Marneros et al., 2005; 
Sakaguchi et al., 1997). In the adult, the mature RPE provides photoreceptor 
cells with metabolic support, recycles visual pigment, phagocytoses 
photoreceptor outer segment membranes, and maintains the blood-retina barrier 
and the health of the choroidal vasculature (Arjamaa et al., 2009; Sheridan et 
al., 2009). Hypoxia and Hif signalling at the level of the RPE has been proposed 
to play a critical role in the regulation of proangiogenic cytokines in the 
development of sight-threatening pathological choroidal neovascularisation in 
age-related macular degeneration (Stefansson et al., 2010).  
Whereas the role of Vhl and Hif signalling in the developing neuroretina has 
been studied in detail (Caprara et al., 2011; Kurihara et al., 2010; Lange et al., 
2011), little is known about the function of these factors in the RPE on the 
developing eye and its vasculature. Conditional inactivation of Hif1a in the 
developing RPE has been shown to have no effect on the development of the 
eye and its vasculature (Marneros et al., 2005). The consequences of Hif1a 
activation in the developing RPE, however, remain unclarified. 
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3.2 Aims  
The aim of this chapter was to explore the function of Vhl and Hif1a signalling in 
the RPE on the developing eye and its vasculature. This was addressed by 
characterizing the ocular and vascular development of mice with a tissue-
specific conditional knockout of Vhl in the RPE. Furthermore, I aimed to 
delineate distinct roles of Hif1a in the RPE for ocular and vascular development 
by characterizing mice with conditional inactivation of both Vhl and Hif1a in the 
RPE.   
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3.3 Methods and results 
3.3.1 Conditional inactivation of Vhl in the RPE leads to Hif1a 
mediated aniridia and microphthalmia  
To characterise the effect of Vhl inactivation in the RPE on eye development, 
knockin mice expressing cre recombinase under the control of the pigmented 
epithelium specific promoter trp1 (tyrosinase related protein 1, referred to as 
C57Bl6trp1-cre mice) were mated with Vhlfloxed/floxed mice (Haase et al., 2001). The 
macroscopic phenotype of Vhltrp1-creKO mice and control littermates was 
assessed at different time points during development (n=6-8 animals per 
genotype and timepoint). Abnormal ocular and iris development in Vhltrp1-creKO 
mice were observed with 100% penetrance (figure 3.1A, B). The eye growth of 
Vhltrp1-creKO mice was similar to littermate controls during fetal development. 
Postnatally, however, Vhltrp1-creKO mice developed significant microphthalmia with 
a mean diameter of 2.1 ±0.13 mm compared with 3.0 ±0.21 mm in control mice 
at one month old (p<0.0001, figure 3.1C). To evaluate whether the observed 
phenotype in Vhltrp1-creKO mice is mediated by Hif1a, mice with conditional 
inactivation of both Vhl and Hif1a in the pigmented epithelium were generated. 
This was achieved by crossing Vhl;Hif1aflox/flox mice with mice expressing cre 
recombinase under the trp1 promoter. Vhl;Hif1atrp1-creKO mice demonstrated 
normal iris and ocular development resulting in a normal postnatal ocular 
diameter of 2.8 mm at one month of age (s.d. ±0.22, figure 3.1A-C). These data 
suggest that Vhl dependent Hif1a degradation is essential for normal iris and 
ocular development.  
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Figure 3.1 Conditional inactivation of Vhl in the RPE leads to Hif1a mediated aniridia and 
microphthalmia. Representative images of Vhl
trp1-creKO
, Vhl;Hif1a
trp1-creKO
 and control mice (A) 
and corresponding enucleated eyes (B) at one month of age. Timecourse of eye growth in 
Vhl
trp1-creKO
 (red line), Vhl;Hif1a
trp1-creKO
 (green line) and control mice (blue line, C). Error bars 
indicate ±SD. M=month, E=embryonic, P=postnatal. 
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3.3.2 Conditional inactivation of Vhl in the RPE increases levels of 
Hif1a, Hif2a and downstream angiogenic factors 
To assess the specificity of cre expression in pigmented epithelial cells, ocular 
sections of C57BL/6trp1-cre mice were stained for cre recombinase at E14.5. 
C57BL/6trp1-cre mice demonstrated a strong expression of cre in the RPE and in 
a few neuroretinal cells of the distal optic cup, the primordium of the iris and 
ciliary body (figure 3.2A). This data is in line with the original publication 
describing the C57BL/6trp1-cre mouse line and indicates a strong and specific 
expression of cre recombinase in the RPE and iris (Mori et al., 2002).  
To determine the effect of targeted deletion of Vhl in the developing RPE on 
ocular distribution of Hif1a and Vegf, Hif1a immunohistochemistry and Vegf in-
situ immunohistochemistry was performed on ocular sections of Vhltrp1-creKO, 
Vhl;Hif1atrp1-creKO and littermate controls at E14.5. Vhltrp1-creKO mice demonstrated 
a strong activation of Hif1a in the RPE which was absent in both Vhl;Hif1atrp1-
creKO and control mice (figure 3.2 B-G). In situ hybridisation demonstrated 
increased Vegf expression in the RPE of both Vhltrp1-creKO and Vhl;Hif1atrp1-creKO 
mice (figure 3.2 H-J) indicating that RPE-specific inactivation of Vhl leads to a 
Hif1a-independent upregulation of Vegf in the RPE. Increased Vegf expression 
apparent in the neuroretina of these animals indicates secondary non-cell 
autonomous effects that are independent of Hif1a. 
To determine the concentration of the Vhl target proteins Hif1a, Hif2a as well as 
Vegf at the onset of microphthalmia, protein concentration was measured in 
whole eyes of Vhltrp1-creKO, Vhl;Hif1atrp1-creKO and control mice at P0 by ELISA 
119 
 
(range 5-7 mice per group). Hif1a, Hif2a and Vegf protein levels were 
significantly increased in Vhltrp1-creKO mice compared with littermate controls 
(p=0.002 for Hif1a, 0.01 for Hif2a and 0.01 for Vegf). In contrast, Vhl;Hif1atrp1-
creKO mice revealed similar Hif1a levels and significantly increased Hif2a and 
Vegf protein levels compared with littermate controls (p=0.01 for Hif2a and Vegf, 
figure 3.2K).  
To determine further the effect of Hif stabilisation in the RPE on ocular levels of 
downstream target genes, the expression of Epo, Flt1, Pdgf-b and Vegf mRNA 
was measured in whole eyes of Vhltrp1-creKO, Vhl;Hif1atrp1-creKO and control mice at 
P0 by real-time PCR (n=7 per group). Epo mRNA levels were increased in both 
Vhltrp1-creKO and Vhl;Hif1atrp1-creKO mice compared with littermate controls 
(p=0.03). Flt1 levels were increased in Vhltrp1-creKO mice compared with littermate 
controls (p=0.08). Vhl;Hif1atrp1-creKO mice, however, revealed normal Flt1 levels 
compared with littermate control. Pdgf-b and Vegf RNA levels appear to be 
increased in both Vhltrp1-creKO and Vhl;Hif1atrp1-creKO mice compared with littermate 
controls although this did not reach statistical significance (p=0.2 for Pdgf-b, 
p=0.27 for Vegf, figure 3.2L).  
Taken together, these data suggest that RPE-specific inactivation of Vhl leads to 
early stabilisation of Hif1a in the pigmented epithelium and a Hif1a-independent 
increase of Vegf in the RPE. Subsequently, a Hif1a-dependent increase in Flt1 
and Hif1a-independent increases in Vegf and Epo levels suggest primary RPE-
specific and secondary neuroretinal perturbation of angiogenic factors. 
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Figure 3.2 Conditional inactivation of Vhl in the RPE increases levels of Hif1a, Hif2a and 
downstream angiogenic factors. (A) Representative cre immunohistochemistry in C57BL/6
trp1-
cre
 mice at E14.5 demonstrates a specific cre expression in the RPE. (B-G) Representative Hif1a 
immunohistochemistry in Vhl
trp1-creKO
, Vhl;Hif1a
trp1-creKO
 and control mice at E14.5 shows an RPE-
specific activation of Hif1a in Vhl
trp1-creKO 
mice which is absent in Vhl;Hif1a
trp1-creKO
 and control 
mice. (H-J) Representative Vegf in situ hybridization (performed by M.Powner, IoO UCL) 
demonstrating increased expression of Vegf in the RPE and neuroretina in Vhl
trp1-creKO 
and 
Vhl;Hif1a
trp1-creKO 
mice. (K) ELISA data: Quantification of Hif1a, Hif2a and Vegf protein levels in 
Vhl
trp1-creKO
, Vhl;Hif1a
trp1-creKO
 and control mice at birth (range 5-7 animals per group). (L) RT-PCR 
data: Quantification of Epo, Flt-1, Pdgf-b and Vegf mRNA levels in Vhl
trp1-creKO
, Vhl;Hif1a
trp1-creKO
 
and control mice at birth (n=7 eyes per group, performed by A.Georgiadis, IoO, UCL). *= p<0.05. 
Error bars indicate mean ±s.e.m. Scale bars: 75µm in row D, 50µm in row A’ and K-M,150µm A’. 
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3.3.3 Conditional inactivation of Vhl in the pigmented epithelium 
results in early abnormal ocular development and retinal 
degeneration in the adult 
To further elucidate the developmental defect in Vhltrp1-creKO eyes, histology on 
H&E stained paraffin sections was assessed at different pre- and postnatal time 
points (range 3-5 mice per genotype per timepoint, figure 3.3A-U). In line with 
the macroscopical examination, Vhltrp1-creKO eyes revealed a rudimentary 
development of the iris and ciliary body and reduced RPE pigmentation from 
E17 onwards (figure 3.3H,I). At E17 rather than the typical forward extension 
and thinning of the periphery of the optic cup demarcating the beginnings of the 
development of the ciliary body and iris, Vhltrp1-creKO mice show a lack of growth 
and forward extension of the pigmented layer and an abnormal backward folding 
extension of the neuroepithelium (figure 3.3I). By P7, the retina of Vhltrp1-creKO 
mice began to fold and form rosettes which increased over time in both number 
and size becoming most prominent at P31 (figure 3.3L,M). Although the eye 
growth of Vhltrp1-creKO mice was significantly reduced in postnatal development, 
the lens developed normally and occupied the vitreous cavity and the anterior 
chamber in the young adult (figure 3.3N). Vhl;Hif1atrp1-creKO mice in contrast 
showed a normal iris and ciliary body development and normal ocular growth 
with both anterior chamber and vitreous cavity and retina remaining preserved 
(figure 3.3O-U). Nonetheless, Vhl;Hif1atrp1-creKO showed a few irregularities in 
retinal layering in the periphery and a persistent hyaloid vasculature at P31 
(figure 3.3T,U). Taken together, these data support the initial finding that Vhl 
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dependent Hif1a degradation is essential for normal iris, RPE and ocular 
development and indicates that it is associated with retinal degeneration in the 
adult. 
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Figure 3.3 Vhl
trp1-creKO 
mice show early defects in iris and RPE development associated with retinal degeneration and microphthalmia in 
the adult that are mediated by Hif1a. Representative H&E histology in Vhl
trp1-creKO
, Vhl;Hif1a
trp1-creKO
 and control animals at E17 (columns A,B,C), 
P1 (column D), P7 (column E) and P31 (columns F,G). Scale bars: 250 µm in column A, 25 µm in column B, 20 µm in column C-F, 500 µm in 
column G. 
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3.3.4 Conditional inactivation of Vhl leads to a Hif1a mediated 
abnormal morphology and reduction of RPE cells 
To determine the effect of Vhl inactivation on RPE morphology and survival, we 
characterised the RPE in further detail by semithin and ultrastructural analysis, 
and quantified apoptosis by caspase 3 immunohistochemistry at P0 (n= 4-5 
animals per group).  
Vhltrp1-creKO mice demonstrated a 60 % (s.d. ±4%) reduction in the number of 
RPE cells compared with littermate controls t P0 (figure 3.4A,D,J; p<0.0001). 
Ultrastructural analysis revealed a dysmorphic RPE with dystrophic changes 
and a reduction in the content of melanin granules. The remaining granules 
appeared to be irregularly shaped, and melanin granules with the typical 
fusiform shape were scarce in number. Although the remaining RPE cells were 
sparse and the thickness of the RPE reduced, Bruch’s membrane was 
preserved (figure 3.4B,E). Furthermore, Vhltrp1-creKO mice demonstrated a 
significant increase of apoptotic cells in the RPE and in the pigmented iris 
(p<0.0001, figure 3.4C,F,K,M). The rate of apoptosis in the developing neural 
retina, however, was similar to that of littermate controls at birth (p=0.22, figure 
3.4L). Vhl;Hif1atrp1-creKO mice, in contrast, demonstrated a normal RPE cell 
number and morphology and a normal rate of apoptosis in the RPE, iris and 
neuroretina compared with wildtype controls (figure 3.4G-M). These findings 
indicate that Hif1a-mediated cell death is responsible for reduction in RPE and 
pigmented iris cell number in Vhltrp1-creKO mice and suggest a critical role for Vhl 
in regulating Hif1a levels for normal RPE, iris and eye development. 
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Figure 3.4 Conditional inactivation of Vhl in the RPE results in Hif1a mediated apoptosis 
and dystrophy of RPE cells. Semithin (A,D,G) and electron microscopy histology (B,E,H) show 
a reduced and dystrophic RPE in Vhl
trp1-creKO
 compared with Vhl;Hif1a
trp1-creKO
 and control 
littermates at P0. Representative caspase-3 immunohistochemistry (C,F,I) demonstrate 
increased apoptosis in the RPE and iris in Vhl
trp1-creKO
 compared with Vhl;Hif1a
trp1-creKO
 and 
control littermates at P0. Quantification of RPE cells (J) and apoptotic cells in the RPE, retina 
and iris in Vhl
trp1-creKO
, Vhl;Hif1a
trp1-creKO
 and control littermates at P0 (K-M). * = p<0.05, ANOVA 
Test. Error bars = ±SEM. Scale bars: 20 µm in A,D,G, 5 µm in B,E,H and 50 µm in C,F and I. 
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3.3.5 Conditional inactivation of Vhl results in Hif1a mediated 
reduced proliferation of retinal precursor cells 
To determine the effect of RPE cell death in Vhltrp1-creKO mice on neuroretinal 
development, the rate of neuroretinal cell proliferation was assessed by 
phospho-histone H3 immunohistochemistry at birth (range 4-5 mice per group).  
Conditional inactivation of Vhl in the RPE was associated with a significant 
reduction of mitotic cells in the proliferation zone of the developing retina 
compared with littermate controls (p=0.009, figure 3.5A-F, J). Additional 
inactivation of Hif1a in the RPE in Vhl;Hif1atrp1-creKO mice resulted in a normal 
rate of neuroretinal cell proliferation compared with control animals (figure 3.5G-
J). The level of proliferation in RPE and in the pigmented iris cells, however, was 
similar in Vhltrp1-creKO, Vhl;Hif1atrp1-creKO and control mice at birth (p=0.35 for RPE, 
p=0.27 for iris cell proliferation, figure 3.5K-L).  
These data demonstrate that Hif1a stabilisation in the pigmented epithelium in 
Vhltrp1-creKO mice is associated with secondary effects on neuroretinal cell 
proliferation and retinal development that may contribute to the development of 
microphthalmia. 
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Figure 3.5 Conditional inactivation of Vhl in the RPE results in Hif1a mediated reduction 
of proliferating retinal precursor cells. Representative phospho-histone H3 (PH3) 
immunohistochemistry staining in the eye, anterior chamber and retina in Vhl
trp1-creKO
, 
Vhl;Hif1a
trp1-creKO
 and controls at P0 (A-I). Relative quantification of the number of proliferating 
cells in the retina, iris and RPE in Vhl
trp1-creKO
 compared with Vhl;Hif1a
trp1-creKO
 and control 
littermates at P0 (J-L). Error bars indicate mean ±SEM. * = p<0.05, ANOVA Test. Scale bars: 
300 µm in A,D,G, 100 µm in B,E,H and 80 µm in C,F,I. 
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3.3.6 Conditional inactivation of Vhl in the RPE alters expression 
levels and distribution of Pax6 and Otx2  
Since microphthalmia and aniridia have been associated with mutations in Pax6 
(Hill et al., 1991; Jordan et al., 1992), Otx2 (Matsuo et al., 1995) and Mitf (Cheli 
et al., 2010), the cellular distribution of Pax6 and Otx2 and the global expression 
levels of Otx2, Pax6 and Mitf was assessed in the eyes of Vhltrp1-creKO, 
Vhl;Hif1atrp1-creKO and control mice at birth by immunohistochemistry and RT-
PCR respectively. Immunohistochemistry demonstrated a similar distribution of 
Pax6 in the central neuroretina of Vhltrp1-creKO, Vhl;Hif1atrp1-creKO and control mice 
(figure 3.6A-F). Within the distal retina, i.e. the primordium of the iris, however, 
Pax6 expressing cells were reduced in Vhltrp1-creKO mice compared with 
Vhl;Hif1atrp1-creKO and control mice (figure 3.6B). Pax6 RNA expression was 
significantly decreased in Vhltrp1-creKO compared with control mice at birth 
(p=0.02, figure 3.6G). Vhl;Hif1atrp1-creKO mice in contrast showed normal global 
Pax6 expression levels compared with wildtype controls. These data suggest 
that conditional inactivation of Vhl in the RPE and pigmented iris progenitor cells 
leads to reduced levels of Pax6 expressing cells in the distal part of the optic 
cup by birth which may contribute to the abnormal iris development.  
Immunohistochemistry staining for Otx2 revealed similar Otx2 levels in the 
neuroretina of Vhltrp1-creKO and control mice, increased staining in the neuroretina 
of Vhl;Hif1atrp1-creKO mice and normal staining in the RPE in both Vhltrp1-creKO, 
Vhl;Hif1atrp1-creKO compared with control mice (figure 3.6 H-M). Global Otx2 RNA 
expression levels were also similar in Vhltrp1-creKO mice compared with control 
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animals suggesting that conditional inactivation of Vhl results in microphthalmia 
that is independent of Otx2. Global Otx2 mRNA levels were twofold increased in 
Vhl;Hif1atrp1-creKO mice compared with Vhltrp1-creKO and control mice (p=0.0001, 
figure 3.6N) suggesting that other Vhl dependent molecules affect neuroretinal 
Otx2 expression and localisation in a Hif1a-dependent manner.  
Furthermore RT-PCR analyses demonstrated similar global expression levels of 
Mitf in Vhltrp1-creKO and Vhl;Hif1atrp1-creKO eyes compared with littermate controls 
(p=0.5, figure 3.6O). Although subtle and regional differences in Mitf expression 
cannot be excluded, these findings suggest that the development of 
microphthalmia in Vhltrp1-creKO mice may be independent of Mitf. 
Taken together these data highlight the critical role of Vhl and Hif1a signalling in 
the RPE for normal distribution and expression of important transcription factors 
involved in ocular development. The findings indicate that conditional 
inactivation of Vhl in the pigmented epithelium leads to microphthalmia and 
aniridia, in a mechanism that involves Hif1a-dependent increased RPE and iris 
apoptosis, reduced proliferation of retinal progenitor cells, and reduced Pax6 
expression in the distal optic cup. 
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Figure 3.6 Conditional inactivation of Vhl in the RPE affects expression levels and 
localisation of Pax6 and Otx2 in the neuroretina. Representative immunohistochemistry and 
global relative mRNA levels for Pax6 (A-G), Otx2 (H-M) and Mitf (O, RNA levels only) in Vhl
trp1-
creKO
, Vhl;Hif1a
trp1-creKO
 and littermate control mice at birth. Vhl
trp1-creKO
 mice demonstrate reduced 
Pax6 staining in the anterior retina (B) and decreased global Pax6 expression (G) compared 
with Vhl;Hif1a
trp1-creKO
 and littermate control mice. Otx2 expression is mislocalised and increased 
in Vhl;Hif1a
trp1-creKO
 mice compared with Vhl
trp1-creKO 
and control mice (H,M). Scale bars: 150µm in 
rows B,I; 75µm in rows E,L. GCL, ganglion cell layer; NBL, neuroblast layer; RPE, retinal 
pigment epithelium. Error bars indicate mean ±SEM. * = p<0.05. 
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3.3.7 Conditional inactivation of Vhl in the RPE causes persistence of 
embryonic vascular structures and the formation of chorioretinal 
anastomosis in the adult  
As Hifa stabilisation in the RPE was found to be associated with an early 
increase in angiogenic factors, the vascular phenotype of the anterior (figure 
3.7A-F) and posterior chamber (figure 3.8A-O) was investigated in Vhltrp1-creKO 
and littermate controls by in vivo ICG angiography and immunohistochemistry 
(n=4-6 animals per group). In vivo ICG angiography demonstrated a perfused 
vascular network in the anterior chamber of Vhltrp1-creKO mice at P21 (figure 3.7E) 
consistent with a persistent pupillary membrane. However, collagen IV stained 
cryosections demonstrated vascular staining in the corneal stroma, indicating 
that this vasculature may be situated within the cornea (figure 3.7F). 
Vhl;Hif1atrp1-creKO mice, in contrast, exhibited a normal vasculature of the iris and 
ciliary body and an avascular cornea (figure 3.7H,I). Furthermore, Vhltrp1-creKO 
mice demonstrated a persistent hyaloid vasculature (figure 3.8F,G) and a 
disorganised retinal vasculature with abrogated vascular layering and 
chorioretinal anastomosis at P21 (figure 3.8H-J). Similarly, Vhl;Hif1atrp1-creKO 
mice exhibited persistent hyaloid vessels, a dense intra retinal vascular network 
with abrogated vascular layering and chorioretinal anastomosis (figure 3.8K-O). 
These vascular changes were associated with macroscopic intraretinal and 
vitreous bleedings (figure 3.8L inlay). These data suggest that Vhl mediated 
Hif1a regulation is essential for normal vascularisation of the anterior chamber 
whereas other Vhl regulated pathways control vascularisation of the retina.  
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Figure 3.7 Vhl
trp1-creKO
 mice exhibit a Hif1a dependent abnormal vascular phenotype in the 
anterior chamber. Infrared imaging (A,D,G), indocyanin-green angiography (B,E,H) and 
collagen IV stained cryosections (C,F,I) of Vhl
trp1-creKO
, Vhl;Hif1a
trp1-creKO
 and control littermates at 
P21 show a perfused vascular network in the anterior chamber of Vhl
trp1-creKO
 mice which is 
absent in Vhl;Hif1a
trp1-creKO
 and control mice. AF-SLO = autofluorescence scanning laser 
ophthalmoscope ICGA= indocyanin-green angiography. AC = anterior chamber. CB = ciliary 
body. Scale bar: 75 µm. 
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Figure 3.8 Vhl
trp1-creKO 
mice show a Hif1a independent persistence of the hyaloid vasculature and a disorganised retinal vasculature. 
Indocyanin-green angiography (A,E,I) and corresponding collagen4 stained retinal flatmounts (B-D, F-H, J-L) show a persistent hyaloid 
vasculature in Vhl
trp1-creKO
 and Vhl;Hif1a
trp1-creKO
 mice at P21. Vhl
trp1-creKO
 and Vhl;Hif1a
trp1-creKO
 mice demonstrate a disorganised retinal vasculature 
with retinal vessels growing in the outer retina (F-O). Vhl;Hif1a
trp1-creKO
 exhibit a dense and disorganised retinal vasculature (L,M,N) which can be 
associated with intraretinal haemorrhage (inlay L). FM = flatmount; SLO = scanning laser ophthalmoscope. Scale bar: 1 mm for B,F,J and 50 µm 
C-D, G-H and K-L. 
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To characterise the vascular phenotype in more detail, the ocular vasculature 
was examined on cryosections at different timepoints during retinal vascular 
development (n=4-5 animals per group per timepoint, figure 3.9A-P). Compared 
with littermate controls, Vhltrp1-creKO mice revealed a normal retinal vasculature 
until postnatal day 7, demonstrating a superficial vascular network and vessels 
diving into the outer plexiform layer in the central retina (figure 3.9H). In 
temporal association with the observed rosette formation, Vhltrp1-creKO mice 
exhibit disorganised retinal vasculature and chorioretinal anastomosis from P14 
onwards (figure 3.9I,J). Vhl;Hif1atrp1-creKO mice present with a similar 
disorganised retinal vasculature and chorioretinal anastomosis as seen in Vhltrp1-
creKO mice from P14 onwards (figure 3.9O,P).  
These data indicate that Vhl expression in the RPE is critical for normal layering 
of the retinal vasculature and maintenance of the blood-retina barrier that is 
independent of Hif1a. 
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Figure 3.9 Conditional inactivation of Vhl in the RPE results in disruption of the retinal 
vascular architecture and in the formation of chorioretinal anastomosis. Representative 
collagen-4 stained cryosections of control (A-D), Vhl;Hif1a
trp1-creKO
 (G-J) and Vhl
trp1-creKO
 mice (M-
P) at different time points during development demonstrate a disorganised retinal vasculature 
and chorioretinal anastomosis (I,O) in Vhl;Hif1a
trp1-creKO
 and Vhl
trp1-creKO
 mice. GCL, ganglion cell 
layer; NBL, neuroblast layer; Cho, choroid; INL, inner nuclear layer, ONL, outer nuclear layer; 
Scale bar: 25 µm.  
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3.3.8 Conditional inactivation of Vhl in the RPE causes retinal 
degeneration in the adult  
To determine the long-term consequences of Vhl deletion in the RPE, retinal 
changes were examined in adult Vhltrp1-creKO mice in detail by 
immunohistochemistry and electroretinography (range 5-7 animals per group). 
Adult Vhltrp1-creKO mice (8 weeks) develop a severe retinal degeneration with 
absent retinal lamination, a reduction of rhodopsin and recoverin expression, 
and reduced synapse formation as shown by GFAP, rhodopsin, recoverin and 
CtBP immunohistochemistry (figure 3.10F-H). These morphological changes 
were associated with absent photopic and scotopic ERG function at all light 
intensities tested (figure 3.10I,J,P,Q). Additional inactivation of Hif1a in the RPE 
restores retinal lamination but does not abrogate GFAP activation or rescue 
rhodopsin and recoverin expression, or synapse formation (figure 3.10K-M). 
This is associated with detectable scotopic a-waves at light intensities higher 
than 0.1 cd.s/m2 indicating the presence of functioning photoreceptor cells, but 
highly-attenuated b-waves consistent with reduced formation of synapses that is 
essential for bipolar cell activation (figure 3.10N-Q).  
These data suggest that Vhl expression in the RPE during development is 
critical for the maturation of a normal functioning retina. Vhl-dependent Hif1a 
degradation in the RPE promotes normal retinal layering but does not appear to 
control maturation of the outer retina, which may depend on other Vhl-
dependent factors such as Hif2a. 
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Figure 3.10 Conditional inactivation of Vhl in the RPE results in retinal degeneration in the adult which is partly dependent on Hif1a. 
Compared with littermate control (A-E) Vhl
trp1-creKO
 demonstrate an extensive retinal degeneration with absent retinal layering (F), increased GFAP 
associated scarring (G), decreased rhodopsin and recoverin expression and reduced synapses formation (G,H) which is associated with absent 
photopic and scotopic ERG function (I,J). Additional inactivation of Hif1a in the RPE (K-O) restores retinal layering (K) but still results in increased 
GFAP activation (L), reduced rhodopsin and recoverin expression and decreased synapsis formation (L,M). This is associated with traces of a-
waves at high light intensities in the scotopic ERG (N,P) and absent photopic ERG responses (O,Q). Mean b-wave amplitude (±s.e.m.) under 
photopic and scotopic condition at different light intensities (P,Q). Scale bar (column A-C): 50 µm. Scale, column D: 0.2 mV/div; column E 0.1 
mV/Div.
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3.4 Discussion 
In the eye, oxygen plays a critical role in both physiological vascular 
development and common blinding diseases. The RPE is essential for normal 
ocular development and is implicated in the pathogenesis of hypoxia-induced 
retinal vascular disease (Stefansson et al., 2010). However, the role of the 
oxygen sensing VHL/HIF1a pathway in the RPE and its contribution to the 
development of the eye and its vasculature has not previously been examined. 
In this chapter I investigated the function of Vhl and Hif1a in the developing RPE 
using a tissue-specific conditional knockout approach. Deletion of Vhl in the 
RPE results in a significant increase of Hif1a and Hif2a protein which is 
associated with a severe developmental phenotype, including the development 
of aniridia, microphthalmia and a strong pathological vascular phenotype in the 
anterior and posterior segments. Interestingly, aniridia, microphthalmia and the 
anterior vascular phenotype, but not the vascular phenotype in the retina, could 
be rescued by additional deletion of Hif1a in the RPE. These findings indicate 
that Vhl-dependent regulation of Hif1a in the RPE and pigmented iris cells is 
critical for normal ocular and iris development whereas other Vhl-dependent 
pathways in the RPE determine normal retinal vascularisation. The results also 
suggest that ocular hypoxia may be a previously unrecognised mechanism in 
the development of microphthalmia and that reduced systemic oxygenation, for 
example in placental insufficiency, could have major effects on ocular 
development through activation of HIFs in the RPE. 
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The results in this chapter demonstrate that conditional inactivation of Vhl in the 
RPE is associated with Hif1a-dependent increased apoptosis of RPE and 
pigmented iris cells. This finding is consistent with the results of recent studies 
which show that conditional inactivation of Vhl in the neuroretina is associated 
with increased apoptosis of photoreceptor cells (Kurihara et al., 2010; Lange et 
al., 2011). It is important to point out that Hif1a regulates not only survival genes 
via its control of cellular proliferation, metabolism and vasomotor control (Sharp 
and Bernaudin, 2004), but can also induce expression of pro-apoptotic factors. 
Hif1a can promote p53-mediated hypoxia-induced apoptosis in neurons of the 
CNS (Halterman et al., 1999), in part by upregulation of pro-apoptotic genes 
such as Bnip3, Nix, Igfbp3 and also by downregulation of anti-apoptotic genes 
like Bcl2 (An et al., 1998; Bacon and Harris, 2004; Carmeliet et al., 1998). These 
Hif1a-mediated pro-apoptotic mechanisms may be responsible for the RPE and 
iris cell loss in Vhltrp1-creKO mice and contribute to the observed microphthalmia 
and aniridia. These findings are consistent with the finding that toxic ablation of 
the RPE in vivo results in disorganisation of the retinal layer and an immediate 
arrest of eye growth (Raymond and Jackson, 1995). Furthermore, RPE cell loss 
in Vhltrp1-creKO mice is associated with a secondary reduction in proliferating iris 
and retinal progenitor cells that may further contribute to the development of 
aniridia and microphthalmia.  
Mutations in various transcription factors, including the microphthalmia-
associated transcription factor (Mitf), the paired box gene 6 (Pax6) and the 
orthodenticle protein homolog 2 (Otx2) are associated with the development of 
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aniridia and microphthalmia (Fuhrmann, 2010). Mitf plays a key role in 
melanocyte differentiation, proliferation and survival. Mitf knockout mice develop 
severe microphthalmia which is similar to that in Vhltrp1-creKO mice (Cheli et al., 
2010). Inactivation of Mitf results in apoptosis of melanocytes (McGill et al., 
2002) by downregulation of the critical anti-apoptotic mediator Bcl2, which 
protects RPE cells in vitro (Liang et al., 2000). The findings in this chapter 
indicate that conditional inactivation of Vhl in the RPE is associated with normal 
global expression levels of Mitf. Although regional differences in Mitf expression 
in the eyes of Vhltrp1-creKO mice cannot be excluded, these data suggest that 
conditional inactivation of Vhl in the RPE results in microphthalmia that is 
independent of Mitf.  
Pax6 is one of the key transcription factors involved in the complex process of 
eye development and plays multiple distinct roles in lens, iris and retinal 
development, involving interactions with other transcription factors (Hever et al., 
2006). Haploinsufficiency of Pax6/PAX6 has been implicated in a number of 
congenital eye disorders in both humans and mice, including aniridia, 
microphthalmia and anterior segment malformations. The results of this chapter 
demonstrate that conditional inactivation of Vhl in the RPE is associated with a 
reduction of Pax6 in the distal optic cup and pigmented iris primordium which 
appears to be Hif1a-dependent. Normal Pax6 expression in the distal optic cup 
is essential for iris development and reduced expression at this site results in iris 
hypoplasia (vis-Silberman et al., 2005). The data suggest that a Hif1a-mediated 
loss of the RPE and the pigmented iris primordium can reduce Pax6 expression 
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in the distal optic cup and may therefore contribute to the absent iris 
development in Vhltrp1-creKO mice. Future studies will have to address the 
interaction of Vhl-Hif with the Pax6 pathway to elucidate further the 
developmental mechanisms responsible for aniridia.  
Otx2 is a transcription factor involved in the regional specification of the eye, 
particularly the RPE in early development (Martinez-Morales et al., 2001). After 
eye regions are specified, Otx2 expression is up-regulated in post-mitotic 
neuroblasts that will eventually differentiate into the various cell types of the 
neural retina (Bovolenta et al., 1997). While Otx2 homozygous embryos display 
a severe head phenotype lacking the anterior neuroectoderm, heterozygous 
deletion of Otx2 can be associated with eye anomalies including anterior 
segment malformations and microphthalmia (Acampora et al., 1995; Matsuo et 
al., 1995). The results presented in this chapter demonstrate that conditional 
inactivation of Vhl in the RPE does not affect Otx2 expression in the retina and 
RPE suggesting that microphthalmia in Vhltrp1-creKO mice may be independent of 
Otx2. However, inactivation of both Vhl and Hif1a results in mislocalised and 
increased Otx2 expression in the neuroretina suggesting that other Vhl-
dependent mechanisms may affect neuroretinal Otx2 expression and 
localisation in a Hif1a-dependent manner. 
Furthermore, conditional inactivation of Vhl in the RPE results in severe retinal 
degeneration with undetectable photopic and scotopic ERG responses in the 
adult. Additional inactivation of Hif1a in the RPE restores retinal lamination and 
detectable scotopic ERG a-wave responses that indicate the presence of 
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functioning photoreceptor cells. The reduced formation of synapses that are 
essential for bipolar cell activation, in these animals may account for the 
persistent attenuation of ERG b-waves. These data suggest that Vhl expression 
in the RPE during development is critical for the maturation of a normal 
functioning retina. Vhl-dependent Hif1a degradation in the RPE promotes 
normal retinal layering but does not appear to control maturation of the outer 
retina, which may depend on other Vhl-dependent factors such as Hif2a. 
 
Whereas conditional inactivation of Hif1a in the RPE results in a normal ocular 
and vascular phenotype (Marneros et al., 2005), the conditional inactivation of 
Vhl in the RPE leads to striking anterior and posterior vascular changes. Adult 
Vhltrp1-creKO mice demonstrate persistence of the pupillary membrane and the 
hyaloid vasculature that usually regress early in development (Ito and Yoshioka, 
1999). These embryonic vascular structures may persist in response to an early 
proangiogenic environment and high Vegf levels derived from RPE and 
pigmented iris cells and subsequently in response to secondary changes in the 
neuroretina. Interestingly, the anterior vascular phenotype, but not the retinal 
vascular phenotype is rescued by additional conditional inactivation of Hif1a. 
This indicates an important primary role of Vhl-dependent Hif1a regulation for 
iris cell survival and the vascular development of the anterior chamber. The 
increased expression of Vegf and other angiogenic factors in the RPE and 
secondarily in the neuroretina in Vhltrp1-creKO mice may also be responsible for the 
dysmorphic and disorganised retinal vascular phenotype. Additional inactivation 
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of Hif1a in the RPE did not abrogate Vegf overexpression in the RPE or 
neuroretina nor rescue the vascular phenotype. This indicates that other Vhl 
regulated downstream molecules, such as Hif2a, may be responsible for Vegf 
expression in the RPE, the secondary increase of angiogenic factors in the 
neuroretina and the associated vascular phenotype. Retina-specific inactivation 
of Vhl leads to a similar but milder vascular phenotype compared with Vhltrp1-
creKO mice, including the persistence of hyaloid vasculature and the pupillary 
membrane (Kurihara et al., 2010; Lange et al., 2011). In contrast to our results, 
Kurihara et al reported that a combined inactivation of Vhl and Hif1a in the 
neuroretina rescues the vascular phenotype suggesting that the observed 
phenotype was Hif1a-mediated. This difference may be explained by the 
different localisation of Vhl inactivation (RPE vs. neuroretina) suggesting that the 
consequences of HIF1a stabilisation in the neuroretina differ from those of 
HIF1a in the RPE. Furthermore, our findings demonstrate that conditional 
inactivation of Vhl or Vhl;Hif1 results in the secondary formation of chorioretinal 
anastomoses. These vascular malformations were evident from P10 onwards 
although Hif1a and Vegf protein levels are already significantly upregulated at 
birth. Oshima et al have shown that mice with overexpression of Vegf in RPE 
develop normal retinal and choroidal vasculature without spontaneous CNV 
formation. However, perturbation of the RPE and the Bruch’s membrane by 
subretinal injection leads to the development of choroidal neovascularisation in 
transgenic mice overexpressing Vegf in the RPE (Oshima et al., 2004). 
Therefore it is possible that spontaneous perturbation of the blood-retina barrier 
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by Hif1a-mediated RPE cell death in Vhltrp1-creKO mice might promote the 
observed formation of chorioretinal anastomoses.  
 
3.5 Conclusion 
Work in this chapter has shown the importance of Vhl and Hif1a signalling in the 
RPE for normal eye growth, iris development and vascular integrity. Appropriate 
regulation of Hif1a by Vhl is essential for normal RPE and iris development, 
ocular growth and vascular development in the anterior chamber, whereas Vhl 
dependent regulation of other downstream molecules is critical for maintaining 
normal retinal vasculature. Ocular hypoxia may be a previously unrecognised 
mechanism in the development of microphthalmia, and reduced systemic 
oxygenation, for example in placental insufficiency, could have major effects on 
ocular development through activation of HIF in the RPE. 
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4. The role of oxygen sensing mechanisms in 
myeloid cells in the development of retinal and 
choroidal neovascularisation  
 
4.1. Introduction 
Oxygen gradients and hypoxic microenvironments are common features in 
development and in ischaemic and inflammatory disease. Bone marrow-derived 
myeloid cells such as neutrophils, dendritic cells and macrophages are a diverse 
group of mononuclear cells that are attracted to these hypoxic and ischaemic 
microenvironments and mediate the local immune response in development, 
health and disease (Ransohoff and Cardona, 2010).  
During development, myeloid progenitors from the yolk sac colonise the 
developing central nervous system and contribute to the direction of the invading 
vasculature (Streit, 2001), the removal of apoptotic cells (Parnaik et al., 2000) 
and synaptic pruning (Stevens et al., 2007). In health, circulating and resident 
myeloid cells are quiescent and functionally dormant. In disease, however, 
myeloid cells are activated and recruited to areas of ischaemia and inflammation 
contributing to angiogenesis and inflammation (Noonan et al., 2008). Myeloid 
cells that migrate into non-perfused and ischaemic tissue encounter a very 
challenging microenvironment which is characterised by low levels of oxygen 
and glucose and high concentrations of lactate and reductive metabolites (Nizet 
and Johnson, 2009; Saadi et al., 2002). In order to survive and maintain their 
function in oxygen deprived condition, myeloid cells must adapt to the 
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demanding environment. It is widely accepted that this adaptive response to 
hypoxia in myeloid cells is mediated by activation of hypoxia-inducible 
transcription factors. Hif1a activation in myeloid cells orchestrates the metabolic 
shift to anaerobic glycolysis (Cramer et al., 2003), extends the lifespan of 
functional neutrophils by inhibiting apoptotic pathways (Walmsley et al., 2005) 
and increases the production and secretion of inflammatory and angiogenic 
molecules such as tumour necrosis factor (TNF), vascular endothelial growth 
factor (Vegf) and nitric oxide (figure 4.1, (Burke et al., 2002; Peyssonnaux et al., 
2005). Conditional inactivation of Hif1a in myeloid cells results in a reduced 
inflammatory response in experimental models of acute inflammation, including 
arthritis and inflammatory skin disease (Cramer et al., 2003) which highlights the 
critical role of Hif1a signalling in myeloid cells for inflammatory processes.  
In the eye, myeloid cells control blood vessels branching and fine-tune vascular 
density and remodeling during retinal and hyaloid vascular development 
(Kurihara et al., 2011; Stefater, III et al., 2011). In the adult, the retina contains 
three distinct populations of myeloid-derived cells including perivascular 
macrophages, parenchymal microglia and a recently described population of 
dendritic cells (Xu et al., 2007b). Replenishment of myeloid populations in the 
healthy retina has been suggested to be accomplished both by in situ 
proliferation of resident cells (Kloss et al., 1997; Lee et al., 1994) and via 
recruitment of bone marrow (BM)-derived macrophages (Xu et al., 2007a). 
Under pathological condition, e.g. in response to tissue insults, circulating 
monocyte precursor cells are quickly recruited to injured retinal tissue and 
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differentiate into tissue macrophages and microglia (Caicedo et al., 2005) which 
carry out phagocytosis of tissue debris and release a diverse array of vascular 
and proinflammatory mediators. The conventional understanding is that 
macrophages can be subdivided into a M1 (classically activated) or M2 
(alternatively activated) population. M1 macrophages are characterised by a 
pro-inflammatory phenotype and activated by lipopolysaccharide and interferon 
gamma to promote T-helper-1 (TH1) responses and secrete bactericidal factors. 
M2 macrophages, in contrast, exhibit an immunosuppressive phenotype and 
release cytokines that promote a TH2 response (Mantovani et al., 2002). 
Compelling evidence indicates that activated microglia and macrophages play a 
critical role in the development of retinal and choroidal neovascularisation. 
Activated microglia/macrophages have been found to be markedly increased in 
the retina in human diabetic retinopathy and in subretinal membranes in age-
related macular degeneration (Skeie and Mullins, 2009; Zeng et al., 2008b). 
Macrophages were also found to be increased in mouse models of retinal and 
choroidal neovascularisation and suggested to promote pathological 
angiogenesis (Sakurai et al., 2003). Systemic depletion of macrophages by 
clodronate liposomes has been shown to significantly reduce Vegf levels and 
hamper the development of retinal and choroidal neovascularisation in the OIR 
and laser CNV mouse model (Kataoka et al., 2011; Sakurai et al., 2003). 
Although there is no direct proof yet, these results raised the possibility that 
activated blood-recruited macrophages and microglia are promoting the 
development of retinal and choroidal neovascularisation by expressing 
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angiogenic factors including VEGF. The role of Hif1a signalling in myeloid cells 
and its contribution to Vegf expression and the development of retinal and 
choroidal neovascularisation, however, is largely unknown. 
 
4.2. Aims 
The aim of this chapter is to investigate the role of oxygen sensing mechanisms 
in myeloid cells in the development of pathological ocular neovascularisation. In 
particular I aim to determine the roles of Hif1a, its downstream effector protein 
Vegf, and its upstream regulator Vhl, in myeloid cells during the development of 
retinal and choroidal neovascularisation. 
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Figure 4.1 Hif activation in myeloid cells in microenvironments of hypoxia. Myeloid-derived 
phagocytes such as monocytes and neutrophils have low levels of Hif as they circulate in the 
oxygen-rich blood. When recruited to tissue sites of ischaemia, they transmigrate across the 
endothelium and encounter decreasing oxygen tensions which results in Hif activation. HIF 
activity promotes phagocytosis of cell debris and pathogens; inhibits apoptosis to increase 
phagocyte lifespan; stimulates the release of granule proteases, vascular endothelial growth 
factor (VEGF, which increases vascular permeability) and pro-inflammatory cytokines (such as 
tumour necrosis factor (TNF), interleukin 1 (IL-1) and IL-12); and activates the production of 
nitric oxide by inducible nitric oxide synthase. Adapted from (Nizet and Johnson, 2009). 
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4.3. Methods and results 
The work presented in this chapter was kindly supported by Christiana Ruhrberg 
(Department of Cell Biology, Institute of Ophthalmology, UCL, London) who 
provided the C57BL/6lysMcre mice and Alessandro Fantin (Department of Cell 
Biology, Institute of Ophthalmology, UCL, London) who assisted with 
experimental procedures, in particular with the staining and imaging of the 
ocular samples.  
 
4.3.1 Spatial and temporal distribution of myeloid cells in the OIR 
model 
To investigate the spatial and temporal distribution of myeloid cells in the 
development of retinal neovascularisation in the OIR model, knockin mice 
expressing cre recombinase under the control of the myeloid specific promoter 
lysM (lysozyme M, referred to as lysMcre mice) were crossed to Rosa26YFP 
mice. 50% of the resulting offspring (referred to as Rosa26-YFPlysMcre mice) 
expressed cre recombinase under the myeloid cell specific lysM promotor which 
resulted in conditional deletion of a floxed stop codon and consequent YFP 
expression under the transcriptional control of the Rosa26 locus.  
Rosa26-YFPlysMcre mice and littermate controls were exposed to 75% hyperoxia 
from postnatal day 7 to 12 and then returned to room air. Retinal flatmounts and 
ocular cryosections were dissected 2 and 5 days after oxygen incubation (i.e. 
p14 and p17) and stained with anti-collagen4 and anti-YFP. Rosa26-YFPlysMcre 
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mice demonstrated equally distributed and ramnified YFP positive myeloid cells 
in the vascular and avascular area at P14 (figure 4.2B, B’). At P17, YFP and IB4 
expressing myeloid cells accumulated in the area of neovascularisation and 
were closely associated with neovascular tufts (figure 4.2D, D’). Depending on 
the size of the neovascular tufts, 4-10 myeloid cells surrounded each area of 
vascular proliferation that extended towards the vitreous (figure 4.2D’,E). 
As cre recombinase can have cell toxic effects that may compromise normal cell 
survival and function (Loonstra et al., 2001), the effect of cre expression in 
myeloid cells on vascular changes in the OIR model was investigated. 
Compared with littermate controls, Rosa26-YFPlysMcre exhibited a similar area of 
vasoobliteration (41.8±1.2% vs. 42.9±3.4%, p=0.7) at P14 indicating that cre 
expression in myeloid cells has no effect on vessel regression during the 
hyperoxic phase in the OIR model. At P17, Rosa26-YFPlysMcre demonstrated a 
similar area of vasoobliteration (26.5±1.8% vs. 29.5±1.8%, Mann-Whitney-Test 
p=0.6) and retinal neovascularisation (21.1±0.7% vs. 20.8±1.1%, p=0.7) 
compared with littermate controls indicating that cre expression in myeloid cells 
has no effect on the vascular changes in the OIR model (figure 4.2 F,G). 
Taken together, these data demonstrate that lysMcre positive myeloid cells 
accumulate at sites of retinal neovascularisation in the OIR model and that cre 
expression in myeloid cells has no effect on the vascular response in the OIR 
model. These data indicate that B6C57lysmCre mice are a suitable tool to study 
the role of Hif1a activation and Vegf expression in myeloid cells in the 
development of retinal neovascularisation in the OIR mouse model.  
152 
 
 
 
Figure 4.2 LysMcre expressing myeloid cells accumulate around retinal 
neovascularisation in the OIR model. Representative retinal flatmount of a Rosa26-YFP
lysMcre
 
mouse and littermate control in the OIR model stained with the vascular marker isolectin B4 and 
an antibody for YFP on postnatal day (P) 14 (A,B) or P17 (C,D). B’ and D’ show higher 
magnification images of the areas shaded in B,D. Examples of arteries (a), veins (v), the area of 
vasoobliteration (vo) and nevoascularisation (nv) are indicated in A and C. Note ramified YFP-
positive myeloid cells at P14 (B’) and strongly IB4-and YFP-positive myeloid cells associated 
with a neovascular tuft at P17 (D’). Retinal crosssection of a Rosa26-YFP
lysMcre
 mouse stained 
with Ib4, anti-YFP and Dapi demonstrates the pretretinal localisation of the neovascularisation 
and surrounding lysMcre positive myeloid cells (E). Quantification of the area of vasoobliteration 
and neovascularisation in control and Rosa26-YFP
lysMcre
 mice at P14 and P17 shows no effect of 
cre expression in myeloid cells on the vascular changes in the OIR model (F,G). Scale bar: 
150µm in A-D, and 50µm in B’, D’ and E. 
153 
 
 
4.3.2 Conditional inactivation of Hif1a or Vegf in myeloid cells 
reduces the development of retinal neovascularisation in the OIR 
model 
 
To determine the role of Hif1a signalling and Vegf expression in myeloid cells in 
the development of retinal neovascularisation, C57Bl6lysMcre mice were mated 
with Hif1afloxed/floxed (Ryan et al., 2000) or Vegfa-floxed mice (Gerber et al., 
1999). The resulting offspring (referred to as Hif1alysMcre and VegflysMcre) exhibit a 
cell-specific deletion of the Hif1a and the Vegf gene in approximately 75-95% of 
neutrophils and peritoneal macrophages (Cramer et al., 2003) and have a 
normal postnatal viability and no deviant phenotype.  
 
Hif1alysMcre and VegflysMcre mice were exposed to 75% hyperoxia from postnatal 
day 7 to 12 and then returned to room air. Retinal flatmounts were dissected 5 
days after oxygen incubation (i.e. P17) and stained for the retinal vasculature 
with anti-IB4 antibodies. The area of vasoobliteration and neovascularisation in 
Hif1alysMcre and VegflysMcre mice was assessed at P17 and normalised to 
littermate controls (n= range 8-18 independent eyes per group). Results were 
compared using an ANOVA test with a Tukey post test to correct for multiple 
testing.  
 
Hif1alysMcre mice demonstrated a similar area of ischaemia at P17 compared with 
littermate controls (85.8±25.3% vs. 100±13.6%, p=0.14). The area of retinal 
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neovascularisation, however, was significantly reduced compared with littermate 
controls at P17 (48.7±19.7% vs. 100±25.7%, p=0.001). Similarly, conditional 
inactivation of Vegf in VegflysMcre mice resulted in a normal area of 
vasoobliteration (123.1±56.3% vs. 100±13.6%, p=0.1) and a significant 
reduction of retinal neovascularisation (47.8±33.5% vs. 100±25.7%, p=0.003) 
compared with littermate controls (figure 4.3).  
These data indicate that Hif1a activation and Vegf expression in myeloid cells 
has no effect on the revascularisation of the ischaemic area but contributes 
substantially to the development of retinal neovascularisation in the OIR model. 
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Figure 4.3 Conditional inactivation of Hif1a or Vegf in myeloid cells reduces retinal 
neovascularisation in the OIR mouse model. (A-F) Representative vessel stained retinal 
flatmounts (column A) and images with higher magnification (column B) at P17 after OIR 
induction demonstrate a similar area of vasoobliteration (outlined in white) and a reduced area of 
neovascularisation (highlighted in yellow) in Hif1a
lysMcre
 and Vegf
lysMcre
 mice compared with 
littermate controls. (I, J) Relative quantification of the area of vasoobliteration and 
neovascularisation in control, Hif1a
lysMcre
 and Vegf
lysMcre
 mice at P17. Error bars indicate ±SEM. 
Scale bar: 1mm in column A, 500µm in column B. * t-test p<0.005. 
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4.3.3 LysM cre expressing myeloid cells accumulate around laser-
induced choroidal neovascularisation 
As myeloid cells have been shown to be important mediators in the development 
of choroidal neovascularisation (Sakurai et al., 2003), the temporal and spatial 
distribution of lysMcre expressing myeloid cells was investigated in Rosa26-
YFPlysMcre mice in the laser-induced CNV model. Three focal laser burns were 
applied to the RPE of 6-8 weeks old Rosa26-YFPlysMcre mice and littermate 
controls (range 3-4 animals per group) using an Argon laser. As macrophage 
infiltration was reported to peak 3 days after laser injury (Sakurai et al., 2003) 
and CNV size analysis is routinely performed at 14 days after laser injury 
(Balaggan et al., 2006), the choroid and RPE were harvested at these 
timepoints and stained for the macrophage marker F4/80, the myeloid and 
vessel marker isolectin B4 (IB4) and for YFP.  
Immunohistochemical analysis demonstrated that lysMcre expressing myeloid 
cells accumulate within and around choroidal neovascularisation at 3 and 14 
days after CNV induction (figure 4.4A, B). The majority of YFP positive cells 
were positive for F4/80 and IB4 and therefore likely to be macrophages (figure 
4.4B1-3, wavy arrows). Some YFP positive cells, however, were negative for IB4 
and F4/80 (figure 4.4B1-3, arrowheads) indicating that they may be myeloid cells 
other than macrophages which are recruited from the blood stream, such as 
monocytes or neutrophils. Only a few cells that were F4/80 and IB4 positive 
were negative for YFP (figure 4.4B1-3, arrows) demonstrating a high efficiency of 
lysMcreYFP expression in myeloid cells.  
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To determine if cre expression in lysM positive myeloid cells influences the 
development of laser-induced choroidal neovascularisation, the area of CNV 
was assessed in Rosa26-YFPlysMcre mice and littermate controls at 3, 7 and 14 
days after laser application using fluorescein angiography. Compared with 
littermate controls, Rosa26-YFPlysMcre mice demonstrated a similar area of 
choroidal neovascularisation in the early phase of the angiography at 3 
(100±41.9% vs. 98.0±45.1%, p=0.97), 7 (100±85.1% vs. 120.3±46.7%, p=0.24) 
and 14 days after laser CNV induction (100±90.4% vs.74.1.0±42.6%, p=0.97). In 
the late phase of the angiography, Rosa26-YFPlysMcre mice revealed a similar 
degree of leakage compared with control animals at 3 (100±41.7% vs. 
93.9±33.0%, p=0.58), 7 (100±49.3% vs. 92.1±38.9%, p=0.87) and 14 days after 
laser (100±48.1% vs. 68.1±20.1%, p=0.74). This data suggests that cre 
expression in lysM activated myeloid cells does not influence the area and the 
leakage of laser-induced CNV at 3, 7 and 14 days after laser.  
 
Taken together, these data demonstrate that lysMcre expressing myeloid cells 
accumulate at sites of choroidal neovascularisation in the laser CNV mouse 
model and that cre expression in these cells does not influence CNV formation. 
These data suggest that lysMcre mice are a suitable tool to study the role of 
Hif1a signalling and Vegf expression in myeloid cells in the development of 
laser-induced choroidal neovascularisation.  
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Figure 4.4 LysMcre expressing myeloid cells accumulate around laser-induced choroidal 
neovascularisation. Representative laser-induced CNV lesions on RPE/choroidal flatmounts 
stained for YFP, F4/80 and IB4 of a control (A) and a Rosa26-YFP
lysMcre 
mouse (B) 3 days after 
laser CNV induction. Wavy errors indicate cells that are positive for YFP, F4/80 and IB4, 
arrowheads show cells that are positive for YFP but negative for F4/80 and IB4 and arrows 
indicate cells that are negative for YFP but positive for F4/80 and IB4. Representative 
fluorescein angiograms (C-H) and relative quantification of CNV lesions in control and Rosa26-
YFP
lysMcre
 littermates 3, 7 and 14 days after laser injury (I-J). Scale bar: 10µm for A, B. 
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4.3.4 Conditional inactivation of Hif1a or Vegf in lysMcre myeloid 
cells reduces laser-induced CNV formation 
 
To determine the role of Hif1a and Vegf in myeloid cells in the development of 
choroidal neovascularisation, C57Bl6lysMcre mice were mated with Vhlfloxed/floxed 
(Haase et al., 2001) Hif1afloxed/floxed (Ryan et al., 2000) or Vegfa-floxed mice 
(Gerber et al., 1999). 6-8 weeks old VhllysMcre, Hif1alysMcre, VegflysMcre and 
wildtype controls (range 5-9 animals per group) were assessed in the laser CNV 
model and fluorescein angiography was performed 3, 7 and 14 days after laser 
injury.  
 
VhllysMcre mice demonstrated a similar area of choroidal neovascularisation in the 
early phase of the angiography at 3 (112±27.4 vs. 100±31.3%, p=0.38), 7 
(97.2±33.3% vs. 100±32.0%, p=0.97) and 14 days after laser CNV induction 
(90.9±22.5% vs. 100±31.0. p=0.94) compared with littermate controls indicating 
that conditional inactivation of Vhl in the myeloid cell lineage has no effect on the 
development of laser-induced choroidal neovascularisation. Hif1alysMcre mice 
revealed a similar area of choroidal neovascularisation in the early phase of the 
angiography at 3 days (94.2±10.0 vs. 100±31.3%, p=0.65), a reduced area of 
choroidal neovascularisation at 7 days (71.4±7.0% vs. 100±32.0%, p=0.34) and 
a significantly reduced area of choroidal neovascularisation at 14 days after 
laser injury (41.6±2.7% vs. 100±31.0. p=0.94, p=0.01). Similarly, VegflysMcre mice 
demonstrated a normal area of choroidal neovascularisation in the early phase 
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of the angiography at 3 days after laser injury (114.9±20.4% vs. 100±31.3%, 
p=0.67), a reduced area of choroidal neovascularisation at 7 (75.6±5.6% vs. 
100±32.0%, p=0.19) and a significantly reduced area of choroidal 
neovascularisation at 14 days after laser injury (35.3±9.6% vs. 100±31.0. 
p=0.009).  
 
Taken together, these data indicate that both Hif1a activation and Vegf 
expression in myeloid cells contribute substantially to the development of 
choroidal neovascularisation. Conditional inactivation of Hif1a or Vegf in myeloid 
cells has no effect on the area of CNV at 3 days after laser but reduces the size 
of choroidal neovascularisation at 7 and 14 days after laser treatment.  
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Figure 4.5 Conditional inactivation of Hif1a or Vegf in myeloid cells reduces CNV 
development. Representative fluorescein angiograms (early phase, 90sec) at 3, 7 and 14 days 
after laser injury in control (A-C), Vhl
lysMcre
 (D-F), Hif1a
lysMcre
 (G-I) and Vegf
lysMcre
 mice (J-L). 
Relative quantification of CNV lesion size at 3, 7 and 14 days after laser injury assessed on 
fluorescein angiograms (M). Error bars indicate SEM. * = ANOVA p<0.05. 
162 
 
 
4.4 Discussion 
Adaptive cellular responses to low levels of oxygen play a critical role in both 
physiological vascular development and in common neovascular blinding 
diseases. Myeloid cells are involved in normal retinal vascular development and 
implicated in the pathogenesis of hypoxia-induced retinal vascular disease. 
However, the role of the oxygen sensing Vhl/Hif1a pathway in myeloid cells in 
the development of pathological ocular neovascularisation has not previously 
been examined. In this chapter I investigated the function of Hif1a signalling and 
Vegf expression in myeloid cells in the development of retinal and choroidal 
neovascularisation using a tissue-specific conditional knockout approach and 
mouse models of retinal and laser-induced choroidal neovascularisation.  
Myeloid cells accumulate at sites of retinal and choroidal 
neovascularisation 
Results shown in this chapter demonstrate that lysMcre expressing myeloid cells 
accumulate at sites of retinal and choroidal neovascularisation in the OIR and 
CNV mouse model. This finding is in line with studies demonstrating that 
myeloid cells are a critical component in the formation of retinal and choroidal 
neovascularisation (Espinosa-Heidmann et al., 2003; Nishimura et al., 1990; 
Sakurai et al., 2003). The origin of myeloid cells that are recruited to the site of 
retinal and choroidal neovascularisation has been the subject of much inquiry. 
Results of this chapter demonstrate that the majority of lysM expressing myeloid 
cells that are recruited to the CNV lesion are positive for the macrophage and 
microglia markers F4/80 and IB4. Since these markers are expressed on both 
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resident microglia and infiltrating systemic macrophages it is impossible to 
deduce from this dataset if the myeloid cells surrounding the CNV lesion are 
recruited from the retina or the blood stream. Some of the lysM expressing 
recruited cells, however, were negative for both F4/80 and Ib4 suggesting that 
myeloid cells other than macrophages are recruited to CNV lesions such as 
circulating monocytes or neutrophils. This hypothesis is in line with recent 
findings demonstrating that the lysM promoter is active in neutrophils (Cramer et 
al., 2003) and that circulating neutrophils infiltrate sites of CNV as early as day 1 
after laser injury (Zhou et al., 2005). Systemic depletion of macrophages and 
neutrophils by intravenous administration of clodronate liposomes has been 
shown to reduce the number of myeloid cells at sites of choroidal 
neovascularisation (Espinosa-Heidmann et al., 2003; Sakurai et al., 2003; Shi et 
al., 2011). Furthermore, mice deficient in the macrophage chemotactic protein 
(MCP)-1, which is secreted by RPE cells in the direction of choroidal vessels to 
attract circulating monocytes during inflammatory responses (Holtkamp et al., 
1999), demonstrate a reduced CNV lesion size (Luhmann et al., 2009). These 
findings suggest that circulating myeloid cells accumulate and contribute to the 
development of choroidal neovascularisation. In addition, resident retinal 
microglia cells were suggested to migrate towards areas of laser injury in the 
outer retina and to contribute to the development of laser-induced choroidal 
neovascularisation (Combadiere et al., 2007).  
In the OIR model, both microglia and circulating myeloid cells were shown to 
accumulate at sites of retinal neovascularisation. Depletion of these cells by 
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local or systemic administration of clodronate liposomes was shown to reduce 
the neovascular response in the OIR model indicating that both circulation-
derived and resident myeloid cells contribute to the development of retinal 
neovascularisation (Ishida et al., 2003; Kataoka et al., 2011). These data are in 
line with the findings in this chapter indicating that both circulating and resident 
lysM positive myeloid cells are recruited to sites of retinal and laser-induced 
choroidal neovascularisation.  
 
 
Hif1a activation and Vegf expression in myeloid cells contribute to the 
development of retinal and choroidal neovascularisation  
Work in this chapter has shown that conditional inactivation of Hif1a or Vegf in 
myeloid cells reduces the development of pathological retinal and choroidal 
neovascularisation. This data is in line with the hypothesis that myeloid cells 
contribute to the development of retinal and choroidal neovascularisation by 
secreting proangiogenic factors. In the CNV mouse model, macrophage 
recruitment and Vegf expression has been shown to coincide and peak at 3 
days after laser injury. Systemic depletion of circulating myeloid cells using 
clodronate liposomes reduces both myeloid recruitment and Vegf expression 3 
days after laser injury indicating that circulating myeloid cells contribute to the 
secretion of proangiogenic factors including Vegf (Sakurai et al., 2003). 
Furthermore, resident retinal microglia cells expressing the CX3C chemokine 
receptor 1 (CX3CR1) – a chemokine involved in the adhesion and migration of 
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leukocytes - migrate towards laser-induced choroidal neovascularisation and 
contribute to CNV formation by expressing proangiogenic factors including Vegf 
(Combadiere et al., 2007). Likewise, in the OIR model, both resident and 
circulating myeloid cells have been shown to accumulate at sites of retinal 
neovascularisation (Ishida et al., 2003; Kataoka et al., 2011). The results of this 
chapter demonstrate that Vegf expression in myeloid cells contributes 
substantially to the development of retinal and choroidal neovascularisation in 
the OIR and CNV mouse model. This data is in line with recent findings 
demonstrating that intravitreous administration of Vegf164 neutralizing aptamers 
reduces both myeloid cell adhesion at the neovascular front and the 
development of pathological neovascularisation (Ishida et al., 2003). 
Furthermore it has been shown that conditional inactivation of Vegf in myeloid 
cells leads to a reduction of pathological vessels in tumours suggesting that 
myeloid cell derived Vegf is a common culprit in the development of pathological 
angiogenesis (Stockmann et al., 2008). 
Work presented in this chapter further indicates that Vegf expression in myeloid 
cells may be driven by Hif1a signalling in pathological angiogenesis. This 
suggestion is based on the finding that myeloid-cell-specific inactivation of both 
Vegf or Hif1a causes a similar reduction of retinal and choroidal 
neovascularisation in the OIR model and the laser CNV model.  
In the OIR model, lysM expressing myeloid cells were found in the 
vasoobliterative area at P14 which is characterised by significant tissue hypoxia 
and activation of Hif1a in cells of the inner retina (Mowat et al., 2010). Hypoxia 
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has been shown to induce accumulation of Hif1a in primary human 
macrophages and mouse bone marrow–derived macrophages in vitro (Burke et 
al., 2002) and to increase the expression of Vegf120 and Vegf164 in circulating 
monocytes in a rat model of proliferative retinopathy (Ishida et al., 2003). The 
challenging hypoxic microenvironment in the vasoobliterative area may therefore 
induce Hif1a activation and Vegf expression in resident and infiltrating myeloid 
cells which contribute to the development of retinal neovascularisation.  
In the CNV model, however, Hif1a activation in myeloid cells is more likely to 
occur in response to an inflammatory microenvironment than to tissue hypoxia 
as the oxygen saturation at the level of the RPE is very high (Linsenmeier and 
Braun, 1992; Yu and Cringle, 2006). Proinflammatory cytokines such as Ccl2 
are released from the injured RPE in the laser-induced CNV model (Liu et al., 
2011) and may induce Hif1a signalling and Vegf expression in myeloid cells 
(Hong et al., 2005). Intraocular injection of neutralizing antibodies against Ccl2 
has been shown to reduce macrophage infiltration, Vegf levels and the 
development of choroidal neovascularisation by mechanisms which may involve 
Hif1a mediated Vegf expression (Itaya et al., 2007). Activation of Hif1a signalling 
in myeloid cells by inflammatory mechanisms may therefore be an important 
contributor to the expression of Vegf and aberrant angiogenesis in the laser-
induced CNV model and in inflammatory retinal vascular disease such as AMD. 
The finding that conditional inactivation of Hif1a results in a similar reduction of 
neovascularisation as conditional inactivation of Vegf in myeloid cells, suggests 
that Vegf is the principle downstream effector of Hif1a in myeloid cells in the 
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development of retinal and choroidal neovascularisation. However, it cannot be 
excluded that other Hif1a dependent factors in myeloid cells, such as Epo, 
contribute to the development of neovascularisation in the OIR and CNV mouse 
model. Furthermore, Hif1a activation in myeloid cells has been shown to be 
directly involved in regulating myeloid cell survival in hypoxic microenvironments 
(Walmsley et al., 2005) and to contribute to the recruitment of circulating myeloid 
cells to areas of inflammation (Cramer et al., 2003). Inactivation of Hif1a in 
myeloid cells may therefore reduce the recruitment and the survival of infiltrating 
proangiogenic myeloid cells in the OIR and CNV mouse model which may 
contribute to the observed reduction in retinal and choroidal neovascularisation.  
Surprisingly, the results in this chapter demonstrate that conditional inactivation 
of Vhl in myeloid cells has no effect on the development of choroidal 
neovascularisation in the laser-induced CNV model. This result is unexpected as 
inactivation of Vhl in myeloid cells has been shown to activate Hif1a and 
increase oedema and macrophage infiltration in a model of cutaneous 
inflammation (Cramer et al., 2003). However, it may be possible that the Hif1a 
pathway in myeloid cells is already maximally activated in the OIR and CNV 
model and that an additional inactivation of Vhl has no effect on levels of Hif1a. 
Also, it might be possible that other Vhl dependent transcription factors, such as 
Hif2a, are increased in myeloid cells in VhllysMcre mice and counteract the 
proangiogenic effect of Hif1a in myeloid cells. Hif2a activation in myeloid cells 
has been shown to regulate macrophage function such as migration and 
cytokine expression in mouse models of acute and tumour inflammation (Imtiyaz 
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et al., 2010). Future studies will have to address the role of Hif2a in myeloid cells 
in the retina to further understand the role of oxygen sensing mechanisms in the 
development of retinal and choroidal neovascularisation. 
The data presented in this chapter show that Hif1a signalling in myeloid cells 
contribute substantially to the development of retinal and choroidal 
neovascularisation in hypoxic and inflammatory microenvironments possibly by 
driving Vegf expression or by increasing the recruitment of other proangiogenic 
myeloid cells. Future studies will have to assess the expression levels of Vegf in 
myeloid cells and quantify the number of recruited myeloid cells in Hif1alysMcre 
mice in the OIR and CNV mouse model. This may help to answer the question 
whether the reduced neovascular response can be explained by a reduction in 
myeloid specific Vegf expression, by a lack of recruitment of proangiogenic 
myeloid cells or by both.  
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4.5. Conclusion 
 
The work in this chapter has demonstrated that circulating and resident myeloid 
cells accumulate at sites of retinal and choroidal neovascularisation in the OIR 
and laser-induced CNV model and validated the use of LysMCre mice as an 
efficient tool to study the role of oxygen sensing mechanisms in myeloid cells in 
the development of retinal and choroidal neovascularisation.  
Conditional inactivation of Vegf results in a significant reduction of retinal and 
choroidal neovascularisation demonstrating for the first time direct evidence that 
myeloid cell derived Vegf contributes to the development of retinal and choroidal 
neovascularisation. Conditional inactivation of Hif1a in myeloid cells leads to a 
significant reduction in retinal and choroidal neovascularisation, possibly through 
mechanisms involving a decrease in Hif1a mediated Vegf expression or myeloid 
cell recruitment. These findings demonstrate that Hif1a signalling and Vegf 
expression in myeloid cells contribute substantially to the development of retinal 
and choroidal neovascularisation and provide a rationale for developing 
antiangiogenic treatments that target myeloid cells in the eyes. In particular, 
myeloid cell specific inactivation of Hif1a may become an attractive target to 
effectively treat neovascular retinal eye disease. 
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5. Intraocular oxygen distribution and molecular 
mediators in proliferative diabetic retinopathy 
5.1 Introduction 
The normal function and survival of retinal cells is vulnerable to deficiencies in 
oxygen delivery. Insufficient perfusion of retinal or choroidal vessels leads to 
ischaemia and hypoxia that can cause retinal dysfunction and degeneration 
(Osborne et al., 2004). The importance of ischaemia-induced expression of 
retinal cytokines in the development of diabetic retinopathy is widely accepted. 
Ischaemia and hypoxia have been suggested to cause the release of 
proangiogenic factors, such as VEGF, which contribute to the development of 
neovascularisation in proliferative diabetic retinopathy (D'Amore, 1994). 
However, direct evidence of hypoxia in the human diabetic retina is weak and 
most of our understanding is based on oxygen measurements across the retina 
in diabetic animal models using polarographic electrodes (Alder et al., 1983; 
Linsenmeier and Braun, 1992). The direct measurement of oxygen tension 
within the human retina would present a significant risk of adverse effects and 
has not been reported. Measurement of oxygen tension in the vitreous, which is 
believed to reflect global oxygenation of the retina, has demonstrated lower 
levels of oxygen in the vitreous of diabetic individuals compared to non-diabetic 
individuals (Holekamp et al., 2006; Maeda et al., 1992). However, the 
oxygenation of the vitreous may be influenced by active metabolism of oxygen, 
for example by ascorbate (Shui et al., 2009) and does not help identify any 
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regional differences in retinal oxygenation. Experimental investigation in cats 
has demonstrated that measurement of preretinal oxygen tension closely 
reflects oxygenation of the inner retina (Alder and Cringle, 1985; Linsenmeier et 
al., 1981). To date preretinal oxygen measurements have been thoroughly 
mapped in cats and rabbits (Shui et al., 2006) but not yet in humans.  
A causative association between retinal oxygen and the development of retinal 
neovascularisation was first suggested by Michaelson in 1954 (Michaelson et 
al., 1954) and further explored by Wise who speculated that a hypoxia-induced 
growth factor “factor X” was responsible for inducing retinal neovascularisation 
(Wise, 1956). Many candidate cytokines and growth factors have since been 
characterised, and VEGF has emerged as a particularly prominent mediator of 
intraocular angiogenesis (Aiello et al., 1994). The expression of VEGF is 
upregulated by HIF1a, which is activated in hypoxia (Forsythe et al., 1996). The 
concentrations of both VEGF and HIF1a are increased in the vitreous in 
proliferative diabetic retinopathy and appear to correlate with disease activity 
(Wang et al., 2009) suggesting that hypoxia and stabilisation of HIF1a are 
responsible for VEGF production and progression of retinopathy. However, there 
is accumulating evidence that the HIF system can be activated independently of 
hypoxia, for example in an inflammatory microenvironment (Sharp and 
Bernaudin, 2004) which is a common feature in the pathogenesis of proliferative 
diabetic retinopathy (Gardner et al., 2002). The association between ocular 
hypoxia, inflammation, HIF1a and VEGF expression in human proliferative 
diabetic retinopathy, however, has not been clarified yet. 
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5.1.1 Aims 
The aim of this chapter was to analyse the distribution of oxygen across the 
vitreous and retina in proliferative diabetic retinopathy by measuring the 
preretinal oxygen tension in human subjects using an oxygen probe during 
surgery. Furthermore I aimed to investigate the extent to which hypoxia is 
associated with proliferative diabetic retinopathy by correlating intraocular 
oxygen tensions with the concentrations of HIF1a and vitreous cytokines.  
 
5.2 Methods and results 
5.2.1 Ex vivo assessment of sensor accuracy 
To determine the reliability of the oxygen probe before and after gas sterilisation 
6 different probes (figure 5.1A,B) were each tested in 6 sealed containers filled 
with a range of gas mixtures of known oxygen tensions (0-147.4 mmHg). A 
strong correlation between sensor readings and actual oxygen tensions was 
identified, both before (Pearson correlation 0.997, p=0.0001) and after gas 
sterilisation of the probes (Pearson correlation 0.996, p=0.0001, figure 5.1C,D). 
Furthermore, stable oxygen tension readings were recorded 20 seconds after 
transferring the probes from an oxygen rich to an oxygen poor environment (147 
to 6.9 mmHg), and 30 seconds after transferring them within two low oxygen 
environments (6.9 to 0 mmHg, figure 5.1E,F). On the basis of these findings, the 
surgeon allowed the probe to settle for at least 30 seconds at each intraocular 
site in human subjects before recording the oxygen tension. 
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Figure 5.1 Ex vivo assessment of oxygen sensor accuracy.  
A,B) Oxford Optronix Oxygen sensing monitor and probe. C,D) Ex vivo assessment of 
probe accuracy before and after gas sterilisation. The oxygen probe was tested in 6 
different chamber containing different oxygen concentrations (0-150mmHg). r= Pearson 
correlation coefficient. E,F) Timecourse of probe readings when moving the probe from 
an oxygen rich to an oxygen poor environment (147 to 6.9 mmHg), or within two oxygen 
poor environments (6.9 to 0 mmHg).  
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5.2.2 Characteristics of subjects recruited 
14 individuals with advanced proliferative diabetic retinopathy were included in 
this study. 6 of them had type-1 diabetes and 8 of them type-2 diabetes. All 
subjects presented with preretinal neovascularisation despite previous 
panretinal photocoagulation and had developed tractional retinal detachments 
involving the macula. None of the diabetic subjects had a vitreous haemorrhage 
at the time of surgery. 14 subjects without diabetes were included in this study 
as a control group. Ten of them were listed for intraocular surgery for idiopathic 
epiretinal membrane, and 4 of them for idiopathic full-thickness macular hole. 
The age of the subjects with diabetes ranged from 26 to 78 years (mean 52.2 
±13.6), and those in the control group from 58 to 78 years (mean 66.0 ±5.7). 
 
 
Group n Age (mean, range) Years since diagnosis Gender (M/F) 
PDR, diabetes type 1 6 42 (26-65) 24 (15-37) 5/1 
PDR, diabetes type 2 8 58 (46-71) 20 (15-26) 8/0 
Control 14 66 (58-78) 0.8 (0.6-2) 5/9 
 
Table 5.1 Characteristics of study subjects 
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5.2.3 Measurement of intraocular oxygen tension 
The in vivo measurements of intraocular oxygen tensions were kindly performed 
by Panagiotis Stavrakas (2 subjects), Zdenek Gregor (18 subjects) and James 
Bainbridge (8 subjects). Oxygen tensions were measured in the anterior vitreous 
(1), the mid-vitreous (2), at the retinal surface superior to the superotemporal 
arcade (3a), at the retinal surface one disc-macula diameter temporal to the 
macula (3b), at the retinal surface in the mid-periphery (4, superior equator), in 
between (5) and above areas of photocoagulation (6) and above areas of 
tractional retinal detachment (7, figure 5.2A-C). The measurement was 
completed within approximately 5 minutes in each subject. Except for an entry-
site break in one subject, not directly associated with the use of the oxygen 
probe, there were no adverse events. To determine the test-retest variability in 
vivo and to identify any artefactual disturbance of intraocular oxygen tension 
caused by the measurement technique itself, the mid-vitreous oxygen tension 
measurement in 14 subjects was compared at the start and the completion of 
the process. Both measurements were found to be highly correlated (Pearson 
r=0.94, p=0.0001, figure 5.2D). Because the oxygen tensions measured at the 
retinal surface superior to the superotemporal arcade was very similar to that 
temporal to the macula in each group, the 2 values were averaged and used as 
an indicator for preretinal oxygen tension at the posterior pole.  
The mean oxygen tension in the anterior vitreous of diabetic subjects was 47% 
reduced compared with control subjects (5.6 ±1.03 mmHg vs. 10.69 ±1.82 
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mmHg, p=0.023). The mean oxygen tension in the mid-vitreous of diabetic 
subjects was 46% lower than in control subjects (6.03 ±1.08 mmHg vs. 11.12 
±1.67 mmHg, p=0.017). The mean oxygen tension at the retinal surface of the 
posterior pole was 37% higher in diabetic subjects than in control subjects 
(15.42 ±2.55 vs. 9.78 ±0.64, p=0.039). Within the group of control subjects there 
was no significant difference in preretinal oxygen tension between the posterior 
pole and the mid-periphery (9.78 ±0.64 mmHg vs. 8.73 ±0.54 mmHg, p=0.39). In 
contrast, within the group of diabetic subjects the mean oxygen tension at the 
posterior pole was 47% higher than in the mid-periphery (15.42 ±2.55 vs. 8.22 
±1.34, p=0.024, figure 5.2E). No difference in oxygen tension above laser 
photocoagulated areas compared with non lasered areas was detected in the 
diabetic group (9.38 ±4.9 mmHg vs. 8.77 ±4.7 mmHg, p=0.86, figure 5.2G). The 
oxygen tension measured above areas of tractional retinal detachments was 
increased compared with attached retina in the mid-periphery of diabetic 
subjects (15.5 ±8.8 mmHg vs. 8.77 ±4.7 mmHg, p=0.07, figure 5.2H). This 
difference did not reach a significance level but showed a strong trend towards 
increased oxygen levels above areas of tractional retinal detachments compared 
with attached retina in the mid-periphery of diabetic subjects. 
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Figure 5.2 In vivo oxygen measurements. (A,B) Schematic cross section and map of the 
retina indicating the positions of O2 measurements (1 anterior vitreous; 2 mid-vitreous; 3 retinal 
surface of the posterior pole (=(3a+3b)/2); 3a superior arcade; 3b temporal of macula; 4 retinal 
surface in the mid periphery; 5 peripheral retina between laser coagulated areas; 6 peripheral 
retina above laser coagulated area; 7 tractional retinal detachment). (C) Intraoperative picture of 
the O2 probe in position 3a. D) Mean oxygen tension (±SEM) in mmHg at different sites of the 
vitreous in control and diabetic subjects. (E) Correlation of intraoperative oxygen measurements 
in the mid-vitreous at the beginning and end of the recording. (F) Preretinal oxygen tension 
above the superior arcade (3a) and temporal of the macula (3b). (G) Preretinal oxygen tensions 
in the mid peripheral retina (4) above (5) and in between areas of photocoagulation (6) (H). 
Preretinal oxygen tensions in the mid peripheral retina (4) of control and diabetic subjects 
compared with areas with tractional retinal detachment (7). * = p<0.05. NS= no statistically 
significant difference.  
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5.2.4 HIF1a analysis  
To determine whether the observed mid-vitreous hypoxia in PDR is associated 
with an increased activation of oxygen-sensing mechanisms, HIF1a protein 
levels were measured in the vitreous and plasma of diabetic and control 
subjects. HIF1a protein was on average about two fold higher in the diabetic 
vitreous compared with the control vitreous (7.9±12.3 vs. 3.4±7.0 pg/ml, 
p=0.06). Furthermore, HIF1a protein levels in the vitreous of both groups were 
increased compared with the corresponding plasma suggesting an endogenous 
expression and lower turn-over of Hif1a in the eye (figure 5.3A).  
5.2.5 Protein and cytokine analysis 
To investigate the role of cytokines in diabetic retinopathy, the concentration of 
42 cytokines in the vitreous and plasma of diabetic and control subjects was 
measured using multiplex cytokine arrays. Apart from IL-4, IL-13, TGF-α and 
TNF- all cytokines tested were detectable in vitreous and in plasma samples. 
The concentrations of PDGF-AA, PDGF-AB and RANTES could not be detected 
since their levels were greater than could be quantified with reference to the 
standard curve. Among the 35 measured cytokines detected, 10 cytokines were 
found to be significantly altered in the diabetic vitreous compared with the 
control group. Diabetic subjects revealed increased vitreous levels of Eotaxin, 
Flt-3 ligand, GRO (“growth related oncogen)”, IL-6, IL-7, IL-8, IP-10 (CCL22), 
MDC (“macrophage derived cytokine”) and VEGF compared to controls. With 
the exceptions of Eotaxin, MDC and GRO, these cytokines were present at 
higher concentrations in the vitreous than in the corresponding plasma. IL-9 was 
179 
 
 
the only cytokine found to be significantly reduced in the diabetic vitreous 
compared with the control vitreous. The other tested cytokines were present in 
similar concentrations in diabetes and control subjects, or at concentrations 
below the detection limit of the assay (table 3.2).  
 
Figure 5.3 Molecular mediators in the vitreous and plasma of subjects with PDR and 
controls. (A-N) Mean concentration of HIF1a and cytokines (±SEM) in the vitreous and 
plasma of diabetic and control subjects. Analysis performed by Chris Cox (BioAnaLab 
Limited, Oxford, UK). DV = diabetic vitreous; DP = diabetic plasma; CV= control 
vitreous; CP = control plasma of *=statistically significant.   
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 Vitreous Plasma 
  Diabetic group Control group p value Diabetic group Control croup 
EGF 68.9 (1.6-125.6) 86.6 (1.6-134.0) p = 0.2 ND 12.87 (1.6-39.0) 
Eotaxin  12.2 (1.6-27.6) 2.2 (1.6-7.9) p = 0.0001 95.2 (25.7-254) 73.8 (56.8-112.7) 
FGF-2 ND ND NA ND 8.45 (1.6-25.4) 
Flt-3 Ligand  44.3 (1.6-220.6) 6.39 (1.6-68.6) p = 0.002 ND ND 
Fractalkine 3.21 (1.6-22.5) ND NA ND 25.7 (1.6-61.8) 
G-CSF 5.4 (1.6-29.8) 10.1 (1.6-24.4) p = 0.1 15.55 (10.8-24.0) 18.01 (10.57-24.0) 
GM-CSF 7.2 (1.6-75.4) 3.0 (1.6-21.5) NA 16.6 (1.6-51.7) 15.6 (1.6-21.6) 
GRO  105.6 (1.6-380.8) 29.1 (1.6-132.3) p = 0.001 241.2 (184.1-311) 323.2 (114.7-581) 
IFN-α2 3.5 (1.6-26.4) 3.9 (1.6-13.6) NA ND ND 
IFN-γ 2.0 (1.6-7.6 ) ND NA 2.43 (1.6-5.77) 15.71 (1.6-60.44) 
IL-1α 5.79 (1.6-36.81) 2.49 (1.6-14.1) NA ND ND 
IL-1 ND ND NA ND 5.07, (1.6-13.92) 
IL-1Rα ND  2.1 (1.6-9.6) NA 6.08 (1.6-15.3) 3.02 (1.6-8.7) 
IL-2 ND ND NA ND 2.1 (1.6-6.3) 
IL-3 11.2 (1.6-21.3) 14.6 (3.7-29.8) p = 0.4 ND ND 
IL-5 ND 1.76 (1.6-3.77) NA ND 2.06 (1.6-3.9) 
IL-6  127.6 (32.3-565.3) 18.50 (1.6-128.4) p = 0.0004 ND 4.722 (1.6-12.3) 
IL-7 4.9 (1.6-19.0) ND NA ND 5.126 (1.6-19.2) 
IL-8  99.1 (21.3-451.6) 11.2 (1.6-66.4) p = 0.0001 4.28 (1.6-12.82) 3.104 (1.6-6.49) 
IL-9  ND 9.195 (1.6-24.4) p = 0.0036 ND ND 
IL-10 5.48 (1.6-47.8) ND NA 1.99 (1.6-3.55) ND 
IL12 (p40) 5.14 (1.6-47.6) ND NA 23.83 (1.6-82.5) 27.22 (1.6-79.07) 
IL12 (p70) ND 2.04 (1.6-5.1) NA ND 10.83 (1.6-30.59) 
IL-15 3.73 (1.6-14.0) ND NA ND ND 
IL-17 ND 1.84 (1.6-4.93) NA ND 33.62 (1.6-161.72) 
IP-10  1801.0 (334.6-7102) 629.9 (100.2-5685) p = 0.0004 629.9 (433-659) 881.15 (±358.5) 
MCP-1 4021.0 (72.3-10000) 909.6 (1.6-4825.1) p = 0.03 202.91 (129-321) 348.55 (252-551) 
MCP-3 ND ND NA ND 3.18 (1.6-9.54) 
MDC 114.5 (50.0-229.3) 56.9 (1.6-445.1) p = 0.004 1217 (588-1836) 1626 (771.9-3089) 
MIP-1α ND ND NA 3.6 (1.6-11.62 ) 18.5 (1.6-63.92 ) 
MIP-1 5.1 (1.6-31.9) ND NA 9.94 (1.6-18.16) 26.87 (6.25-46.83) 
sCD40L ND ND NA 290.64 (138-470 616.13 (184-2051) 
sIL-2Rα 12.57 (1.6-144.2) ND NA ND ND 
TNF-α ND 1.79 (1.6-4.31) NA 4.94 (1.6-9.14) 6.45 (1.6-11.56) 
VEGF  762.59 (1.6-4899.7) ND p = 0.0008 ND 42.42 (1.6-113.6) 
 
Table 5.2 Vitreous and plasma concentration of cytokines in diabetic and control 
subjects. Values are expressed as the mean (range) in pg/ml. ND = below the detection limit of 
3.2 pg/ml. NA = not assessed, group differences were assessed for all cytokines that were found 
in more than 5 vitreous samples. In bold = significant difference after Bonferroni correction. 
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5.2.6 Correlation of intraocular oxygen tensions, transcription factor 
and vitreous cytokine concentrations  
To explore the hypothesis that retinal oxygenation influences the molecular 
hypoxia sensing pathway and the profiles of cytokines present in the vitreous, 
intraocular oxygen levels were correlated to vitreous HIF1a and vitreous 
cytokine concentrations (figure 5.4). Mid-vitreous oxygen tension did not 
correlate with vitreous HIF1a levels (r=-0.17, p=0.56), VEGF (r=0.17, p=0.6) or 
any cytokine detected (figure 5.4A,B, table 5.3A). However, there was a 
significant positive correlation between HIF1a and Flt-3 ligand (r=0.7, p=0.02), 
G-CSF (r=0.71, p=0.01), IP-10 (r=0.67, p=0.02), MCP-1 (r=0.66, p=0.03) and 
VEGF (r=0.67, p=0.02) and a strong positive correlation between VEGF and 
MCP-1 (r=0.76, p=0.002) and between G-CSF and GRO (r=0.79, p=0.001, table 
3.3). Furthermore, the vitreous concentration of HIF1a was found to correlate 
with the preretinal oxygen tension at the posterior pole (r=0.7, p=0.02). Similarly, 
a strong trend to statistical significance was observed between the vitreous 
concentration of VEGF and the preretinal oxygen tension at the posterior pole 
(r=0. 56, p=0.07, table 3.3).  
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Figure 5.4 Correlation of intraocular oxygen and molecular mediators. Correlation of 
intraocular oxygen levels and vitreous HIF1a levels (row A), vitreous MCP-1 and HIF1a levels 
(row B), HIF1a and VEGF levels (row C) and VEGF levels and MCP-1 (row D) in subjects with 
PDR (column A) and controls (column B). Red line = linear regression. Dotted line = 95% CI, r = 
Spearman correlation factor. P < 0.05 = statistical significant correlation. 
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Analyses  Spearman r p value 
A) Correlation between O2 measurements and cytokines/transcriptions factors 
mid-vitreous O2 HIF1a -0.17 p = 0.56 
mid-vitreous O2 VEGF 0.17 p = 0.6 
preretinal O2 posterior pole HIF1a 0.7 p = 0.02 
preretinal O2 posterior pole VEGF 0.56 p = 0.07 
 
B) Correlation between vitreous Hif1a and cytokines 
HIF1a Flt3 ligand 0.7 p = 0.02 
HIF1a G-CSF 0.71 p = 0.01 
HIF1a IP-10 0.67 p = 0.02 
HIF1a MCP-1 0.66 p = 0.03 
HIF1a VEGF 0.67 p = 0.02 
 
C) Correlation between vitreous cytokines 
GRO  G-CSF 0.79 p = 0.001 
VEGF  MCP-1 0.76 p = 0.002 
 
Table 5.3 Correlation of oxygen, Hif1a and vitreous cytokines in proliferative diabetic 
retinopathy. Number of xy pairs = 13.  
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5.3 Discussion 
The importance of ischaemia-induced expression of retinal cytokines in the 
development of diabetic retinopathy is widely accepted. Ischaemia and hypoxia 
have been suggested to cause the release of proangiogenic factors, such as 
VEGF, which contribute to the development of neovascularisation in proliferative 
diabetic retinopathy (D'Amore, 1994). However, direct evidence of retinal 
hypoxia is weak and there have been no direct measurements of retinal oxygen 
levels in humans. Previous studies on intraocular oxygen in human diabetic 
subjects have investigated oxygen tension in the mid-vitreous (Holekamp et al., 
2005) or preretinal at sites of laser photocoagulation using a fiberoptic oxygen 
probe during surgery (Stefansson et al., 1992). Other groups have measured 
oxygen saturation in retinal vessels of diabetic subjects using a non-invasive 
imaging oximeter (Hammer et al., 2009) or assessed retinal tissue oxygenation 
by magnetic resonance imaging retinal oximetry (Trick et al., 2006). However, 
none of these studies has been able to demonstrate direct evidence of tissue 
hypoxia in the human diabetic retina. Secondly, none of these studies has 
investigated oxygen tensions at different preretinal sites to elucidate the 
presence of potential oxygen gradients along the diabetic retina. Finally, none of 
these studies has investigated the crucial link between oxygen tension, oxygen 
sensing transcription factors and molecular mediators in proliferative diabetic 
retinopathy. 
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In this chapter of my thesis, the feasibility of measuring preretinal oxygen 
tension in human subjects using an optical oxygen sensor during surgery was 
tested. The intraocular distribution and concentration of oxygen was determined 
in subjects with proliferative diabetic retinopathy and non-diabetic individuals. 
Furthermore, the link between oxygen tension, oxygen sensing transcription 
factor and molecular mediators in proliferative diabetic retinopathy was explored 
by correlating intraocular oxygen tensions with hypoxia-inducible transcription 
factors and the concentrations of 42 vitreous cytokines. 
 
Using an optical oxygen sensor we were able to measure the oxygen tension at 
sites in the vitreous and at the retinal surface safely and reliably in human 
subjects undergoing vitreous surgery. Compared to polarographic oxygen 
probes (Maeda et al., 1992; Maeda and Tano, 1996; Stefansson et al., 1981) 
temperature-corrected fiberoptic oxygen probes possess the advantages that 
they do not consume oxygen and have greater sensitivity at low oxygen levels 
(Stefansson et al., 1989). A previous study on intraocular oxygen in human 
subjects assessed mid-vitreous and anterior vitreous oxygenation in non-
diabetic and diabetic subjects using optical oxygen sensors during surgery but 
did not assess preretinal oxygenation because of the technical and surgical 
challenge (Holekamp et al., 2005). Another study did measure preretinal 
oxygenation safely and reliably in human diabetic subjects but focused on areas 
of photocoagulation in the peripheral retina and did not assess preretinal 
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oxygenation at other sites across the vitreous and retina (Stefansson et al., 
1992).  
 
Mid-vitreous O2 tension is decreased in PDR 
Using an optical oxygen sensor I found significantly lower oxygen levels in the 
anterior and mid-vitreous of diabetic subjects compared with control subjects 
which is in line with recently published data (Holekamp et al., 2006). Whereas 
Holekamp and coworkers demonstrated higher oxygen tension in the anterior 
vitreous than in the mid-vitreous (Holekamp et al., 2006), I identified no 
significant difference in oxygen tension between these sites. This may reflect 
differences in the exact location of oxygen measurement between the studies. 
Holekamp used a site near the equator of the crystalline lens whereas in the 
present study we measured 3mm posterior to the posterior pole of the crystalline 
lens; the lower oxygen tension measured at this site may reflect the greater 
distance from the vascularised tissue of the ciliary body. 
Oxygen in the vitreous is derived from the retinal and iris vasculature via 
diffusion (Alder and Cringle, 1990; Shui et al., 2006). As the mid-vitreous site is 
equidistant to all regions of the retina, its oxygen tension represents the overall 
balance between retinal oxygen supply and consumption (Wangsa-Wirawan and 
Linsenmeier, 2003). The low vitreous oxygen tension in PDR may therefore be 
explained by an overall reduced oxygenation of the diabetic iris and retina. 
Areas of microinfarcts in the diabetic retina may not contribute to the oxygen 
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supply to the mid-vitreous and cause mid-vitreous hypoxia. Furthermore, 
vitreous cells are increased in the vitreous of diabetic subjects (Canton et al., 
2004) which may contribute to mid-vitreous hypoxia by consuming oxygen. 
Finally, substances such as ascorbic acid are increased in the vitreous and act 
as an oxygen sink by metabolizing oxygen to water (Shui et al., 2009). Further 
studies will have to investigate if these oxygen sinks contribute to the detected 
low vitreous oxygen levels in PDR. 
 
Preretinal oxygenation is increased at the posterior pole in PDR 
Results of this chapter demonstrate that the diabetic retina is characterised by 
significant intraocular oxygen gradients that were not present in normal controls. 
The diabetic retina reveals significant differences in preretinal oxygen, with high 
oxygen tensions at the posterior pole and steep gradients towards the periphery. 
High oxygen tension measured at the posterior pole of the retina in proliferative 
diabetic retinopathy in this study suggests a rich supply of oxygen from the 
highly-perfused neovascular complexes that develop preferentially in this part of 
the eye (Shimizu et al., 1981). A negative oxygen gradient to the retinal 
periphery suggests that hyperoxia at the posterior pole may compensate to 
some extent for retinal hypoxia more peripherally. The gradient itself, however, 
is indicative that oxygen diffusion from the center to the periphery is either 
physically limited or that the peripheral retina acts as an oxygen sink that cannot 
be saturated. Removal of the vitreous body may facilitate redistribution of 
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oxygen from these neovascular complexes to areas of ischaemia by facilitating 
fluid flow and convection currents across the vitreous cavity (Barton et al., 
2007). Despite hyperoxia at the posterior pole, the oxygen tension in the 
vitreous is lower than in non-diabetic controls, suggesting consumption of 
oxygen elsewhere in the eye.  
 
Preretinal oxygenation in the mid periphery is normal in PDR 
In contrast to the posterior pole, the preretinal oxygen tension in the mid 
periphery in PDR was similar to the one detected in non-diabetic subjects. This 
finding is in opposition to the hypothesis that the retinal periphery in diabetic 
retinopathy is hypoxic (Linsenmeier et al., 1998) and may be explained by the 
advanced state of the disease and increased oxygen supply to the posterior pole 
of the diabetic retina. Oxygen released from the neovascularisation at the 
posterior pole may diffuse along a steep gradient towards the mid-periphery and 
contribute to the normoxic mid-periphery. It is also possible that the retinal tissue 
in the diabetic mid periphery is partly infarcted and therefore consumes less 
oxygen. This may result in a relative normoxia in the mid peripheral retina even 
though the retinal oxygen supply is reduced. Finally, the normal oxygen tension 
in the diabetic mid peripheral retina may reflect the effect of panretinal 
photocoagulation on oxygen availability in these areas (Stefansson, 2006). 
Retinal photocoagulation has been reported to increase inner retinal 
oxygenation in human diabetics (Stefansson et al., 1992). It has been proposed 
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that the ablation of oxygen consuming cells in the outer retina by laser 
photocoagulation allows oxygen fluxes from the choroid to reach the inner retina 
and to account for an oxygen increase (Stefansson, 2006). The results 
presented in this chapter, however, do not demonstrate a difference in oxygen 
tension above areas of photocoagulation compared with non lasered areas in 
diabetic subjects which is in line with previous reports (Maeda et al., 1992). This 
may be explained by the fact that the subjects included in this and Maedas study 
were breathing normal air (21% oxygen) during surgery whereas the individuals 
included by Stefansson were exposed to inhalation of 30% oxygen. Therefore, 
autoregulatory retinal vasoconstriction, as observed by Wilson after retinal 
photocoagulation (Wilson et al., 1988), may have countered and masked the 
effect of the oxygen flux through the laser scar in our study. The surplus of 
oxygen used in Stefansson’s study, however, may have helped to determine the 
difference in oxygen tension between laser treated and non-treated areas, as 
the compensatory effect of the retinal circulation was overpowered (Stefansson 
et al., 1992). To determine the effect of panretinal photocoagulation on vitreous 
oxygenation in advanced proliferative diabetic retinopathy, further studies will 
have to compare vitreous oxygen levels in subjects with non-proliferative 
diabetic retinopathy who have undergone panretinal photocoagulation with 
subjects who have not undergone panretinal photocoagulation.  
 
Limitations of the oxygen measurements performed in this study include the 
design of the study which did not allow us to conduct the study in a masked 
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fashion and the standardisation of the sites where the oxygen probe was kept. 
However, the physicians involved in this study took great care to standardise the 
sites of oxygen measurements and an observer bias is highly unlikely. Another 
possible limitation of our study is the difference in mean age between the group 
of subjects with diabetes and the group of control subjects. However, recent 
evidence demonstrating that oxygen tension in the vitreous is not associated 
with age (Holekamp et al., 2006) validates the direct comparison of the two 
groups in this study. 
 
Hif1a is increased in the vitreous of PDR 
Having established the presence of vitreous hypoxia in the diabetic eye I aimed 
to determine the vitreous concentration of HIF1a which is known to be a critical 
link between tissue hypoxia and adaptive tissue responses. I found increased 
levels of HIF1a protein in the diabetic vitreous compared with the corresponding 
diabetic plasma and control vitreous. This finding is in line with recently 
published data and supports the idea that retinal production, not serum diffusion, 
is the main contributor to increased vitreous HIF1a in subjects with PDR (Wang 
et al., 2009). This hypothesis is supported by immunohistochemistry studies 
showing increased HIF1a and VEGF activity in surgically excised preretinal 
diabetic membranes compared with non-diabetic idiopathic epiretinal 
membranes (bu El-Asrar et al., 2007; Lim et al., 2010). HIF1a protein may be 
released from hypoxic inner retinal cells that undergo apoptosis and lose the 
191 
 
 
integrity of their cell membranes (Barber et al., 2011) or from hypoxic cells in the 
vitreous which are increased in PDR (Canton et al., 2004). Further studies will 
have to address these possibilities and assess the contribution of vitreous cells 
to vitreous cytokines and transcription factors.  
 
Increased vitreous cytokines in PDR 
As HIF1a is known to be a crucial link between tissue hypoxia and the 
expression and secretion of proangiogenic and inflammatory cytokines I 
determined vitreous cytokine levels using multiplex cytokine arrays and 
correlated their concentration to the corresponding HIF1a levels. Multiplex 
cytokine arrays provide a new and powerful method allowing the simultaneous 
measurement of multiple cytokines in one experiment (Banerjee et al., 2007; 
Maier et al., 2006; Maier et al., 2008; Yoshimura et al., 2009). As vitreous 
samples are limited in volume and therefore very precious, multiplex cytokine 
arrays provide an efficient tool to quantify multiple cytokines simultaneously in a 
small volume of vitreous. Among the 42 tested cytokines I found increased 
concentrations of Flt-3 ligand, IL-6, IL-7, IL-8, IP-10 and VEGF in the diabetic 
vitreous compared to the control vitreous and to the corresponding plasma, 
suggesting a local upregulation of these factors by cells in the retina and 
possibly by cells in the vitreous (El-Ghrably et al., 2001). Increased vitreous 
levels of VEGF (Murugeswari et al., 2008), IL-6 (Nakamura et al., 2003), IL-8 
(Petrovic et al., 2007) and IP-10 (bu El-Asrar et al., 2006) have already been 
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described in PDR and associated with the proangiogenic and inflammatory state 
of the diabetic retina. For the first time, I found increased concentration of Flt-3 
ligand and reduced concentration of IL-9 levels in PDR. Flt-3 ligand, expressed 
by immature hematopoietic cells, stimulates proliferation of stem cells, myeloid 
and lymphoid progenitor cells, dendritic cells and natural killer cells (Drexler and 
Quentmeier, 2004). Recent experiments in a mouse model of diabetes have 
shown that exogenous Flt3-ligand treatment is associated with a significant 
reduction in the development of diabetes and an increased production of 
myeloid and plasmacytoid dendritic cells suggesting a role of Flt3-ligand in 
inflammation and the pathogenesis of diabetes (Chilton et al., 2004). IL-9 is a T 
helper cell 2 (Th2) derived cytokine that stimulates cell proliferation and prevents 
apoptosis of Th2 cells. In contrast to the pro-inflammatory T helper cell 1 (Th1) 
subset of CD4 expressing T-lymphocytes, Th2 cells are known to have anti-
inflammatory properties (Berger, 2000). Down-regulation of IL-9 in PDR might 
therefore be associated with decreased Th2 cells and a consequently Th1-
weighted imbalance associated with chronic inflammatory processes in 
advanced diabetic retinopathy. Further work is required to define the specific 
roles of Flt-3 ligand and IL-9 in the pathogenesis of diabetic retinopathy and to 
evaluate their potential as therapeutic targets. Taken together, these results 
demonstrate that multiple cytokines are significantly altered in the vitreous of 
diabetic subjects compared with non-diabetic individuals. Both proangiogenic 
and pro-inflammatory cytokines are expressed and secreted locally in the 
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diabetic eye supporting the concept of a closely linked angiogenic and 
inflammatory element in proliferative diabetic retinopathy. 
 
Vitreous Hif1a does not correlate with mid-vitreous O2 levels but with 
inflammatory cytokines 
To further explore the hypothesis that intraocular oxygen tension influences the 
expression of oxygen sensing molecules and effector proteins in PDR, I 
correlated intraocular oxygen levels with vitreous HIF1a and cytokine levels. If 
we accept that mid-vitreous oxygen tension indicates global retinal oxygenation 
we would anticipate that mid-vitreous hypoxia is associated with increased 
levels of HIF1a, proangiogenic factors and inflammatory cytokines in the 
presence of ischaemic retinopathy. I detected a positive correlation between 
HIF1a and VEGF in the diabetic vitreous which is in line with previously 
published data and supports the important role of HIF1a in the pathogenesis and 
progression of retinal neovascularisation (Wang et al., 2009). However, I did not 
detect a correlation between mid-vitreous hypoxia and vitreous HIF1a levels in 
advanced proliferative diabetic retinopathy. It is possible that the oxygen 
measurements and cytokine analysis of the core vitreous performed in this study 
fail to account sufficiently for the effect of local oxygen and cytokine gradients 
within the retina. Local hypoxia within the inner retina has been shown to result 
in an increase of HIF1a, HIF2a and VEGF protein levels in an animal model of 
ischaemia and hypoxia (Mowat et al., 2010). These molecular pathways may 
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also be active in hypoxic areas within the diabetic retina but may not be 
detectable by the measurements in the core vitreous performed in this study. 
Furthermore, a potential correlation between vitreous hypoxia and HIF1a levels 
may have been masked by the strong inflammatory component in PDR (Maier et 
al., 2008) which can activate HIF1a independent of hypoxia (Dehne and Brune, 
2009). I found increased levels of numerous inflammatory cytokines and 
identified a strong correlation between MCP1 and HIF1a protein in the diabetic 
vitreous. This is consistent with previously published data demonstrating that 
inflammatory cytokines such as MCP-1 can induce HIF1alpha activity (Hong et 
al., 2005). The strong correlation between vitreous VEGF and MCP-1 levels in 
the diabetic vitreous further highlights the close relation between angiogenesis 
and inflammation in advanced proliferative diabetic retinopathy. MCP-1 can 
induce VEGF expression by stabilisation of HIF1a (Hong et al., 2005). On the 
other hand MCP-1 expression can be induced by VEGF which increases the 
MCP-1 promotor activity through binding to the activator protein-1 (AP-1) binding 
site of the MCP-1 promoter region (Marumo et al., 1999; Yamada et al., 2003). 
This data suggests a positive regulatory feedback loop between VEGF and 
MCP-1 expression which may escalate inflammatory responses and 
angiogenesis.  
 
Furthermore, I identified a positive correlation between the preretinal oxygen 
tension at the posterior pole and vitreous levels of HIF1a and VEGF in PDR. 
Although the mid-vitreous HIF1a and VEGF levels reported in this study might 
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underestimate the concentration at the posterior pole (Shimada et al., 2009), the 
positive correlation found between HIF1a, VEGF levels and preretinal 
oxygenation is consistent with the hypothesis that HIF1a and VEGF induce the 
development of neovascular complexes in the posterior retina that are richly 
perfused and supply oxygen to the retina. Upregulation of VEGF may be the 
result of hypoxia-sensing mechanisms elsewhere that I was not able to detect in 
this study, or alternatively, oxygen-independent chronic inflammatory processes 
in advanced proliferative diabetic retinopathy. 
 
Taken together these data suggest that HIF1a is activated by both hypoxia and 
inflammation in advanced PDR and thereby contributes to the proangiogenic 
cytokine profile and the formation of retinal neovascularisation. To investigate 
the hypothesis that local hypoxia is the initiating trigger for inflammation, 
angiogenesis and the progression of diabetic retinopathy using this approach 
further studies are needed that focus on subjects with less advanced 
retinopathy.  
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Figure 5.5 Proposed central role for HIF1a in advanced proliferative diabetic retinopathy. 
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5.4 Conclusion 
In conclusion, I have identified significant intraocular oxygen gradients in human 
subjects with proliferative diabetic retinopathy with high oxygen tensions at the 
posterior pole and steep gradients towards the periphery and the mid-vitreous. I 
have found increased levels of HIF1a protein and downstream adaptive 
mediators such as VEGF in the vitreous of subjects with proliferative diabetic 
retinopathy. These findings are consistent with the hypothesis that HIF1a and 
VEGF induces the development of neovascular complexes in the posterior retina 
that are richly-perfused but nonetheless fail to redress hypoxia in the mid-
vitreous. Upregulation of vitreous HIF1a and VEGF may be a consequence of 
retinal hypoxia at unidentified sites or of chronic inflammatory processes in 
advanced proliferative diabetic retinopathy.  
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6 General discussion 
6.1 The role of oxygen sensing mechanisms in development 
6.1.1 The roles of Vhl and Hifa’s in development 
Oxygen sensing mechanisms and the Vhl-Hif pathway are essential for normal 
development of different organ systems. Homozygous deletion of Vhl in mice 
leads to mid-gestational embryonic death secondary to failed placental 
vasculogenesis between embryonic day (E) 10.5 and 12.5 (Gnarra et al., 1997). 
Similarly, mouse embryos with homozygous deletion of Hif1a die during 
midgestation at E10.5 and are characterised by cardiac and vascular 
malformations (Kotch et al., 1999; Ryan et al., 1998). These findings 
demonstrate that both Hif1a activation and its stringent regulation by Vhl are 
essential for development of life. Systemic Hif2a knockout mice, in contrast, 
demonstrate various phenotypes, including embryonic lethality secondary to 
vascular defects (Peng et al., 2000), perinatal lethality due to decreased 
catecholamine production (Tian et al., 1998), postnatal lethality caused by 
progressive multiorgan failure (Scortegagna et al., 2003), or even normal 
viability into adulthood (Ding et al., 2005). The range of phenotypes of Hif2a 
deficient mice may depend on different genetic backgrounds and gene targeting 
strategies in different laboratories and suggests an important but - compared 
with Vhl and Hif1a - less critical role of Hif2a in murine development.  
In order to elucidate the role of Vhl and Hifa’s during development, cell specific 
knockout approaches using the Cre/loxP mediated recombination system have 
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been established. In line with the observation in this thesis, conditional 
inactivation of Vhl in developing tissues results in a severely abnormal growth 
and vascular development in different organ systems. Conditional inactivation of 
Vhl in developing thymocytes results in Hif1a mediated apoptosis of thymocytes 
and a significantly reduced size of the thymus in the adult (Biju et al., 2004). 
Similarly, conditional disruption of Vhl in chondrocytes during endochondral 
bone development leads to a Hif1a mediated reduction in proliferating 
chondrocytes and the development of severe dwarfism (Pfander et al., 2004). 
These findings are in line with results of this thesis showing that inactivation of 
Vhl in the RPE results in RPE apoptosis and secondarily in the development of 
microphthalmia. Conditional inactivation of Vhl in developing hepatocytes, 
however, does not result in growth defects of the liver (Rankin et al., 2005) 
suggesting that different tissues are differently susceptible to the effects of Hif 
activation during development. In addition to controlling organ growth and 
development, Vhl has also been shown to play a critical role for normal vascular 
development in different organ systems. Conditional inactivation of Vhl in 
hepatocytes (Rankin et al., 2005), thymocytes (Biju et al., 2004), epidermis 
(Boutin et al., 2008) or renal cells lead to an increase in angiogenesis and 
vascular density which is independent of Hif1a (Rankin et al., 2005). These 
findings suggest that other Vhl dependent molecules, such as Hif2a, regulate 
the angiogenic response in the Vhl knockout mice by driving the expression of 
proangiogenic genes including Vegf and Epo.  
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These data demonstrate that Vhl controls the growth and development of 
different organ systems, including the skeleton, the thymus and the eye, by 
depressing Hif1a activity and furthermore regulates vascular development by 
controlling other transcription factors, such as Hif2a. Also, these findings 
suggest that reduced systemic oxygenation, for example in placental 
insufficiency, may have major effects on the development and growth of organs 
through activation of HIF.  
6.1.2 The roles of Vhl and Hifa’s in development of the eye 
Work in this thesis has shown that molecular oxygen-sensing mechanisms play 
a critical role in the development of the eye and its vasculature. Activation of 
Hif1a in the RPE and iris during development results in aniridia and 
microphthalmia whereas activation of other Vhl dependent molecules, e.g. Hif2a, 
causes an abnormal development of the retinal vasculature.  
In the eye, the choroidal vasculature is the first vascular system to develop and 
provide adequate oxygen levels to the primordium of the eye (Saint-Geniez and 
D'Amore, 2004). As the retina matures and grows, the demand for oxygen and 
nutrition increases and the retina experiences a physiological period of reduced 
oxygen availability (Chan-Ling et al., 1995). Recent evidence from the 
developing murine retina indicates hypoxic areas and Hif1a activation 
throughout all retinal layers (Kurihara et al., 2010). This hypoxic period in the 
developing retina has been suggested to contribute to the regulation of 
developmental photoreceptor death (Maslim et al., 1997; Mervin and Stone, 
2002) and to control normal retinal vascularisation in a Hif dependent manner 
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(Caprara et al., 2011; Chan-Ling et al., 1995). In contrast to the retina, there is 
no evidence of hypoxia or Hif activation in the RPE during development 
(Kurihara et al., 2010). This finding is in line with results presented in this thesis 
and may be explained by the close proximity of the RPE to the oxygen rich 
choroidal vessels which are characterised by a high blood flow and a surplus 
supply of oxygen (Wangsa-Wirawan and Linsenmeier, 2003). During retinal 
development, Hif1a levels in the inner retina decrease with age as the retina 
becomes vascularised and supplied with oxygen from the retinal vasculature 
(Kurihara et al., 2010; Ozaki et al., 1999). Furthermore, the increased oxygen 
saturation in the systemic circulation after birth (Rodesch et al., 1992) results in 
increased oxygen diffusion from the choroid to the retina which is accompanied 
by a considerable reduction of Hif1a protein levels in the deep retinal layers 
soon after birth (Kurihara et al., 2010). Even after the retina and its vasculature 
has been fully developed, Hif1a protein can be found to a low extend in the GCL 
indicating a role for Hif1a signalling in the adult retina (Grimm et al., 2005; 
Hughes et al., 2010), Hif2a in contrast, is predominantly found in endothelial 
cells of the hyaloid vessels and in retinal vessels of the superficial primary 
plexus during retinal development. In the adult murine retina, however, Hif2a is 
expressed by vascular endothelial cells as well as by cells within the GCL, INL, 
and retinal pigment epithelium (Ding et al., 2005). These observations 
demonstrate the responsiveinss of the retinal tissue to hypoxic events during 
development through mechanisms including the activation of Hifa proteins. Hif1a 
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and Hif2a appear to have specific spatio-temporal activation and expression 
patterns indicating distinct roles for both isoforms during retinal development. 
Results in this thesis demonstrate that activation of Hif1a in the RPE and iris is 
detrimental during development and can cause cell death which is associated 
with development anomalies including microphthalmia and aniridia. Due to its 
close proximity to the oxygen rich choroidal vasculature, the RPE is unlikely to 
encounter hypoxia during development. Ocular hypoxia secondary to reduced 
systemic oxygenation, for example in placental insufficiency, however, could 
have major effects on oxygen levels at the level of the RPE and may be a 
previously unrecognised mechanism in the development of microphthalmia 
through mechanisms involving RPE specific activation of Hif1a. Future studies 
may test this hypothesis by exposing pregnant mice to reduced levels of oxygen 
in an oxygen incubator to determine if a decrease in systemic and RPE 
oxygenation results in Hif1a activation, RPE apoptosis and the development of 
microphthalmia in the offspring.  
Results in this thesis further indicate that Vhl not only regulates Hif1a in the 
developing RPE but also controls the activity of other molecules and thereby 
normal retinal and choroidal vascularisation. The biological activity of Vhl is 
closely linked to the regulation of Hif1a and Hif2a and only a few other potential 
Vhl dependent molecules have been reported, most notably α-tubulin, 
fibronectin and the transcription factor Sp1 (Czyzyk-Krzeska and Meller, 2004). 
Recent work has demonstrated that Vhl dependent inactivation of Hif2a in the 
developing liver controls normal vascular development and prevents the 
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formation of cavernous liver haemangioma in the adult (Rankin et al., 2005). 
These findings suggest that Vhl dependent inactivation of Hif2a in the 
developing RPE may be essential for normal retinal and choroidal vascular 
development. To elucidate the role of Hif2a in the RPE for retinal and choroidal 
vascular development, future studies will have to assess the temporal and 
spatial expression of Hif2a in the neuroretina and RPE by immunohistochemistry 
and protein analysis at prenatal and postnatal timepoints. Furthermore, the 
characterisation of transgenic mice with conditional inactivation of Hif2 in the 
RPE will help to understand the role of Hif2a in the RPE in ocular and vascular 
development. Finally, studies on transgenic mice with a conditional inactivation 
of both Vhl and Hif2a in the RPE may prove or disprove the hypothesis that the 
vascular phenotype in Vhltrp1-creko mice is mediated by activation of Hif2a in the 
RPE. In the possible event that these mice exhibit microphthalmia, analysis of 
transgenic mice with conditional inactivation of Vhl, Hif1a and Hif2a in the RPE 
will elucidate whether the vascular phenotype observed in Vhltrp1-creko mice is 
mediated by Hif2a or by other Vhl dependent factors. 
 
6.2 The role of oxygen sensing mechanisms in neovascular eye disease 
6.2.1 The role of Hif in the RPE in the development of AMD and choroidal 
neovascularisation 
Hypoxia and activation of Hif’s in the RPE have been suggested to play an 
important role in the development and progression of AMD and choroidal 
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neovascularisation (Stefansson et al., 2010). There is compelling evidence 
showing that patients with AMD can have decreased ocular blood flow and 
retinal haemodynamics (Ciulla et al., 2001; Friedman et al., 1995; Harris et al., 
1999) and that a reduced choroidal perfusion is correlated with increased AMD 
severity (Grunwald et al., 1998; Grunwald et al., 2005). Measurements of blood 
flow, perfusion pressure and oxygen tension in the retina and at the optic nerve 
head have indicated that a decreased choroidal circulation results in tissue 
hypoxia in AMD patients (Grunwald et al., 2005; Metelitsina et al., 2008). This 
has led to the current hypothesis that hypoxia activates Hif signalling in the RPE 
in AMD which contributes to disease progression and the development of CNV. 
Indeed, recent studies have demonstrated that both HIF1A and HIF2A are 
activated in the endothelium, in macrophages and in the RPE in choroidal 
neovascular membranes in subjects with AMD (Inoue et al., 2007; Sheridan et 
al., 2009). Although the experiments presented in this thesis focus on the 
consequences of Hif signalling in the RPE during development, some basic 
mechanisms of Hif signalling in the RPE may be deduced for the adult situation.  
Results in this thesis have shown that activation of Hif1a in the developing RPE 
induces RPE cell death and is followed by a secondary retinal degeneration in 
the adult. RPE cell loss and retinal degeneration are also central hallmarks in 
the pathogenesis of geographic atrophy (GA), the late stage form of atrophic 
AMD (Kinnunen et al., 2011). Recent work has demonstrated that individuals 
with GA exhibit increased apoptosis of photoreceptor and RPE cells compared 
with healthy controls (Dunaief et al., 2002). The question whether RPE cell loss 
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affects photoreceptor cell death or vice versa has been subject of much debate. 
The weight of opinions, however, supports the view that gradual failure of the 
RPE is the initial cause of GA and precedes retinal degeneration (Marshall, 
1987; Sarks, 1976; Young, 1987).  
The reason for RPE cell loss in GA has been suggested to depend on hypoxia 
and progressive oxidative insults by reactive oxygen species (ROS) (Jiang et al., 
2008; Szaflik et al., 2009). ROS are increasingly produced in the mitochondria of 
the ageing RPE (Brennan and Kantorow, 2009) and upon hypoxia and can 
contribute to Hif1a stabilisation by preventing its degradation (Brunelle et al., 
2005; Guzy et al., 2005; Kaelin, Jr., 2005). The findings that choroidal perfusion 
is reduced with age (Lutty et al., 1999) and that choriocapillaris vessels 
obliterate in the evolution of GA before retinal and RPE changes can be 
observed (Sarks, 1976), raise the possibility that hypoxia at the levels of the 
RPE increases both ROS and Hif1a in the early stages of GA which results in 
RPE cell loss and secondarily in retinal degeneration. This hypothesis is 
supported by the finding of this thesis that activation of Hif1a in the RPE results 
in cell apoptosis and secondarily in severe retinal degeneration. Activation of 
Hif1a in the RPE by hypoxia due to choroidal hypoperfusion may therefore be a 
so far unrecognised mechanism for RPE cell loss and disease progression in 
GA. Future immunohistochemical studies will have to determine whether Hif1a is 
stabilised in the RPE and associated with apoptosis in areas of choroidal 
vasoobliteration in early GA. These experiments may provide a rationale for 
developing treatment modalities to inhibit Hif1a stabilisation in the RPE in early 
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GA to prevent the sequel of RPE hypoxia, RPE cell death, retinal degeneration 
and loss of vision.  
 
Results in this thesis have shown that activation of Hif’s in the RPE is associated 
with an increase in the levels of angiogenic factors in the eye including Flt-1, 
Epo and Vegf. Whereas the increased expression of Flt1 appears to be 
dependent on Hif1a activation, Epo and Vegf overexpression appear to be 
independent of Hif1a suggesting that other Vhl dependent molecules such as 
Hif2a may drive the expression of these angiogenic factors in the RPE. These 
data suggest that Hif1a and Hif2a control specific sets of target genes in the 
RPE and that Hif2a rather than Hif1a induces Vegf and Epo expression in the 
RPE. Furthermore, results in this thesis demonstrate that the increased 
expression of angiogenic factors in the RPE was associated with retinal vascular 
anomalies and the development of chorioretinal anastomosis which again 
developed independently of Hif1a in the RPE. These data suggest that Hif2a 
activation in the RPE contributes to the expression of Vegf and other angiogenic 
factors in the RPE and induces secondary vascular changes in the retina and 
choroid. This hypothesis is in line with experimental data demonstrating that 
stabilisation of Hif2a controls Vegf and Epo expression in the liver (Rankin et al., 
2007) the brain (Chavez et al., 2006) and in the eye (Morita et al., 2003). If we 
accept that human RPE cells respond similar to Hif activation as developing 
murine RPE cells, it is plausible that activation of Hif2a signalling in the RPE by 
e.g. hypoxia or inflammation induces Vegf and Epo expression in the RPE and 
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may therefore be a so far unrecognised mechanism in the development of 
neovascular changes in AMD. This hypothesis is supported by recent studies 
showing a strong activation of Hif2a and Vegf in the RPE of patients with AMD 
(Sheridan et al., 2009). In vitro studies, in contrast, have indicated that HIF1A is 
the main HIF isoform induced in the RPE upon hypoxia and regulates VEGF 
expression (Forooghian et al., 2007; Zhang et al., 2007c). Furthermore, siRNA 
against Hif1a was shown to decrease the hypoxia-induced upregulation of Vegf 
in RPE cells (Zhang et al., 2007b). This discrepancy between the results 
presented in this thesis and the literature may be explained by the different 
systems in which the experiments were conducted (in vitro vs. in vivo) and/or by 
the different developmental stage of the RPE analysed (embryonic vs. adult).  
Future studies will therefore have to determine the roles of Hif1a and Hif2a 
signalling in the adult RPE and to prove or disprove their potential contribution to 
RPE cell death and the development of choroidal neovascularisation. Hifa’s 
activation in the adult RPE may be achieved by exposing the RPE to hypoxia or 
by inactivation of Vhl in the RPE. Future studies will have to investigate whether 
systemic exposure to low levels of oxygen, e.g. by keeping mice in a sealed 
chamber with reduced oxygen levels, may be sufficient to activate Hif1a in the 
RPE. However, this may prove to be difficult as the choroidal circulation carries 
an immense surplus of oxygen (Wangsa-Wirawan and Linsenmeier, 2003) 
which may be sufficient to degrade Hif1a despite of systemic hypoxia. 
Furthermore, it has to be kept in mind that systemic hypoxia induces adaptive 
responses in other organs, e.g. expression of Epo in the kidney to the 
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circulation, which may have an impact on the RPE and would present a 
significant confounding factor. A more localised activation of Hif1a in the RPE 
would therefore be desirable and may be achieved by inducing choroidal 
vasoocclusion in mice by laser photoactivation of an intravenously injected 
photosensitive dye (e.g. rose Bengal) (Kramer et al., 2009). This technique has 
been reported to result in a temporary occlusion of the central retinal artery 
when aiming the laser beam at the central retinal artery. Intravenous injection of 
a photosensitive dye in mice followed by lasering of the choroidal vasculature 
may therefore induce temporary choroidal occlusion resulting in tissue hypoxia 
and activation of Hif1a in the RPE. Induction of reproducible vasoocclusion and 
tissue hypoxia in this model, however, may be difficult to obtain as demonstrated 
in models of retinal vascular occlusion (Osborne et al., 2004). Future studies will 
have to investigate whether choroidal vascular occlusion is achievable and 
represents a reliable model to induce hypoxia and Hif activation in the RPE. 
Alternatively, Hif’s may be activated in the adult RPE by using tissue specific 
knockout technology of Vhl. Inactivation of Vhl in the adult RPE may be 
achieved by subretinal delivery of a viral vector expressing cre-recombinase 
under the control of an RPE-specific promoter (e.g. the trp-1 or the Bestrophin 
promotor (Iacovelli et al., 2011)) to animals carrying the floxed Vhl allele. Hif1a 
immunohistochemistry as applied in this work will help to identify RPE specificity 
and to determine how efficient the Lox-Cre recombination event was. The 
consequences of Hif1a and Hif2a activation in the adult RPE cells may be 
assessed by e.g. electroretinography, ultrastructural analysis of the RPE and 
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analysis of the retinal and choroidal vasculature. Should RPE apoptosis and/or 
spontaneous neovascularisation be evident, subretinal delivery of viral vector 
expressing cre recombinase under the control of an RPE-specific promoter to 
adult Vhl;Hif1aflox/flox and Vhl;Hif2aflox/flox mice will help to further delineate 
specific roles of Hif1a and Hif2a in the adult RPE. Alternatively, transgenic mice 
expressing cre recombinase under the control of an RPE specific and tamoxifen 
inducible promotor (e.g. the iCreER (Longbottom et al., 2009) or the 
iCreBestrophin mouse line (Le et al., 2008)) may be crossed to Vhlflox/flox, 
Vhl;Hif1aflox/flox and Vhl;Hif2aflox/flox mice to study the role of Hif signalling in the 
adult RPE. These approaches may help to understand whether Hif activation in 
the adult RPE induces spontaneous angiogenesis originating from the retinal 
circulation as seen in transgenic mice overexpressing Vegf in the rod 
photoreceptor (Okamoto et al., 1997) or from the choroidal vasculature as seen 
in the developmental study of this thesis. Should spontaneous development of 
neovascularisation be absent, choroidal neovascularisation may be induced in 
these mice by using the CNV laser model. Finally, analysis of mice with a 
conditional knockout of different Hif isoforms in the RPE in the laser-induced 
CNV model will help to define the role of Hifs in the RPE in the development of 
choroidal neovascularisation. These experiments will help to find out if Hif’s are 
an appropriate target for the development of therapy in choroidal neovascular 
disease. 
  
210 
 
 
 
 
Figure 6.1 Proposed regulatory role of HIF1a and HIF2a in the pathogenesis of AMD. 
Schematic presentation of (A) dry AMD with drusen (arrow) and (B) exudative AMD with 
choroidal neovascularisation (asterisk). (C) Proposed regulatory role of Hif signalling in AMD 
pathology. Drusen formation between Bruch's membrane (BM) and RPE cells and choroidal 
hypoperfusion decreases oxygen delivery from choriocapillaris to the RPE and induce hypoxia. 
The aged RPE has a reduced capacity to respond to the continuous oxidative stress which leads 
to accumulation of lysosomal lipofuscin that is an antioxidant and increases oxidative stress 
damage in RPE cells. Both hypoxia and oxidative stress are major stimuli for NF-κB signalling 
which contributes to HIF activation and development of inflammation. In some cases chronic 
stress and hypoxia may induces Hif1a mediated cell apoptosis and rupture of BM which evokes 
choroidal neovascularisation. Adapted from (Arjamaa et al., 2009). 
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6.2.2 The role of Hif in myeloid cells in the development of retinal and 
choroidal neovascularisation 
Bone marrow-derived myeloid cells, such as macrophages, neutrophils and 
dendritic cells have an important role in regulating the development and 
maintenance of blood vessels in development and disease. A common feature 
of many diseases, including tumour, inflammatory and ischaemic disease, is a 
decrease in oxygen levels in the affected tissue (Murdoch et al., 2008). Hypoxia 
develops within these tissues because of inadequate vascular perfusion due to 
vasoobliteration in ischaemic disease or due to disorganised and immature 
blood vessels in tumour disease. These areas of hypoxia attract circulating 
myeloid cells by releasing hypoxia-induced chemoattractants such as VEGF, 
MCP-1 and endothelins (Murdoch et al., 2008) and present a very challenging 
microenvironment characterised by hypoglycaemia, acidosis and hypoxia.  
Experimental data provided in chapter 4 of this thesis demonstrate the 
importance of Hif1a activation and Vegf signalling in myeloid cells in the 
development of retinal and choroidal neovascularisation. Conditional inactivation 
of Hif1a in myeloid cells results in a substantial reduction of neovascularisation 
in the OIR and laser CNV mouse models indicating that Hif1a activation by 
hypoxia and/or inflammation in myeloid cells plays a pivotal role in inducing 
pathological angiogenesis.  
The importance of HIF signalling in myeloid cells present in inflammatory and 
hypoxic microenvironments is widely established. The principle that myeloid 
cells respond to hypoxia was demonstrated by the initial finding from Knighton 
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and colleagues showing that macrophages exposed to hypoxia secrete 
angiogenic factors and are more effective in promoting angiogenesis in vitro 
(Knighton et al., 1983). These initial findings were supported by in vivo 
experiments showing that myeloid cells express higher levels of proangiogenic 
Hif target genes including Vegf in avascular and hypoxic areas of tumours 
(Harmey et al., 1998; Lewis et al., 2000). In addition to inducing angiogenesis, 
Hif1a signalling in myeloid cells has been shown to be critical for macrophage 
self-aggregation, invasion and motility as well as for killing of bacteria and ATP 
generation in areas of tissue hypoxia (Cramer et al., 2003). Activated 
microglia/macrophages have been found to be markedly increased in the retina 
in human diabetic retinopathy and in subretinal membranes in age-related 
macular degeneration (Skeie and Mullins, 2009; Zeng et al., 2008b) - two 
conditions that are characterised by tissue hypoxia and inflammation 
(Stefansson et al., 1992; Stefansson et al., 2010). Similarly, macrophages were 
found to accumulate in areas of hypoxia and acute inflammation in mouse 
models of retinal and choroidal neovascularisation and have been suggested to 
promote pathological angiogenesis by secreting Vegf (Sakurai et al., 2003). 
Recent work has shown, that deletion of the hypoxia response element (HRE) 
from the Vegf promoter in mice results in a significant reduction of Vegf levels 
and neovascularisation in both the OIR and the laser-induced CNV mouse 
model (Vinores et al., 2006). These data support the findings presented in this 
thesis and indicate that Hif1a signalling plays a significant role in the 
development of retinal and choroidal NV through mechanisms including 
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regulation of Vegf expression. However, it may also be possible that inactivation 
of Hif1a in myeloid cells reduces other Hif1a dependent proangiogenic 
cytokines, e.g. erythropoietin, and decreases the recruitment and survival of 
infiltrating proangiogenic myeloid cells (Cramer et al., 2003; Walmsley et al., 
2005) which may contribute to the observed reduction in neovascularisation in 
the OIR and CNV model. Future studies will have to assess the number of 
recruited myeloid cells to retinal and choroidal NV and assess the expression 
levels of Vegf and Epo in Hif1alysMcre-YFP myeloid cells to determine if a reduction 
of proangiogenic cytokines, an impaired recruitment or both contribute to the 
reduced neovascular response. These experiments will help to define the 
mechanism involved in the development of pathological neovascularisation and 
may provide a rationale for developing therapies that are capable of selectively 
inhibiting Hif1a or Vegf signalling in myeloid cell or alternatively their recruitment 
to pathological neovascularisation.  
 
6.2.3 The role of hypoxia and Hif signalling in proliferative diabetic 
retinopathy in man 
It is widely accepted that hypoxia plays a critical role in the development and 
progression of diabetic retinopathy (Stefansson, 2006). Work in this thesis has 
confirmed that oxygen tension in the mid vitreous of patients with PDR is 
significantly lower than that of non-diabetic patients (Holekamp et al., 2006; 
Stefansson, 2006). The oxygen availability in the vitreous will ultimately be the 
result of the net delivery and consumption of oxygen within the eye. The 
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observed mid vitreous hypoxia in PDR may therefore be explained by an overall 
reduction of oxygen availability in the diabetic retina which may be associated 
with a reduced oxygen diffusion from areas of retinal vasoobliteration to the mid 
vitreous. However, direct evidence of retinal tissue hypoxia in PDR in man is still 
lacking and measurements of oxygen tension in the vitreous overlying the retina 
in chapter 5 of this thesis suggest normal to increased retinal oxygen tension in 
PDR. This may be explained by the advanced stage of disease in which retinal 
neovascularisation increases oxygen levels at the posterior pole and areas of 
microinfarction and panretinal photocoagulation reduce oxygen consumption 
and thereby improve oxygen diffusion from the choroid to the inner retina in the 
peripheral retina. Studying the role of hypoxia in early diabetic retinopathy may 
therefore be the more informative disease stage to elucidate the role of hypoxia 
in the aetiology of this disease. This may be achieved by measuring the oxygen 
tension at the retinal surface of subjects with non-proliferative diabetic 
retinopathy who undergo retinal surgery for e.g. retinal detachment or macular 
oedema. A pre-operative assessment of areas of retinal vasoobliteration by 
fluorescein angiography may further help to identify areas of hypoperfusion 
which may consequently become the focus of oxygen measurements. A 
significant limitation of oxygen measurement using a probe during surgery is its 
invasive nature which almost excludes the possibility to study early changes in 
diabetic retinopathy for which surgery is not indicated. Assessing the retinal 
oxygen tension by non-invasive methods, e.g. by MRI (Trick and Berkowitz, 
2005), may in the future provide an efficient tool to analyse retinal oxygenation 
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in early diabetic retinopathy and help to define the role of hypoxia in the 
development of diabetic retinopathy. 
Although not yet proven, it is conceivable that tissue hypoxia due to capillary 
nonperfusion in early diabetic retinopathy plays a significant role in the 
development of diabetic retinopathy. Therefore, oxygen sensing mechanisms 
and adaptive response to hypoxia may have an important role in the 
development and progression of DR (Caprara and Grimm, 2011). However, 
additional information about the role of HIFs in the pathology of this disease, 
particularly in the development of the neovascular response, is needed.  
Results in chapter 5 of this thesis have demonstrated that HIF1a and its 
downstream factor VEGF are significantly increased in the vitreous of diabetic 
subjects compared with non-diabetic subjects. These findings are in line with 
results of a recent study demonstrating that both VEGF and HIF1a are 
increased in the vitreous in PDR and appear to correlate with disease activity 
(Wang et al., 2009). Therefore it has been suggested that tissue hypoxia in DR 
induces HIF1a stabilisation in the inner retina which drives VEGF expression 
and progression of PDR (Stefansson, 2006). However, results in this thesis 
indicate that mechanisms other than hypoxia may contribute to HIF activation in 
PDR. It is widely established that inflammation and oxidative stress which are 
common features involved in the aetiology and progression of DR (Gardner et 
al., 2002) can induce HIFA stabilisation (Dehne and Brune, 2009; Yuan et al., 
2008). It may therefore be possible that the described strong inflammatory 
microenvironment in PDR may contribute to HIF activation and the expression of 
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angiogenic and inflammatory cytokines in advanced PDR. Future studies will 
have to analyse HIF1a and its downstream factors in vitreous samples, or ideally 
in retinal biopsies of non-perfused areas, of subjects with non-proliferative 
diabetic retinopathy who undergo retinal surgery for e.g. retinal detachment or 
macular oedema. This may help to define the role of Hif signalling in early 
diabetic retinopathy and its contribution to the progression of the disease and 
may provide a rationale for developing treatment modalities targeting Hif1a.  
Furthermore, the cell types that stabilise Hif1a protein in PDR remain to be 
identified. The finding that HIF1a protein levels are increased in the diabetic 
vitreous compared with the corresponding diabetic plasma supports the 
hypothesis that Hif1a is stabilised locally in retinal cells and is not derived from 
cells in the circulation. This is supported by immunohistochemical studies 
showing increased HIF1a and VEGF activity in surgically excised preretinal 
diabetic membranes compared with non-diabetic idiopathic epiretinal 
membranes (bu El-Asrar et al., 2007; Lim et al., 2010). Evidence from 
experimental models of diabetic retinopathy and ROP indicate that Mueller cells 
and astrocytes react to hypoxia by stabilisation of Hif1a and contribute to Vegf 
expression and disease progression (Ly et al., 2011; Mowat et al., 2010). The 
observed increase of HIF1a protein in the diabetic vitreous may therefore be 
explained by its release from hypoxic inner retinal cells that undergo apoptosis 
and lose integrity of their cell membranes (Barber et al., 2011). As Hif1a is 
normally degraded intracellularly by Vhl dependent proteasomal degradation, 
Hifa’s derived from apoptotic inner retinal cells may accumulate in the diabetic 
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vitreous and be conserved. Additionally, cellular components are increased in 
the hypoxic diabetic vitreous (El-Ghrably et al., 2001; Esser et al., 1993) and 
may contribute to the observed increase of HIF1a protein in the vitreous. Recent 
studies have shown that lymphocytes, neutrophils and macrophages 
accumulate in areas of hypoxia and are attracted to the vitreous fluid in patients 
with PDR (Canton et al., 2004; Esser et al., 1993). These cells may not only 
contribute to mid vitreous hypoxia by consuming oxygen, but may also respond 
to mid vitreous hypoxia by stabilizing HIF1a and expressing VEGF which may 
contribute to the disease progression (El-Ghrably et al., 2001; Malecaze et al., 
1994). This hypothesis is supported by experimental data presented in this 
thesis demonstrating the importance of Hif1a signalling in myeloid cell in retinal 
vascular disease in mice. Hif1a expressing myeloid cells were closely 
associated with preretinal neovascular tufts in the vitreous in the OIR mouse 
model. These cells may further invade sites of hypoxia in the mid vitreous and 
contribute to the cytokine milieu by Hif1a stabilisation. Future studies will have to 
elucidate the role of Hif signalling in vitreous macrophages in the development 
of retinal neovascularisation in PDR in more detail by determining their 
expression profile of Hif1a and Hif1a target genes, including Vegf and Epo. The 
identification of vitreous macrophages that induce pathological 
neovascularisation would open a wide new field of research and possibly lead to 
new targets for therapy. These pilot experiments may lead to further studies 
addressing potential therapeutical approaches that may include early surgical 
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vitrectomy or local molecular therapies modulating the phenotype of vitreous 
macrophages.  
6.3 Outlook and therapeutic implications 
6.3.1 Modifying adaptive responses to retinal hypoxia 
 
Relieving retinal hypoxia has been suggested to be a potential treatment option 
to prevent the neovascular response and the associated complications in 
neovascular eye disease including PDR and vasoocclusive disease. Clinical 
management for patients with these conditions currently includes panretinal 
photocoagulation or in more severe cases vitrectomy. Both interventions can 
reduce the development of retinal neovascularisation by increasing the oxygen 
delivery to the hypoxic retina (Stefansson, 2006). 
As these treatments are very invasive procedures and linked to potential 
adverse events, recent studies have suggested that molecular interference with 
the translation of hypoxia into molecular responses might become a promising 
treatment modality. As an alternative to improving retinal oxygen supply, the 
retina may be protected against the effects of local hypoxia by manipulating 
adaptive responses so as to inhibit harmful consequences and, potentially, to 
promote beneficial adaptive responses. Intraocular delivery of anti-VEGF 
antibodies can effectively control pathological neovascularisation and oedema. 
Clinical trials of VEGF inhibitors have demonstrated a significant benefit in age-
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related macular degeneration (Martin et al., 2011) and considerable potential in 
diabetic retinopathy (Avery et al., 2006). 
While these results demonstrate the enormous potential of local antiangiogenic 
therapy for retinal vascular disease there are considerable limitations. The short 
half-lives of Vegf antibodies in the eye necessitate multiple repeated intraocular 
injections that are not cost effective and cumulatively increase the risk of sight-
threatening local adverse effects. Furthermore, anti VEGF therapy has been 
associated with systemic adverse effects including nonocular haemorrhage and 
stroke (Tolentino, 2011). While non-specific VEGF inhibitors target 
angiogenesis, they fail to address the underlying hypoxia and to consider 
appropriate endogenous compensatory responses including neuroprotective 
mechanisms and appropriate vascular remodelling. Future therapeutic strategies 
should therefore consider how to protect and promote appropriate retinal 
responses to hypoxia. An improved understanding of oxygen sensing and the 
HIF pathway may potentially help to identify new therapeutic modalities to 
promote neuroprotection and appropriate vascular remodelling, while preventing 
hypoxic/oxidative stress and pathological angiogenesis. 
6.3.2 Manipulation of Hif signalling in retinal ischaemia 
Due to its central role as a master-regulator of responses to hypoxia/ischaemia, 
HIF is a potentially relevant target for treating vascular disease in the eye. HIF 
signalling can be manipulated by RNA interference, by direct protein inhibition, 
or by modifying its degradation by PHD or VHL.  
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6.3.2.1 Activation of HIF signalling to improve neuroprotection  
Activation of HIF signalling, for example by prolyl-hydroxlyase inhibition, offers a 
potential therapeutic option to improve ischaemic tolerance in retinal vascular 
disease by upregulating beneficial HIF dependent processes such as metabolic 
adaptation, neuroprotection and appropriate revascularisation (Sears et al., 
2008). Systemic stabilisation of Hif by inhibition of prolyl-hydroxylases has been 
shown to protect against oxygen-induced retinopathy when applied in the early, 
non-proliferative phase of the OIR model (Sears et al., 2008). This finding is 
consistent with an observed protective effect of Epo supplementation on 
vascular and neuronal survival in the early phase of this model (Chen et al., 
2009). Systemic stabilisation of HIF in the proliferative stage of the OIR model, 
however, exacerbates pathological neovascularisation (Sears et al., 2008). 
These findings indicate that activation of Hif signalling can have both beneficial 
and detrimental effects in neovascular eye disease depending on the stage of 
disease progression. Pharmaceutical activation of Hif may therefore only be 
suitable in early, non-proliferative retinal vascular disease, in order to improve 
ischaemic tolerance by upregulating beneficial HIF dependent processes such 
as metabolic adaptation and neuroprotection. This approach, however, has to be 
carefully evaluated as it may involve a significant risk of Hif1a mediated cell 
death as shown in this thesis.  
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6.3.2.2 Inhibition of HIF signalling to suppress neovascularisation  
Based on its central role in regulating angiogenic factors such as VEGF, 
inactivation of HIF signalling has been proposed to be a promising treatment 
option to inhibit pathological angiogenesis in neovascular eye disease. 
HIF inhibition may be achieved by RNA interference using small interfering RNA 
(siRNA) or small hairpin RNA (shRNA), by controlled activation of PHDs or by 
small molecule inhibitors that specifically target different HIF isoforms. In vitro 
studies have shown that HIFa RNA and protein expression can be effectively 
targeted using siRNA and shRNA (Mowat, 2009). Local inhibition of Hif by naked 
siRNA in vivo, however, has been shown to be difficult to achieve (Mowat, 2009) 
and may risk non-specific effects on extracellular receptors (Kleinman et al., 
2008) and significant host immune effects (Alexopoulou et al., 2001). Viral or 
non-viral delivery of DNA constructs carrying HIF siRNA or shRNA to retinal 
cells may evade these problems and enable more efficient and prolonged 
delivery of interfering RNA. Furthermore, the use of cell specific promotors, such 
as the myeloid specific lysM promotor (Clausen et al., 1999), may be used to 
restrict shRNA and siRNA expression to the cells of interest. Furthermore, 
controlled activation of PHDs may be an efficient approach to reduce HIF levels. 
Viral or non-viral delivery of plasmids expressing different isoforms of PHD 
under a cell specific promotor may be used to reduce Hif activity in the cells of 
interest. As different isoforms of PHDs exhibit differential control over HIF1a and 
HIF2a (Appelhoff et al., 2004; Takeda et al., 2008), isoform specific activation of 
PHDs may allow to specifically induce degradation of HIF1a or HIF2a. 
Furthermore, small molecule inhibitors that specifically inhibit individual HIFa 
222 
 
 
isoforms are currently being investigated. Among these, YC-1, a small molecule 
inhibitor that specifically targets HIF1a, has been demonstrated to be a potent 
inhibitor and is currently undergoing clinical trials in cancer treatment (Yeo et al., 
2003). Finally, antibody fragments known as intrabodies are sufficiently small to 
penetrate the cell membrane and the cytoplasmic space and have been shown 
to effectively inhibit HIF1a activity in vitro (Groot et al., 2008). Future studies 
may focus on the generation of intrabodies that are specific for HIF1a or HIF2a 
and assess their safety and efficacy in reducing HIF levels in vivo. 
 
Systemic HIF inhibition – a viable treatment option? 
Inhibition of Hif1a signalling by systemic administration of Digoxin has been 
shown to suppress the development of retinal and choroidal neovascularisation 
(Yoshida et al., 2010). Systemic administration of HIF inhibitors, however, 
provides a significant risk as HIF signalling pathways play a key role in multiple 
organs including the intestine, lung, heart, liver and the kidney (Stroka et al., 
2001; Wiesener et al., 2003). In particular, in the context of human ROP, 
systemic inhibition of HIF during postnatal organ development may pose an 
even greater risk of side effects. Therefore, systemic HIF inactivation, 
particularly in new born infants, is unlikely to be a viable therapeutic option and 
should be avoided. To minimise the potential risk for systemic side effects of HIF 
inhibitors, future efforts should focus on intraocular administration of Hif 
inhibitors in proliferative neovascular eye disease.  
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Local inhibition of HIF in neovascular eye disease 
Mounting evidence in the literature indicates that intraocular inhibition of Hif can 
reduce the development of retinal and choroidal neovascularisation. Intravitreal 
injection of anti-HIF1a shRNA has been shown to inhibit experimental CNV 
(Zhang et al., 2010). Similarly, local delivery of siRNA targeting Hif1a has been 
demonstrated to reduce Hif1a and Vegf protein levels by 90% and 65% 
respectively and suppress the neovascular response in the OIR mouse model 
(Xu et al., 2011). In line with these findings, intraocular injection of YC-1 has 
been reported to reduce pathological retinal neovascularisation in the retina of 
mice (DeNiro et al., 2010). Although these initial results are promising, great 
care needs to be taken to assess the feasibility, efficacy and safety of such 
therapy. Given the complexity of the HIF signalling system, in which multiple 
PHD and HIF isoforms regulate the transcription of numerous genes that 
intersect with multiple other signalling pathways, successful intervention is likely 
to depend on careful molecular targeting and on the timing of intervention. 
Whether targeting of PHDs can be sufficiently selective to avoid side effects, will 
require careful investigation. Target specificity may be improved by defining the 
cellular distribution of the PHD isoforms and their interaction with HIF isoforms in 
the retina, with a view to cell-specific targeting. Further animal studies will be 
needed to assess both safety and efficacy of HIF interference and to elucidate 
whether it may become a potential target for the treatment of proliferative 
retinopathies in man. 
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6.4 Conclusion 
 
Insight into tissue oxygenation and oxygen sensing mechanisms in the retina will 
improve our understanding of the role and the consequences of hypoxia in 
retinal vascular diseases and is essential for the development of new 
treatments. Fluxes in oxygen tension represent perhaps the most important 
variable in physiology, and animal tissues have developed a number of adaptive 
mechanisms to cope both with low physiological oxygen levels and with hypoxic 
clinical conditions. This thesis has investigated the role of oxygen and oxygen 
sensing mechanism in health and disease. Among these mechanisms is the 
response mediated by the transcription factor HIF1a which has roles both in 
embryonic development and various retinal vascular disease pathologies. Even 
though the understanding of HIF1 oxygen sensing mechanisms has increased 
considerably in recent years, there are several areas where knowledge is 
lacking. For example, expression and activation mechanisms of HIF1, HIF2a, 
HIF3a and endogenous antagonists such as prolyl-hydroxylases in the different 
retinal cell types still need further study. Future investigations that aim to block 
HIF pathways might be of interest for treating retinal vascular disease, such as 
diabetic retinopathy or age-related macular degeneration in which an 
overwhelming, uncontrolled vascular response is associated with sight 
threatening vascular complications. The importance of HIF1a for 
neuroprotection, however, has to be carefully respected when considering 
HIF1a inhibition as an antiangiogenic therapy in the retina. Further 
understanding of the oxygen-sensing molecular mechanisms in the retina might 
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hopefully provide new tools to develop efficient treatments for various vascular 
retinopathies that are related to inflammation and hypoxia.  
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Appendix 
1) Gene names, NCBI accession numbers and mRNA coding sequences. 
Gene name Accession no. Coding sequence 
Hif1a  NM_010431.1 258-2768 
HIF1a NM_001530.2 285-2765 
Hif2a  NM_010137.3 382-3006 
HIF2a NM_001430.3 489-3101 
mβ-actin NM_007393.3 80-1207 
hβ-actin NM_001101.2 85-1212 
 
2) PCR primers and conditions: 
a) trp cre genotyping  
primers (5’-3’) 
Cre forward  AGG TGT AGA GAA GGC ACT TAG C 
Cre reverse  CTA ATC GCC ATC TTC CAG CAG G 
PCR reaction: 
30 cycles of: 
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30s 94˚C 
30s 60˚C 
1min 72˚C 
Product of 411bp in cre positive animals. 
b) lysM cre genotyping  
primers (5’-3’) 
Cre forward  AGG TGT AGA GAA GGC ACT TAG C 
Cre reverse  CTA ATC GCC ATC TTC CAG CAG G 
PCR reaction: 
30 cycles of: 
30s 94˚C 
30s 60˚C 
1min 72˚C 
Product of 411bp in cre positive animals. 
c) Vhl genotyping 
VHLflox/flox genotyping primers to distinguish floxed/wild-type alleles. 
Flox 1  AGAGCGGCTTCACTTGTTTTTCAT 
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Flox 3  CCCAGTTCCCGGTCAGGTTC 
PCR reaction: 
35 cycles of: 
 30s 94˚C 
 5s 56˚C 
 30s 72˚C 
Product of 457bp wild-type, 637bp floxed.  
d) Hif1a genotyping 
Hif1aflox/flox genotyping primers to distinguish floxed/wild-type alleles. 
HF :15’ tgatgtgggtgctggtgtc 3’ 
HR3: 5’ ttgtgttggggcagtactg 3’ 
Amplification program: 53 degrees C x35 
PCR reaction: 
35 cycles of: 
 30s 94˚C 
 45s 53˚C 
 60s 72˚C 
279 
 
 
72C 10 mins 
4C ad infinitum 
Product of 200 bp for wild-type and 250bp for floxed genes 
 
Figure Appendix 1. Genotyping PCR for Hif1a, Vhl and cre recombinase in 
C57B6-trpcre, Hif1atrp1-cre, Vhltrp1-creKO, Vhlfl/fl;Hif1afl/fl and Vhl;Hif1atrp1-creKO mice  
Real-time PCR: 
Murine Pax6 forward: 5’-CAGTTCTCAGAGCCCCGTAT-3’  
Murine Pax6 reverse: 5’-CCACCAAGCTGATTCACTCC-3’.  
Murine Mitf forward: 5’-TGAGTGCCCAGGTATGAACA-3’.  
Murine Mitf reverse: 5’-GGATCCATCAAGCCCAAAA-3’.  
Murine Otx2 forward: 5’-GGTATGGACTTGCTGCATCC-3’.  
Murine Otx2 reverse: 5’-CGAGCTGTGCCCTAGTAAATG-3’.  
Murine Epo forward: 5’-TCTGCGACAGTCGAGTTCTG-3’.  
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Murine Epo reverse: 5’-CTTCTGCACAACCCATCGT-3’.  
Murine Flt-1 forward: 5’-CCTCTGCATTTGGCATTAAGA-3’.  
Murine Flt-1 reverse: 5’-AGAGCTTTGTACTCACTGGCTGT-3’.  
Murine Pdgfa forward: 5’-GGCTGGCTCGAAGTCAGAT-3’.  
Murine Pdgfa reverse: 5’-TGTCTCCAAGGCATCCTCA-3’.  
Murine Pdgfb forward: 5’-CGGCCTGTGACTAGAAGTCC-3’. 
Murine Pdgfb reverse: 5’- GAGCTTGAGGCGTCTTGG-3’. 
Murine -actin forward: 5’-AAGGCCAACCGTGAAAAGAT-3’.  
Murine -actin reverse: 5’-GTGGTACGACCAGAGGCATAC-3’.  
Murine Vegf forward: 5’-GACTTGTGTTGGGAGGAGGA-3’. 
Murine Vegf reverse: 5’-TCTGGAAGTGAGCCAATGTG-3’. 
 
Real-time PCR cycle: 
50˚C 2 minutes, 95˚C 10 minutes 
then 40 cycles of: 
94˚C 30 seconds 
60˚C 1 minute. 
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